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ABSTRACT 
Genital infection with herpes simplex virus type 2 (HSV -2) is increasingly common 
worldwide. The aims of this thesis were to investigate the epidemiology and natural 
history of genital herpes among GUM attendees with symptomatic genital herpes, and 
among HIV-l infected individuals. In our study of GUM attendees in the UK, we 
demonstrated HSV -1 to account for 9% of first episodes of genital herpes. These findings 
are in contrast with observations made elsewhere in the UK, where HSV -1 has accounted 
for >50% of first-episode cases. As most individuals with genital HSV -2 infection remain 
clinically misdiagnosed, the need for improved diagnostic methods to detect genital HSV 
infection is warranted. We compared the performance of virus culture and PCR in 
patients clinically diagnosed with genital herpes. PCR increased HSV detection in 
patients with both early and late presentations and in first and recurrent diseases. PEG 
precipitation was the most sensitive specimen preparation method of choice. A HSV 
positive PCR was also associated with heterosexuals, early presentation, and visible 
genital ulceration. HSV -1 and HSV -2 genital infections were also associated with white 
and black ethnicity respectively. This suggests that host susceptibility and behavioural 
factors may influence the epidemiological patterns of genital herpes. Current data support 
the use of HSV type-specific serology and PCR to diagnose HSV infections. In addition 
to PCR, we evaluated the performance of type-specific serology (HerpeSelect EIA, Focus 
Technologies, Cypress, California, USA) for the diagnosis of HSV infection. Our 
findings indicated that increasing the assay cut-off from 1.1 to 3.1 increased specificity 
and maintained sensitivity. By performing an inhibition EIA using an inhibition value of 
lV 
~60% we minimised false positive results from Ugandan and Kenyan sera. Recent data 
has implicated HSV-2 as a co-factor in HIV transmission. We therefore investigated the 
seroepidemiology of HSV infection among 850 HIV-infected individuals. HSV-2 
seroprevalence was 63% and increased with age and was associated with female gender, 
heterosexuals and black ethnicity. A follow-up of 123 HSV-2 seronegative persons 
revealed a HSV -2 seroconversion rate of 10% which was associated with HPV infection 
and gonorrhoea. Only 21 % of the seroconverters received a clinical diagnosis of genital 
herpes, and this was more likely in persons diagnosed HIV -1 positive before 1997 (pre-
HAART era). To investigate the effects of HAART on HSV-specific immunity, we 
studied the kinetics of HAART-induced reconstitution of HSV-specific T-cell responses 
in HIV-l infected persons at different stages of clinical disease using an ELISPOT assay. 
Successful HAART proved to resolve HSV-specific immunity restoration which 
coincided with HAART-induced CD4 gain. HSV-specific IFN-y responses correlated 
with CD4 counts. Responses similar to those of HIV -negative healthy controls were seen 
at CD4 counts >450 cells/mm3• 
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1. Chapter 1. Main Introduction 
There are 8 types of human herpes vIruses (Table 1.1). Among the alpha 
herpesviruses, two biologically distinct subtypes of herpes simplex virus (HSV) exist. 
One third of the world's population has been shown to be infected with either subtype 
(HSV-l and HSV-2) (Whitley et ai., 1998). HSV is the main cause of genital ulcer 
disease (GUD) in the developed world and also accounts for a significant proportion 
of GUD cases in developing countries (Serwadda et ai., 2003; Bruisten et ai., 2003). 
HSV-l is traditionally associated with orofacial infections but can also cause genital 
infections. HSV-2 is associated with genital infections. In the USA, 22% of 
individuals aged 12 years or over are HSV-2 seropositive (Fleming et ai., 1997). In 
the developing world, HSV-2 prevalence ranges between 60-90% (Narouz et aI., 
2002). 
HSV infection is life-long. Following primary infection either by direct contact with 
mucosal surfaces or abraded skin, HSV migrates from the nerve endings to the local 
sensory or autonomic ganglia, where it establishes a latent state (Yeung-Vue et ai., 
2002). The establishment of latency is a common feature of the herpesvirus family to 
evade the human immune response. Reactivation of the virus occurs commonly and 
can be triggered by local or systemic stimuli such as immunodeficiency, trauma, 
fever, menstruation, ultra-violet rays, and sexual intercourse (Kirchner et ai., 2000). 
Upon reactivation, infective virions travel down the sensory axons to replicate in the 
epithelial cells of the skin or mucosa at or near the site of original infection. Genital 
herpes is of public health importance due to its morbidity, psychological impact, 
frequency of recurrence and rare but serious neonatal damage which may occur from 
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maternal transmission of HSV (Brugha et al., 1997). Clinical presentations of genital 
herpes may be as a first or a recurrent episode. The infection is classified as a primary, 
initial or non-primary and recurrent (Brugha et al., 1997). Primary infections occur in 
persons lacking immunity to both HSV types. Non-primary infection may occur in 
individuals with previous exposure to one HSV type. HSV infections are often 
asymptomatic and present with mild symptoms. The virus can be shed and transmitted 
in the absence of recognised disease and male to female transmission is more efficient 
for HSV - (Corey & Handsfield, 2000; Mertz et aI., 1992). 
HSV -2 IS prevalence is high among individuals infected with human 
immunodeficiency virus-l (HIV -1). The strong epidemiological association between 
HIV -1 and HSV -2 may reflect common risk factors for infection. In addition, there is 
also evidence for a more direct biological interaction between the two viruses. 
Prospective studies have shown HSV -2 to increase the risk of HIV -1 acquisition and 
transmission by approximately two-fold (Blower et al., 2004; Celum et al., 2004). 
Genital ulceration due to HSV-2 is thought to increase HIV-l transmission by 
increasing the levels of HIV -1 shedding through genital lesions, and by providing a 
portal of entry for the virus (Mbopi-Keou et al., 2003). There is also evidence to show 
plausible biological interactions between HIV -1 and HSV -2, with HIV -1 increasing 
the clinical expression of HSV -2 (Holmberg et al., 1988). In individuals with cellular 
immunodeficiency caused by HIV-l, HSV-2 reactivation is associated with greater 
frequency of HSV -2 shedding and increased HIV -1 viremia (Fauci, 1988; Posavad et 
al., 2004). Studies are currently underway to determine whether the use of anti-
herpetic agents such as acyclovir, can reduce the risk of HIV-l transmission. A 
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greater understanding of the natural history of HSV -2 infection is required to 
understand the possible role it plays in the dissemination and acquisition of HIV -1. 
Table 1.1. The different members of the herpes family 
Herpes virus type Family 
Herpes simplex virus type 1 (HSV -1) Alpha 
Herpes simplex virus type 2 (HSV-2) Alpha 
Varicella zoster virus (VZV) Alpha 
Cytomegalovirus (CMV) Beta 
Human herpes virus -6 (HHV -6) Beta 
Human herpes virus-7 (HHV-7) Beta 
Epstein-barr virus (EBV) Gamma 
Human herpes virus-8 (HHV-8) 
Gamma 
Kaposi's sarcoma- associated herpes virus (KSHV) 
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1.1 THE BIOLOGY OF HSV-2 
1.1.1 Virion characteristics 
HSV-l and HSV-2 are members of the sub-family a-herpe Vlru e (Figure 1.1). The 
vIrIon has a distinct large virion structure (ISO-200nm) compri ing of a core 
containing linear double-stranded DNA an ico ahedral cap id containing L62 
hexagonal capsomers surrounded by an amorphou tegument containing additional 
viral proteins, and an outer membrane envelope studded with viral glycoprotein . 
Linear double-stranded DNA 
Amorphous 
Tegument 
• 
150-200 nm 
Figure 1.1. HSV virion structure 
Glycoproteins 
Lipid envelope 
.. 
Cap id 
// 
~ ... 
• 
The virion has four major components: Double- tranded DNA the ico ah dral ap id 
shell, the viral tegument and the lipid membrane en elope with glycoprotein pike . 
- 4 -
1.1.2 Genome Organisation 
The HSV genome consists of approximately 150,000 base-pairs, encoding at least 80 
gene products. The genome consists of two covalently linked segments called Long 
(L) and short (S) based upon their relative length. Each segment contains unique 
regions of sequences (UL or US) which are flanked with inverted repeat sequences. 
Some viral genes and their products are named by their relative position from left to 
right in the UL or US region and some are alternatively named upon their function. 
The genome also consists of other elements which orchestrate replication and 
processing and packaging of newly synthesised genomes. 
1.1.3 Virus entry into the cell 
Virus entry involves the function of a number of glycoproteins (gB, gC, gD and the 
gH/gL heterodimer). An interaction between gC and heparin sulphate moieties on the 
host cell initiates virus attachment (Figure 1.2). Although this initial step enhances 
infection, it is not an absolute requirement, since gC has been shown to be dispensable 
for viral growth and replication in vitro (Igarashi et ai., 1993). In addition, cells that 
do not express heparin sulphate remain permissive at low levels (Shieh et ai., 1992; 
WuDunn et ai., 1989). Virion attachment is stabilised by interactions of the gO 
protein with recently identified cellular receptors referred to as 'herpes virus entry' 
proteins (HVE). Fusion of the viral envelope with the cellular membrane occurs 
through an undetermined mechanism involving proteins gD, gB and the gH/gL 
heterodimer. Fusion results in the nucleocapsid and some tegument proteins being 
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released into the cytoplasm of the cell. Fusion results in the nucleocapsid and some 
tegument proteins being released into the cytoplasm of the host cell. The nucleocapsid 
and some of the tegument proteins get transported via microtubules into the nucleu 
for the initiation of viral replication whi le other tegument proteins remain in the 
cytoplasm. 
gO receptors 
Figure 1.2. HSV entry into cells 
Binding of HSV to heparan sulphate chains on cell surface proteoglycan (HSPG) 
initiates cell contact. Viral glycoproteins gB or gC can mediate binding. H V gO can 
bind to entry receptors, including HVE (1), a member of the TNF-receptor fam ily; 
nectin-l or nectin-2; (II) two related members of the immunoglobulin uperfamily or 
(III) sites generated in heparan sulfate by the action of specific 3-0- ulfotran fera e . 
Binding of gO to its receptors activates viral fu ion. 
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1.1.4 Virus replication 
HSV genes are expressed in 3 classes: immediate early (IE or a), early (E or ~) and 
late (L or y) (Figure 1.3a). Immediate early genes are transcribed immediately after 
infection and activate transcription of early genes. Early gene products replicate viral 
DNA, which in tum stimulates the expression of late genes. The initiation of IE gene 
transcription is followed by the recruitment of cellular transcriptional machinery to IE 
gene promoters. The virion protein (VP 16) has been shown to enhance IE protein 
expression (Batterson et al., 1983) and interact with numerous cellular proteins (Katan 
et ai., 1990; Kristie & Sharp, 1990) resulting in increased activity of the cellular 
transcriptional machinery on IE gene promoters. 
An important event in HSV gene expression is the shutdown of IE and E gene 
expression. ICP4 can repress itself by binding to repressor elements in its own 
promoter leading to a reduced IE and E gene expression or alternatively IC8 may 
reduce transcription from the parental genome following viral DNA replication 
(Godowski & Knipe, 1985). In addition, HSV may shut down host transcription, 
replication and translation (Roizman & Tognon, 1983). For instance, the virion 
associated protein (VHS) degrades mRNA early in infection (Kwong et ai., 1988) and 
ICP22 modifies the binding ability of the host RNA polymerase II complex following 
infection (Spencer et ai., 1997). 
DNA replication occurs within replication compartments of infected cells and both 
viral DNA and replication proteins are localised to cellular structures called ND 1 0 
sites. Replication compartments form at these sites as viral DNA synthesis proceeds. 
- 7 -
The linear HSV DNA circularises upon entry into the nucleus and replication is 
initiated at one of the three origins of replication (OriL or OriS) located in the UL or 
US region of the genome (Figure l.3b). Seven genes essential for viral replication 
have been identified (UL9, UL29, UL5, UL52, UL8, UL30, UL42) which encode a 
single-stranded DNA binding protein, a helicase-primase complex, and a DNA 
polymerase. In addition, 'non-essential' E gene products for viral DNA replication 
may also be expressed (e.g. Thymidine kinase). Synthesis of L gene products is 
required for capsid assembly, however, the mechanism of DNA cleavage and 
packaging is not very well understood. The route of virion egress from an infected cell 
remains controversial. It is thought that enveloped virions fuse with the outer nuclear 
membrane, releasing nucleopcapsids into the cytoplasm that re-envelope by budding 
into the Golgi compartment, which then get secreted from the cell in a vesicular route 
(Skepper et al., 2001). 
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Figure 1.3a. Productive HSV replication cycle in an infected cell. 
Stages of HSV infection include: (1) Receptor binding and membrane fusion ; (2) 
Release of the viral nucleocapsid and tegument in the cytopla m of the cell and 
nucleocapsid transport to the nuclear pore; (3) Release of the viral DNA into the 
nucleus; (4) Transcription and translation of viral immediate early (IE) and early (E) 
genes; (5) Viral DNA synthesis; (6) Transcription and translation of viral late (L) 
genes; (7) capsid assembly and DNA packaging; and (8) Egres of progeny virion 
(Adapted from Taylor et al., 2002). 
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Figure 1.3b. HSV DNA replication 
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Stages of HSV replication are: (1) UL9, the origin binding prot in binds to pecific 
sites at origin (ori L or ori S) and begin to unwind the virus DNA; (2) The ingle-
stranded DNA binding protein, rCP8, is recruited to the unwound DNA; (3) UL9 and 
rCP8 recruit the five remaining replication proteins to the replication fork ' (4) DNA 
replication proceeds via a theta replication mechanism' and (5) witche to a rolling-
circle replication mechanism (Adapted from Taylor et ai., 2002). 
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1.1.5 Virus latency and reactivation 
The major site ofHSV latent infection is the trigeminal ganglia or the sensory neurons 
in the ganglion tissue for oro labial herpes infection or the sacral ganglia for genital 
infection. Following initial primary infection at the oral or genital mucosal surface, 
HSV travels along the neuronal axon to the neuronal cell body (Figure l.4a). Once 
within the neuron, the virus enters a quiescent state in which lytic genes are not 
expressed. However, controversy exists over whether lytic cycle viral genes are 
transcribed during latency. Several investigators have proposed that a limited array of 
viral genes is expressed during latency (Khanna et al., 2004). During latency, the viral 
genome persists in the nucleus of the neuron as circular extra-chromosomal DNA. 
Viral transcripts called Latency associated transcripts (LATs) have been found in 
HSV latently infected neurons. The role of LATs in latency is poorly understood as 
LATs are not an absolute requisite for the establishment and maintenance of latency 
in most animal models (Taylor et al., 2002). Studies in LAT negative viruses have 
demonstrated increased immediate early gene expression in neurons, suggesting LA Ts 
to limit viral gene expression and promote a latent state (Garber et al., 1997). In 
addition, LATs may protect neurons from apoptosis allowing neuronal survival during 
latent infection (Perng et aI., 2000). HSV transcriptional silence during latency allows 
the virus to evade immune surveillance, until signals are generated that cause virus 
reactivation. Upon reactivation, new progeny virions are generated, resulting in the 
virus travelling through the neuron to the site of primary infection to re-initiate the 
lytic cycle (Figure l.4b). 
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The effectiveness of the immune response to primary HSV -1 infection may determine 
the likelihood of a reactivation event. The observation that lymphocytes and their 
cytokine products persist in latently infected trigeminal ganglia of mice suggest a 
possible continuing role for the immune system in controlling HSV -1 recurrences (Liu 
et al., 2000). Several studies have demonstrated the presence of CD8+ T cells for 
prolonged periods in the trigeminal ganglia (TG) after HSV -1 infection, and have 
shown these cells to surround neurons following in vivo induced reactivation of HSV-
1 from latency (Cantin et aI., 1995; Liu et al., 2000; Liu et al., 1996; Shimeld et al., 
1995; Shimeld et al., 1996). In one study, CD8+ T cells present in the trigeminal 
ganglia 14 days after HSV-l corneal infection could completely block HSV-l 
reactivation from latency for at least 2 weeks in explanted TG cultures (Liu et al., 
2000). In addition, IFN-y has also shown to inhibit HSV-l reactivation, ICPO 
promoter activity, gC promoter activity in latently infected neurons (Decman et al., 
2005; Halford et al., 2001). 
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A. Lytic replication in 
epitheJ' I cells 
B. 
EST ABLlSHMENT 
OF LATENCY 
Viral capsid moves 
down axon by retrogade 
transport 
REACTIVATION 
FROM LATENCY 
Viral capsid moves down 
axon by anti·retrogade 
transport 
Recurrent infection at site 
of initial infection 
Figure 1.4a and l.4b. HSV Latency and Reactivation 
Sensory neuron 
Infection of en ory 
neuron in ganglia; ite 
of latency 
Appropriate timulu 
reactivate latent 
Stages of HSV latency are as follow : (a) HSV replicates in epithelial cell or the 
genital mucosa, enters the sensory neurons and travel up the axon to the neuronal cell 
body, where it establishes a latent state; and (b) Upon appropriate timulu , the viru 
can reactivate, travel back down the axon and re-establish lytic replication (Adapted 
from Taylor et aI. , 2002). 
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1.2 THE NATURAL HISTORY OF HSV-2 INFECTION 
Genital HSV infection may be symptomatic or asymptomatic, with symptomatic 
infection being generally described as first-episode or recurrent disease. Infection is 
classified as primary, initial non-primary and recurrent. Subsequent reactivation from 
the ganglionic neurons results in viral shedding into the vagina, and the perianal or 
penile skin (Wald et ai., 2000). A recent study of 157 patients with a first episode of 
genital herpes showed 18%, 27% and 54% to have had primary genital herpes, non-
primary first episode, and pre-existing genital herpes respectively (Page et ai., 2003). 
1.2.1 Primary infections 
A primary infection occurs when a person acquires HSV -lor HSV -2 in the absence 
of pre-existing HSV immunity, i.e. the patient has no antibodies against HSV-l or 
HSV-2. Symptomatic HSV-2 primary infections are characterised by genital lesions, 
pain, itching, dysuria, vaginal or urethral discharge and systemic symptoms. The 
lesions are usually painful, and may last for a mean of 16.5 days in men and 19.7 days 
in women (Corey et ai., 1983). The lesions begin as small vesicles, get ulcerated and 
may sometimes crust. The virus is shed from the infected area for a median of 11 days 
following the onset of lesions, and may last for more than 30 days in some patients. 
Prospective studies of HSV -2 serodiscordant couples have shown that most 
individuals seroconvert to HSV-2 in the absence of clinical symptoms (Wald et ai., 
2001; Corey et ai., 2004). Primary infections that are initially silent may become 
symptomatic months or years later. 
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1.2.2 Initial infections 
Initial or non-primary infections are newly acquired infections with one HSV type, in 
the presence of pre-existing antibodies to another HSV type. The development of IgG 
antibodies following HSV infection varies from 21 to over 42 days with most 
individuals having detectable IgG 21-28 days after exposure to infection and probably 
persisting for life (Ashley et al., 1988; Slomka et al., 1995; Ho et al., 1993). IgM 
antibodies are usually detectable 9-10 days after exposure and last 7-14 days, and 
may remain detectable for up to 6 weeks in a minority of individuals (Ho et al., 1992; 
Ashley, 1998). 
1.2.3 Recurrent infections 
The clinical symptoms of recurrent genital herpes are less severe and of shorter 
duration than the primary episode. Recurrences may be symptomatic or 
asymptomatic. Symptomatic recurrences are characterised by the presence of small 
vesicular ulcers which last for a mean of 10.6 days in men and 9.3 days in women 
(Corey et al., 1983). For patients who experience a first episode of genital herpes, the 
risk of recurrent disease is higher among those infected with HSV -2 than HSV-l 
(Engelberg et al., 2003; Wald et al., 2000). In the first twelve months after a first 
episode of genital herpes, the risk of a symptomatic recurrence is 89% with HSV-2 
and 50-57% with HSV-l (Benedetti et al., 1994; Corey et al., 1983; Langenberg et 
al., 1999). Recurrence rates of genital herpes are more frequent in men than women, 
with median monthly recurrence rates rep0l1ed to be 0.43 in men and 0.33 in women 
(Benedetti et al., 1994). Earlier studies have reported HSV recurrences to decrease 
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over time (Knox et a/., 1982; Catotti et ai., 1993). In a study of 664 persons diagnosed 
with genital herpes and followed up for 14 months median recurrence rates within the 
first 12 months of follow up were 1 for HSV-l and 5 for HSV-2. Significantly lower 
rates of recurrences were evident in this population after 12 months. Among patients 
with HSV-2 recurrent disease, a decrease in the number of recurrences was strongly 
associated with longer follow up (Benedetti et a/., 1999). These findings are in 
contrast with observations made elsewhere which showed HSV recurrence rates to not 
decline over time (12 months) in 457 patients (Benedetti et a/., 1994). This could be 
accounted by potential population bias, whereby the authors reported half of the 
patient population to fail to complete the full year of follow-up. 
1.2.4 Atypical manifestations and unrecognised infection 
The clinical manifestations of genital herpes are diverse, with non-classical symptoms 
leading to misdiagnoses of infection. These include herpetic whitlow, erythema 
multiforme, eczema herpeticum and less commonly, gingivostomatitis. The variability 
in clinical symptoms of genital herpes means that identification of HSV -2 infection on 
clinical grounds alone is insufficient and that laboratory assays must be utilised for 
accurate diagnosis and effective clinical management of patients with genital herpes. 
Typical symptoms of primary genital HSV -2 infection include genital lesions, pain, 
itching, dysuria, vaginal or urethral discharge and systemic symptoms. The infection 
can be confused with other genital conditions, leading to four out of five people with 
genital HSV-2 infection remaining un-diagnosed (Corey, 1994). Among HSV-2 
infected individuals 60% of infections may be unrecognized, 20% may be 
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asymptomatic and the remaining 20% being symptomatic recognized infection. A 
study of 779 female STn clinic attendees, of whom 372 were HSV-2 seropositive 
showed only 22% of women who were HSV -2 antibody positive reported symptoms 
(Koutsky et at., 1992). 
1.2.5 Asymptomatic shedding and HSV transmission 
Asymptomatic infection has been implicated in the person-person transmission of 
HSV-2 infection (Mertz et at., 1985; Barton et at., 1987). Asymptomatic shedding 
occurs when the virus is present on the mucosal or skin surface of an individual in the 
absence of clinical symptoms, and is most common during the period before and after 
a clinical recurrence. In a prospective study of 144 discordant couples, where one 
partner had recurrent genital herpes, and the other had no serological or clinical 
evidence of HSV-2 infection, the risk of HSV-2 transmission during asymptomatic 
shedding was 69% (Mertz et at., 1992). In another study involving 27 women with 
recurrent genital herpes, asymptomatic shedding was detected in 80% of those 
followed up for more than 50 days, with the virus being shed asymptomatically 
overall on 1 % of the days (Brock et at., 1990). To evaluate the temporal relation 
between asymptomatic and symptomatic episodes, Wald et al (1995) calculated the 
rate of asymptomatic shedding within seven days of a symptomatic recurrence. 
Results demonstrated that 30% of asymptomatic shedding episodes occur 7 days 
preceding an episode and 20% occurs in the 7 days after an episode (Wald et at., 
1995). 
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The time since HSV acquisition may also influence the rate of asymptomatic 
shedding. As it is observed for symptomatic recurrent disease, the frequency of 
asymptomatic shedding is significantly higher with genital HSV-2 than HSV-l 
infection. A prospective study showed that asymptomatic shedding was more 
common in the first 12 months after an HSV-2 first-episode than an HSV-l first 
episode (Koelle et al., 1992). In the same study, the rate of shedding among women 
with primary HSV-2 infection decreased from 4.3% in the first 12 months to 2.3% 
after infection in the following year. Asymptomatic shedding may involve more than 
one genital site with rates of 0.7% and 1.1 % being observed for the cervix/vulva and 
perianal areas (Wald et al., 1995). Among MSM, the perianal area is the most 
common site of asymptomatic virus shedding, and among HIV -1 negative 
heterosexual men, the penile skin is the most common site for virus shedding (Wald, 
2004). Since the natural history of HSV infection is characterised by asymptomatic 
shedding between outbreaks, both recognised and unrecognised infections contribute 
to transmission and spread. 
1.3 DIAGNOSIS OF HSV INFECTION 
The diagnosis of genital herpes is often challenging because its non-classical 
presentations are often misinterpreted by the patient and the physician. A clinical 
diagnosis of genital herpes has a predictive value of 40% (Koutsky et al., 1990), 
indicating that HSV laboratory tests must be utilised to make a definitive diagnosis. 
The detection of HSV in cell culture has been considered the most optimal method for 
the diagnosis of genital herpes in the presence of genital lesions (Ashley, 1993). 
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Serological assays which discriminate between HSV-l and HSV-2 type-specific 
proteins (gG-l and gG-2 respectively), contribute towards the laboratory diagnosis. 
1.3.1 Virus culture and immunofluorescence 
Isolation of HSV in cell culture has long been considered as the 'gold standard' test 
(Ashley, 1993). HSV strains replicate in most cell lines within 12-18 hours and result 
in a cytopathic effect (CPE) within 16-24 hours following inoculation. Although 
specificity of the technique is nearly 100%, there are many limitations. The levels of 
virus shedding, quality of specimen and transport conditions influence sensitivity 
(Wald et ai., 2003; Corey et ai., 1983; Scoular, 2002). The rate of virus recovery 
declines significantly with time since the onset of lesions, from 52-93% for vesicles to 
41-72% for ulcers and 19-27% for crusted lesions (Corey et ai., 1983; Scoular, 2002). 
Furthermore, lack of specimen refrigeration after collection and during transport 
markedly reduces virus viability (Wald et ai., 2003). Type-specific confirmatory 
assays such as immunofluorescence relying on monoclonal antibodies being directed 
to type-specific antigens are used to differentiate between HSV types. 
1.3.2 peR 
PCR is a highly sensitive method used to directly detect and type HSV and has been 
the method of choice for detecting HSV infections of the CNS (Lakeman & Whitley, 
1995). Among patients diagnosed with herpes simplex encephalitis, PCR is 96% 
sensitive and 99% specific (Boivin, 2004). Several published studies have shown the 
optimal genes for HSV amplification to be those coding for thymidine kinase, DNA 
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polymerase, DNA binding protein, gC, gO and gO (Boivin, 2004). Although earlier 
PCR techniques were laborious, expensive and prone to contamination, newly 
developed real-time PCR assays are fully automated and allow virus-specific 
detection within a closed system, with fast tum-around times and low risk of 
contamination (Espy et al., 2001; Burrows et al., 2002). The introduction of Light 
Cycler technology, a commercially available system that performs PCR with real-time 
detection of amplified products by fluorescence resonance energy transfer (Espy et 
al., 2000) has allowed high speed thermal cycling and rapid detection (Kessler et al., 
2000). The melting curve analysis of this instrument differentiates between HSV-l 
and HSV-2 types (Whiley et al., 2004; Schmutzhard et al., 2004; Koenig et al., 2001). 
Due to its increased sensitivity and fast tum-around times, the recommendation of 
PCR to be used as a diagnostic test for HSV detection in genital swabs among 
asymptomatic persons warranted. It is the only suitable virologic test for testing HSV 
in certain clinical settings, such as the diagnosis of neonatal herpes or suspected 
central nervous system HSV infection (Kimberlin, 2004; Boivin, 2004). 
1.3.3 Serology 
At the population level, the number of diagnosed cases of genital herpes significantly 
under-estimates the burden of infection. HSV -2 seroprevalence data can help assess 
the burden although they do not account for cases caused by HSV -1. Serological 
testing can provide useful information in symptomatic patients when direct virus 
detection methods yield negative results and can identify patients with unrecognised 
sub-clinical disease (Ashley, 2001). The western blot has been used for nearly 15 
years, and has been extensively validated. The test produces bands corresponding to 
- 20-
glycoprotein G (gG) and other proteins of HSV that progress in intensity and 
complexity during seroconversion (Ashley, 1998). Studies have documented the 
specificity for HSV-l and 2 by this assay to be 100% (Ashley, 1993). The 
disadvantage of the western blot is that its time consuming, expensive and profiles 
may not always be definitive. The test is therefore unlikely to be developed for 
commercial use (Ashley, 2001). HSV type-specific serology is particularly useful in 
diagnosing HSV infection in asymptomatic individuals (Ashley & Wald, 1999; Wald, 
2002). Currently STI management guidelines favour the screening for STDIHIV in 
selected patients, individuals engaging in high-risk behaviour or those in partnerships 
where the partner remains HSV -2 infected. 
An alternative approach to detect HSV type-specific antibodies is by enzyme 
immunoassay (EIA). In previous years there was limited use for the HSV EIA as it 
was unable to reliably differentiate between HSV-1 and 2 antibodies due to cross-
reactivity (Ashley et al., 1998). Since HSV -1 and HSV -2 share significant sequence 
homology, cross reactivity is a major problem. Glycoprotein G (gG) (gG1 in HSV-1 
and gG2 in HSV-2) is the only known viral protein to predominantly elicit a type-
specific B-cell response (Wald, 2002). gG1, a 238 amino acid envelope protein of 
unknown function (McGeoch et al., 1985), is a prototype antigen for type-specific 
HSV-1 serology (Lee et at., 1986; Sanchez-Martinez et at., 1991) and forms the basis 
of commercially available enzyme immunoassays (Ashley et at. 1998). Its 
counterpart, HSV-2 (gG2) is successfully used as an antigen in type-specific HSV-2 
seroassays (Ho et al., 1992; Lee et at., 1985; Svennerholm et at., 1984). Both gG 1 and 
gG2 contain long stretches of type-unique amino acids that harbour type-specific 
antibody epitopes. Data has shown purified anti-gG2 antibodies to be non-reactive to 
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gG 1 peptides and gG 1 antigens (Liljeqvist et al., 1998). The cleavage product of gG2 
(sgG2), when evaluated in an EIA has a specificity and sensitivity of >98%. In 
addition, monoclonal antibodies directed against sgG2 have identified type-specific 
linear and nonlinear epitopes devoid of cross-reactivity to HSV -1 antigens. Type-
specific IgG antibody responses have also been detected in sera from HSV -infected 
patients by using sgG2 as the antigen (Gorander et al., 2003). Commercially available 
kits based on gG 1 and gG2 demonstrate sensitivity and specificity of 85-100% and 
80-98% respectively, (Leone, 2003). 
1.4 EPIDEMIOLOGY OF HSV-2 INFECTION 
HSV-2 genital infection is highly prevalent worldwide (Fleming et al., 1997; Halioua 
& Malkin, 1999; O'Farrell, 1999), although seroprevalence varies between regions 
and populations. Data taken from 10 developed countries (USA, Canada, Japan, 
Germany, UK, Belgium, France, Italy, Spain and Australia) have estimated 107 
million individuals to be HSV -2 seropositive (Marchant & Roe, 1997). Of those, 86 
million are estimated to have symptomatic disease, although only 21 million have a 
confirmed diagnosis of genital herpes. In addition, HSV-2 seropositivity rates are high 
among HIV -1 infected individuals, ranging from 33% in Rome, Italy (Suligoi et al., 
2002), 65% in Seoul, Korea (Kim et al., 2003), 81 % in HIV -1 positive men in 
Baltimore, USA (Hook et al., 1992), to 95% in HIV -1 positive female commercial sex 
workers in Zaire, Africa (Schomogyi et al., 1998). Several studies have demonstrated 
HSV-2 and HIV-l to be strongly associated with each other (Kjetland et a/., 2005; 
Serwadda et a/., 2003; Wald, 2004; Reynolds & Quinn, 2005). Although preliminary 
evidence suggest that genital herpes may be implicated in the spread and 
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dissemination of HIV-l in both the developing and developed world (Barton et al., 
2005; Ramjee et al., 2005; Wald, 2004) more prospective studies are required to 
determine the possible risk 
1.4.1 Developed world 
Genital herpes is the most common infectious cause of genital ulceration in the 
developed world and the incidence of infection continues to rise. In the National 
Health and Nutrition Examination Survey (NHANES), a large ongoing population-
based study in the USA, an increase in HSV-2 seroprevalence from 16% (midpoint 
1978) to 22% (midpoint 1991) was observed among individuals aged 12 years and 
above in the general population (Fleming et al., 1997). The 30% increase in HSV-2 
seropositivity from 1978-1994 in the general population was associated with a shift 
towards a younger age of acquisition (Johnson et al., 1989). Higher seroprevalences 
were observed among women than men (26 % vs. 18%), and black groups than 
hispanic or caucasian groups (46% vs. 22% vs. 18%). In Europe, the HSV-2 
seroprevalence in the general population ranges from 4% in England and Wales to 
24% in Bulgaria (Pebody et al., 2004). 
1.4.1.1 HSV -2 prevalence in the general population 
Population-based studies have demonstrated HSV-2 prevalence to vary between 
industrialised countries (Table 1.2). In the U.S. general population, HSV-2 antibody 
prevalence has been reported to be 22% (Fleming et al., 1997), whereas rates in the 
United Kingdom general population vary between 3-5% (Vyse et al., 2000). One 
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cross-sectional study among women aged between 18-29 years in low-income 
neighbourhoods in California, USA, demonstrated 35% of individuals to be HSV-2 
seropositive with predictors of HSV-2 infection being black ethnicity, older age, 
lower income, parity, greater number of lifetime male sexual partners, earlier onset of 
sexual intercourse, sexual favours, past history of STDs and cocaine use (Buchacz et 
aI., 2000). 
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Table 1.2. HSV -2 seroprevalence in non high-risk populations of the developed 
world 
Age . % Country Cohort Sex (range) n HSV-2+ Ref 
USA 
National Random sample of Fleming et civilians FIM (12-::::70) 13094 22 1988-1994 (NHANES III} al., 1997 
Washington Family medical FIM (18-45) 315/185 27/15 Brownet 1991-1992 centre attendees al., 1997 
California Low-income F (18-29) 1635 35 Buchacz et 1996-1998 neighbourhoods al., 2000 
UK 
London Antenatal patients F «20-::::35) 3533 10 Ades et al., 1981-1982 1989 
England & Wales Immunocompetent F/M (16-69) 3347 5.113.3 Vyse et al., 1994-1995 individuals 2000 
Canada 
British Columbia Antenatal patients F (15-44) 1215 17 Patrick et 1999 al., 2001 
Sweden 
Malmo Antenatal patients F (15-::::36) 1190 21 Persson et 1990-1993 al., 1995 
Finland 
Helsinki Antenatal patients F « 20-> 41) 997 16 Arvaja et 1988-1989 al., 1999 
Norwa~ 
Oslo Antenatal patients F (NG) 960 27 Eskild et 1992-1994 al., 2000 
France 
National Random sample of Malkinet civilians FIM (35-60) 4412 17 1996 {HERPIMAX} al., 2002 
S~ain 
Madrid Random sample FIM (15-45) 692 3.5 De Ory et 1993-1994 al., 1999 
New Zealand 
Dunedin Ebchart-Random sample FIM 21 372/407 4.3/2.7 Phillips et 1993-1994 
al., 1998 
Australia 
Sydney Antenatal patients F 28 2616 13 Mindel et 1995-1998 al., 2000 
Israel Healthy blood donors 
Tel Aviv FIM (3-79) 3677 7 Davidovici 2003-2004 et al., 2005 
Ja~an 
Central Japan Random sample FIM (20-49) 158/105 1.211.8 Hashido et 1993 from rural towns aI., 1999 
• Age expressed as mean/median in years unless otherwise stated; F, female; M, male 
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1.4.1.2 HSV -2 prevalence among high-risk populations 
Several serological surveys have been conducted among high risk populations (Table 
1.3). Among STn clinic attendees in the Netherlands, HSV-2 seropositivity rates 
range from 32% in Amsterdam (Van de Laar et al., 1998) to 22% in Rotterdam (Roest 
et al., 2001), although only 20% of HSV-2 seropositive individuals had a history of 
genital herpes. In a population of STD clinic attendees in Paris, France 55% of the 
population was HSV -2 seropositive, with older age and female gender being 
predictors of infection (Janier et al., 1999). Studies carried out among STn clinic 
attendees in Rome, Italy and Madrid, Gijon and Malaga, Spain, have reported 27% 
and 25% to be seropositive for HSV-2 respectively (Cusini et al., 2000; Varela et al., 
2001). Findings from Australian serological surveys have shown 65% of heterosexual 
men attending an STn clinic in Sydney, Australia to be HSV-2 seropositive. This is 
an unusual finding as it is the highest recorded prevalence for HSV-2 infection among 
heterosexual men in the developed world (Bassett et al., 1994; Malkin, 2004). In a 
cross-sectional study among STD clinic attendees in the USA without any history of 
genital herpes, 26% were HSV-2 seropositive. Higher rates observed in women, black 
ethnicity and in those aged 30 years or over (P<O.OI) (Whittington et al., 2001). 
Factors that may contribute to the increased rates of HSV-2 infection include 
increasing numbers of sexual partners and failure of safe sexual practices. A reduction 
in the prevalence of prior HSV -1 infection among youths has also been proposed. 
There remains limited evidence to suggest that HSV-l seropositivity provides 
protection against HSV -2 infection. Defining roles of HSV -1 acquisition in childhood 
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may contribute to the increasing number of diagnoses of genital herpes as pre-existing 
HSV-l immunity has shown to attenuate the clinical expression of HSV-2 upon 
infection. 
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Table 1.3. HSV -2 seroprevalence in high-risk populations in the developed world 
Age . Country Cohort Sex N % Ref (ran~e~ HSV-2+ 
USA 
Washington STD clinic attendees F 24 776 43 Koutsky et 1984-1986 al., 1992 
Washington HIV -1 infected women F 27 60 75 Hitti et al., 1989-1995 1997 
Washington STD clinic attendees FIM (~19-~40) 606 26 Whittington 1998 et al., 2001 
UK 
Central London Heterosexual STD clinic F/M (17-69) 347/294 25117 
1992 attendees Cowan etal., 
Homosexuals M {l9-69} 192 27 1994 
France 
Paris STD clinic attendees F/M (NG) 487 55 Janier et al., 1999 
Northern 
France, Paris HIV -1 infected individuals FIM «25->45) 534 59 Andreoletti 
(NG} et al., 2005 
Netherlands 
Rotterdam STD clinic attendees FIM (13-71) 653 Roest et al., 1998 22 2001 
Amsterdam STD clinic attendees FIM «20-~40) 1679 Van de Laar 1986-1988 32 et al., 1998 
Germany 
Jena HIV -1 infected individuals FIM (20-39) 110/272 Wutzler et 1996-1997 66/40 al., 2000 
Italy 
Rome STD clinic attendees FIM (18~53) 941 Mele et al., 1986 41 1988 
Northern Italy STD clinic attendees FIM (18-75) 919 27 Cusini et al., 1997-1998 2000 
S[!ain 
Madrid STD clinic attendees FIM (18-65) 374 Varela et al., 1996-1997 25 2001 
Australia 
Auckland STD clinic attendees FIM «20-~50) 1231171 Perkins et al., 30/22 1991-1992 1996 
Sydney Homosexuals M (NG) 194 65 Bassett et al., (NG} 1994 
Japan 
Osaka Commercial sex workers F 35 70 80 Hashido et 
1985-1989 al., 1998 
-Age expressed as mean/median in years unless otherwise stated; (NG) data not 
available; F, female; M, male 
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1.4.2 HSV -2 seroprevalence in the UK 
In the UK, HSV -2 prevalence ranges from 4-10% in the general population from 16-
69 years, with a trend of increasing seropositivity with age for both sexes (Vyse et ai., 
2000; Morris-Cunnington et ai., 2004). However the above studies did not include 
large numbers of samples from adults in London. Further studies are required to 
determine the burden of HSV-2 infection in the general popUlation of London. In 
selected populations in the UK, HSV -2 prevalence rates of 8% and 23% have been 
recorded among blood donors and STO clinic attendees respectively in London, with 
higher rates in homosexuals and females (Cowan et ai., 1994). This might be because 
females aged between 17-68 years comprised a large proportion of the cohort (42%) 
compared to heterosexuals (35%) or homosexuals (23%). In another study among 
STD clinic attendees in Manchester, UK, HSV-2 seroprevalence was 14% (10% in 
men, 19% in women) (Woolley et ai., 2000). Among genitourinary medicine clinic 
and antenatal clinic attendees in Middlesbrough, the prevalence of HSV -2 antibodies 
is 22% and 8% respectively (Opaneye & Bashford, 2002). These data suggest that the 
overall prevalence for HSV -2 infection is lower in the UK than in the USA, and that 
both countries show similar trends in age and gender associated risk for HSV-2 
infection. 
1.4.2.1 HSV-l as a cause of genital herpes 
Recently, the number of genital herpes cases caused by HSV -1 has been increasing. 
For example in the USA, of 1145 STO clinic attendees who had a positive diagnosis 
of genital herpes, 17% had HSV -1 isolated from genital ulcers, with greater 
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prevalence observed among men who have sex with men (47%) than women (21 %) or 
those of heterosexual orientation (15%). In addition, genital HSV-l infection was four 
times more likely to occur in individuals of white ethnicity than non-white ethnicity 
(Lafferty et al., 2000). Several European studies have explored the changing 
prevalence of HSV -1 and HSV -2 as a causative agent of genital herpes. Recently, 
HSV -1 has accounted for more than 50% of first-episode cases in England (Vyse et 
al., 2000). During the last decade, studies conducted in England (Sheffield, Newcastle 
upon Tyne, and Watford) and Scotland (Edinburgh, Fife and Glasgow) reported that 
HSV -1 accounted for 22-71 % of cases of genital herpes with raising rates evident in 
young female patients with first-episode disease (Woolley & Kudesia, 1990; Ross et 
al., 1993; Tayal & Pattman, 1994; Slomka et al., 1998; Thompson, 2000; Scoular et 
al., 2002). A study of GUM attendees in Edinburgh found that genital herpes due to 
HSV-l was more common in patients born in the UK (Ross et al., 1993). The reason 
for the increasing proportion of HSV -1 genital infections is speculative. Likely 
explanations include reduced HSV-I acquisition in childhood and an increase in oral 
sex practices the last two decades which would lead to oral and genital HSV-l 
infection in adults. 
1.4.3 Developing world 
Globally, genital herpes is the main cause of STO-related genital ulceration followed 
by syphilis and chancroid (Corey, 2000). In support of this observation, a study of 560 
patients with genital ulcer disease (GUO) in South Africa identified HSV-2 in 36% of 
all lesions, which made HSV-2 the most common cause of GUO (Chen et al., 2000). 
In sub Saharan Africa, HSV-2 prevalence is high with HSV-2 seropositivity rates 
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between 40-50% among 20 year olds in the general population despite HSV-l 
acquisition (Kamya et al., 1995; Greenblatt et al., 1988; Gopal et al., 2000). This 
might reflect the dynamics of sexual mixing between geographical regions and 
populations, age at first sexual intercourse, safe sexual practices, access to medical 
care and presence of other sexually transmitted infections. In addition, some 
serological assays may have varying specificities in different geographical 
populations which might explain geographical disparity in HSV seroprevalence rates 
(Hogrefe et al., 2002). 
1.4.3.1 HSV -2 prevalence in the general population 
In rural community studies in Mwanza, Tanzania 44% of women and 24% of men are 
HSV-2 seropositive. Seroprevalence was seen to increase with age at about 30 years, 
and reach a plateau of75% in women and 50% in men (del Mar Pujades Rodriguez et 
al., 2002) (Table 1.4). In rural Ugandan adults aged between 25-29 years, HSV-2 
seroprevalences of 74% and 45% have been observed among men and women 
respectively (Kamali et al., 2003). Cross-sectional surveys of four urban African 
populations in three cities found over 50% of women and over 25% of men to be 
HSV-2 seropositive in Yaounde, Cameroon; Kisumu, Kenya; and Ndola, Zambia 
(Weiss et al., 2001). HSV-2 seroprevalence was seen to increase with age and was the 
highest among 15-29 year olds. In Addis Ababa, Ethiopia, 61 % of women and 50% 
men were documented to be HSV-2 seropositive with predictors of HSV-2 infection 
being older age, increasing number of lifetime sexual partners and positive HIV-1 
serology (Mihret et al., 2002). 
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Table 1.4. HSV-2 seroprevalence in the general population in the developing 
world 
* Age % 
Country Cohort Sex n Ref (range) HSV-2+ 
Africa 
Uganda 
Random sample of 
F/M (l5-~45) Kamali et residents from 15 5411367 71136 
1990-1993 
neighbouring villages 
a/., 1999 
Gambia Random sample of rural Walraven et 
F (15-54) 1317 32 
1999 women a/., 2001 
Ethiopia 
(l5-~45) 
Mihret et 
General population 506 35 
1996 a/., 2002 
Del Mar 
Tanzania 
Sample of 12 rural 
1092 Pujades 
communities in the (15-54) 27 
1991-1994 Rodriguez 
Mwanza region 
et a/., 2002 
Central and South Asia 
Costa Rica Oberle et 
National, random sample F/M (25-59) 766 39 
1984-1985 a/., 1989 
Peru Sample of34 Konda et (18-30) 1635 25 
2000-2002 neighbourhoods a/., 2005 
Asia 
China Lo et a/., 
Random population F/M ~25 76175 18/17 
1995 1999 
*Age expressed as mean/median in years unless otherwise stated; F, female; M, male 
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1.4.3.2 HSV -2 prevalence among high-risk populations 
HSV -2 prevalence rates vary among high-risk populations (Table 1.5). A multi-centre 
study involving sex workers in four different African cities reported HSV-2 
prevalence rates of 91 % in Cotonou, 84% in Yaounde, 94% in Kisumu and 87% in 
Ndola (Morison et al., 2001). In Lagos, Nigeria the seroprevalence of HSV-2 among 
commercial sex workers (CSWs) is 59% (Dada et al., 1998). HSV-2 seroprevalence 
of 43% has been reported among STD clinic attendees in Dar-es-Salaam, Tanzania, 
with 63% of women and 36% of men being HSV-2 antibody positive (Langeland et 
al., 1998). 
The epidemiology of HSV -2 among populations in Central and South America differs 
from those of sub Saharan Africa. Among female sex workers (FSWs), 61 % from 
Mexico City (Conde-Glez et aI., 1999) and 86% from the Mexican-Guatemalan 
border (Uribe-Salas et al., 2003) are reported to be HSV-2 antibody positive. The 
prevalence of HSV -2 infection is documented to be much lower in Asia and the 
Indian sub-continent (ISC) than those in Africa or Central and South America (Weiss, 
2004). A study of HIV-1 negative patients in Pune, India reported 38% of male and 
51 % of female STD clinic attendees to have HSV -2 antibodies compared to 89% in 
FSWs (Reynolds et al., 2003). However, the study highlighted a number of potential 
limitations. Differential follow-up rates between high-risk individuals (those with 
commercial sex worker contacts and greater lifetime numbers of sex partners) and 
low-risk individuals could have resulted in bias. 
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Table 1.5. HSV -2 seroprevalence in high-risk populations in developing countries 
Age * 0/0 Country Cohort Sex (range) n HSV-2+ Ref 
Africa 
South Africa STD clinic attendees with FIM (15-65) 554 49 Chen et al., 1989-1993 GUD 2000 
South Africa Commercial sex workers F (NG) 416 84 Ramjee et al., (NG) 2005 
Nigeria Commercial sex workers F (12-50) 470 59 Dada et al., 1990-1991 1998 
Central African 
Mbopi-Keou Republic HIV -1 positive women F (15-48) 58 91 
1998-1999 et al., 2000 
Malawi HIV -1 positive factory M (18-~45) 279 88 Sutcliffe et 1998 workers al.,2002 
Nigeria Commercial sex workers F (15--~45) 796 59 Dada et al., 1992-1994 1998 
Tanzania STD clinic attendees with F/M 29 70 79 Mwansasu et Pre-2002 GUD al., 2002 
Tanzania STD clinic attendees FIM 27 294 43 Langeland et 1989-1993 al., 1998 
Cotonou (24-32) 433 91 Yaounde (22-34) 328 84 Morison et Kisumu Commercial sex workers F (21-30) 300 94 al., 2001 Ndola (20-28) 332 87 1997-1998 
Central and South Asia 
Mexico City Commercial sex workers F (16->37) 997 61 Conde-Glez 1992 et al., 1999 
Mexico Commercial sex workers F (15-47) 460 86 Uribe-Salas 1998 et al., 2003 
Chile STD clinic attendees F/M (14-70) 200 43 Martinez et 2003 al., 2005 
Asia 
India STD clinic attendees F/M <20-~30 2732 43 Reynolds et 1993-2000 al., 2003 
Bangladesh Commercial sex workers F >50 203 63 Rahman et 1998 (18-30) al .. 2000 
• expressed as mean/median in years unless otherwise stated; (NO) data not Age 
available; F, female; M, male 
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1.4.4 Risk factors for genital herpes 
Several epidemiological studies have estimated the risk of genital herpes acquisition 
to correlate with increasing number of sexual partners, older age, younger age of 
sexual intercourse, unprotected intercourse, past history of STDs, ethnicity, gender 
and socioeconomic status (Nahmias et al., 1990; Fleming et aI., 1997; Obasi et al., 
1999; Wald et al., 1997). A seroepidemiological survey of 40,000 sera from different 
populations on all five continents revealed an increase in risk of acquisition with 
increasing number of lifetime sexual partners (Nahmias et al., 1990). In a study in 
Milan, the prevalence of HSV-2 was 50% in individuals who had more than five 
sexual partners in the previous year, compared to 17% in those who had less than two 
sexual partners (Cusini et al., 2000). Similar findings have been reported in a study 
from Costa Rica, where 28% of monogamous women were seropositive compared to 
75% among those with four or more partners (Rodriguez et aI., 2003). The number of 
years of sexual activity can also increase HSV -2 acquisition (Breinig et al., 1990). 
Numerous studies have shown HSV -2 infection to occur more frequently inwomen 
than men (Gottlieb et al., 2004; Fife et al., 2004; Bunzli et al., 2004). This reflects 
more efficient male to female transmission and sexual contact with older partners who 
are more likely to be positive. However, the latter study had a 53% participation rate 
challenging the representation of the data. In addition, the limited age range (25-74 
years) in the study does not provide information about the HSV prevalence rates 
among adolescents (Bunzli et al., 2004). One prospective study of HSV-2 discordant 
monogamous couples found that the yearly rate of female to male transmission was 
4.5%, whereas that from male to female was 19% (Mertz et ai., 1992). Ethnic origin 
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has shown to influence HSV -2 seropositivity in many large-scale studies. The 
population-based AIDS in Multiethnic Neighbourhoods (AMEN) study, found highest 
HSV-2 seropositive rates in African-American women than Caucasian women and 
men (Siegel et al., 1992). In the USA, HSV-2 seropositivity was higher among black 
ethnicity (Armstrong et at., 2001; Fleming et at., 1997; Turner et at., 2003). However, 
these results must be interpreted with caution as with any statistical model, the 
estimates and confidence intervals are conditional on the assumptions of the model 
(Armstrong et aI., 2001). Increasing age is also associated with increased HSV-2 
seroprevalence. The seroprevalence of HSV-2 is nearly non-existent in individuals 
younger than 12 years of age with peaks occurring by 40 years. This identifies the age 
of acquisition as 15-40 years as expected for a STD (Johnson et at., 1989; Smith & 
Robinson, 2002). In contrast, HSV -1 seroprevalence rises in a linear fashion to 70 
years where approximately 20% of children aged 5 years and younger are HSV-l 
positive (Johnson et at. 1989). A recent study among women aged between 20-49 
years in Norway has shown HSV-2 prevalence to peak at 35 years (Kjetland et at., 
2005). Similar findings have been published elsewhere (Evans et at., 2003; Howard et 
at., 2003). The age-specific increase in HSV -2 prevalence probably reflects exposure 
to different sexual partners in early adulthood. 
1.4.5 Protective effect of condoms 
Inconsistent condom use has been reported among 300 male and female GUM 
attendees in the UK (Handy, 2004). Consistent with these findings, studies in Africa 
have shown occasional condom use in 14% of men and 17% of women (Maharaj & 
Cleland, 2004). A survey of sexual behaviour change among high risk groups in 
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Uganda, have shown little or no change in sexual lifestyle despite the HIV epidemic. 
Multiple sexual partners, minimal condom use in marital relationships, and 
unfaithfulness of spouses were incorporated in their lifestyle (Ntozi et a/., 2003). 
1.4.6 HSV -2 interaction with HIV-1 
Evidence suggests that HSV is a risk factor for the transmission of HIV and that HSV 
reactivation appears to regulate HIV replication. Possible mechanisms include the 
mucosal disruption leading to increased susceptibility to HIV -I and influx of CD4 
cells to herpetic ulcerations providing increased numbers of target cells for HIV-l 
attachment and entry in the genital tract during HSV-2 reactivation (Mbopi-Keou et 
a/., 2005). Several HSV proteins may also increase the expression of HIV-l (Golden 
et a/., 1992). Current studies have suggested HSV -2 to be the commonest 
opportunistic infection in HIV-l positive individuals with prevalence in developed 
countries reaching up to 90% in MSM and 40-60% in intravenous drug users 
(Schacker, 2001). As HSV is the most prevalent cause of GUD worldwide (Lafferty, 
2002) it is likely that this transmission synergy is an important factor in the spread of 
HIV -1. In terms of public health importance, understanding the potential role of STDs 
in the transmission of HI V-I, along with the identification of modifiable co-factors for 
HIV -1 transmission would have important implications for HIV control. 
1.4.6.1 The effect of HSV-2 on HIV-1 
Recent studies have highlighted the role of GUD including genital herpes as a risk 
factor for HIV-l infection (Greenblatt et al., 1988; Keet et a/., 1990; Ahmed et a/., 
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2003; Chen et al., 2000). A two to four fold increased risk of HIV-I acquisition has 
been reported in individuals with genital ulcer disease (Wald & Link, 2002). A meta-
analysis of 9 cohort and nested case-control studies showed that the population-
attributable risk percentages for HIV-I infection were 19% and 47% with a HSV-2 
seroprevalence of22% and 80% respectively (Wald & Link, 2002). 
Several reports have documented a strong association between genital herpes and 
HIV -I in several African countries suggesting an increase in genital herpes to be HIV 
driven (Reynolds & Quinn, 2005). A cross-sectional study conducted among 393 
urban women attending healthcare clinics in Zimbabwe, identified a two-fold 
increased risk in HIV-I acquisition in HSV-2 seropositive individuals compared to 
HSV -2 seronegative persons (Mbizvo et ai., 2002). In a Tanzanian study among HIV-
1 seropositive GUO patients, 71 % from Dar es Salaam and 46% from Mbeya were co-
infected with HSV-2 (Ahmed et ai., 2003). With recent population-based studies from. 
Africa suggesting 90% of individuals with HIV to be co-infected with HSV-2 (Obasi 
et ai., 1999; Gwanzura et ai., 1998), an understanding of the mechanisms underlying 
HIV-I and HSV-2 pathogenesis is essential. 
Studies elsewhere have reported HSV-2 seroprevalence in HIV-l infected individuals 
to range from 75% in pregnant women Seattle, USA (Hitti et ai., 1997) 64% in 
women and 54% in men in Frankfurt, Germany (Rabeneau et ai., 2002) 65% among 
STO clinic attendees in Korea (Kim et ai, 2003), to 91 % in women in Bangui, Central 
African Republic (Mbopi-Keou et ai., 2000). In Melbourne, Australia 61 % of HIV-l 
infected MSM are seropositive for HSV -2 compared to 20% in HIV -1 negative 
persons (Russell et ai., 2001). However discrepancies in data could have arisen as the 
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HIV positive population were older and had a greater number of sexual partners 
compared to HIV negative counterparts. Furthermore the study reported a sizeable 
amount of missing data (12%) specific to the sexual behaviour which could account 
for statistical differences. Among HIV -1 positive heterosexual men in Baltimore, 
USA 63% had a positive HSV-2 antibody status compared to 47% HIV-l negative 
men (Hook et aI., 1992). When compared to women, 78% of HIV -1 infected women 
had a HSV-2 infection compared to 58% in HIV-l uninfected persons (Hook et al., 
1992). These finding demonstrate a high level of co-infection with HSV -2 and HIV-l 
and highlight the importance of HSV-2 in the risk of HIV-l acquisition and 
transmission. 
Genital lesions have been identified as a major risk factor for HIV-l transmission in a 
series of studies conducted in Africa (Kreiss et al., 1989; Cameron et al., 1991). The 
frequency of HSV -2 clinical recurrence and asymptomatic shedding is much higher in 
HIV-l infected individuals than un-infected individuals (Posavad et al., 2004) with 
evidence of HIV -1 shed at high levels in most genital lesions (Kreiss et al., 1989; 
Cameron et al., 1991). These data indicate complex interactions to exist between the 
two viruses and suggest genital herpes to play an important role in the dynamics of 
HIV -1 infection. 
1.4.6.2 The effect of HIV -1 on HSV-2 
HIV-l acquisition is increased in heterosexual men (RR, 2.2; 95% CI, 1.3-3.8) and 
MSM (RR, 2.1; 95% cr, 1.3-3.4) who HSV-2 seropositive. Several studies in 
Zimbabwe and Uganda have demonstrated a four to five-fold increased risk of HSV-2 
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acquisition in persons who are HIV-l positive (McFarland et at., 1999; Kamali et at., 
1999). However information acquired from these studies was limited due to 
population size. In addition the timing of seroconversion for both infections were not 
demonstrated and precise measures of sexual behaviour, sexual exposures, period of 
active genital lesions, viral replication, viral shedding, and physical examinations were 
lacking. In a recent prospective study assessing the risk of HIV -Ion STD acquisition 
in Mombasa, Kenya, HIV -1 infection was highly associated with a significantly 
higher incidence of GUD (McClelland et at., 2005). 
The frequency and severity of HSV-2 shedding has shown to be higher in HIV-l 
infected individuals (Augenbraun et at., 1995). Asymptomatic and symptomatic HSV-
2 shedding is four times more frequent in HIV -1 infected women than in control 
groups, with higher levels shed in women with low CD4 counts (Augenbraun et at., 
1995). Rates of HSV -2 shedding in the oral cavity and genital tract of HIV -1 infected 
women were 70% and 79% respectively (Augenbraun et at., 1995). The above 
findings need to be interpreted with caution as HSV -2 shedding measured at a single 
time point may not necessarily indicate overall shedding rates. It therefore remains 
plausible that a gr~ater proportion of patients may have shed the virus on days 
preceding or following clinical evaluation. Among pregnant HIV -1 positive women 
HSV -2 shedding at delivery may be four times more common in (Hitti et at., 1997). 
Among HIV-l infected MSM, HSV-2 shedding may be six times more frequent than 
uninfected individuals (Schacker et at., 1998a). HSV-2 shedding has shown to occur 
in l()% of 4167 days for HIV -1 positive men compared to 3% of 766 days for HIV-l 
negative men (Schacker et at., 1998a). In addition, symptomatic recurrences and HSV 
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acyclovir-resistant virus strains were also more prevalent In HIV -infected men 
(Severson & Tyring, 1999). 
HIV-1 has also been isolated from genital ulcers (Cameron et al., 1989). In a study of 
HIV-1 infected HSV-2 seropositive men, HIV-1 RNA was isolated from 25/26 genital 
herpes episodes and on 66% of days (Schacker et al., 1998b) which suggest that 
herpetic lesions may facilitate the spread of HIV -1. 
1.4.6.3 Biological mechanisms underlying the HSV -2 and HIV -1 synergy 
Many theories have been put forward to elucidate the mechanism for increased HIV-1 
infection during HSV -2 reactivation. Genital ulcers may provide a portal of entry for 
HIV -1, while ulcers in HIV -1 infected individuals may shed HIV -1 in ulcer exudate 
(Levin, 1993). The deposition of HIV-l infected genital fluids on to the HSV-2 
infected epithelial site may be enough to initiate HIV -1 infection. In addition, the 
disruption of the epithelial barrier by HSV -2 reactivation and infiltration of activated 
CD4 positive cells and macrophages to the herpetic lesion may create an ideal 
microenvironment for HIV -1 replication. 
One study reported co-infection of human CD4 positive cells with HSV -2 and HIV-1 
resulted in unidirectional accelerated replication of HIV -1 (Kucera et al., 1990). The 
degree of immunosuppression influenced by HIV -1 infection is thought to influence 
HSV-2 reactivation. There is a direct relation between CD4 positive cell count and the 
rate of HSV -2 reactivation. In a study of 68 HIV -1 positive men, the OR of anogenital 
HSV -2 shedding among those with a CD4 positive count of <200 cells/mm3 was 2.5 
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(95% CI, 1.1-5.4) when compared to a positive CD4 count of >500 cells/mm3 (Corey 
et a/., 1983; Schacker et a/., 1998a). In addition, HIV-l infection and the resultant 
loss of immune function are associated with an increased severity and duration of 
HSV lesions, as well as increased frequency and duration of HSV -2 reactivation 
(Schacker et a/., 1998a). There also is supporting evidence from studies that show 
HSV-2 and HIV-l also interact at a molecular level, and up-regulate HIV-l 
replication through the long-terminal repeat (LTR) region (Golden et a/., 1992). 
1.5 HOST RESPONSES TO HSV-2 
1.5.1 Immune mechanisms 
T cells are classified into CD4 and CD8 cells with an additional subdivision of CD4 
helper cells into T helper (Th) I and II types. CD4 cells may be further classified into 
those with a Th 1 pattern of cytokine secretion and those with a Th2 pattern. The Th2 
pattern is predominantly characterised by the secretion of cytokines including IL-4, 
IL-5 and IL-13 and the production- of antibodies. The Thl pattern leads to the 
production of cytokines such as IFN- 'Y, IL-12 and TNF-a, and leads to the activation 
ofCD8 T-cells through IL-12 and IFN- 'Y. 
Development of specific T-cell and B-cell immune responses against HSV antigens 
takes several days. Innate mechanisms of immunity include interferons (lFN), 
macrophages and natural killer cells which form the first line of defence (Cunningham 
& Mikloska, 2001). In addition, neutral ising antibodies and specific T lymphocytes 
with cytotoxic activity secrete antiviral cytokines. Immune mechanisms in recurrent 
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HSV-2 genital infection are activated quickly, leading to shorter duration of lesions 
and viral shedding. In recurrent infections, the median duration of lesions and viral 
shedding are 10 days and 4 days respectively, compared to 21 days and 10 days in 
primary infections (Corey, 2002). 
Several studies have highlighted the role of T-cell responses in HSV disease (Koelle 
& Corey, 2003) (Figure l.5a, Figure 1.5b). Immune evasion by HSV is thought to 
occur by the down-regulation of MHC class I responses, via an inter-play with HSV 
infected cell protein ICP47 and transporter associated with antigen presentation (TAP) 
molecule (Figure 1.6). This results in the infected cell escaping the scrutiny of 
cytotoxic CD8 lymphocytes (Koelle & Corey, 2003). Studies on biopsies of human 
recurrent HSV lesions have shown that CD4 cells and macrophages infiltrate around 
the infe~ted cell (Cunningham et a/., 1985). CD4 cells producing interferon-y (lFN- y) 
has been detected in vesicle fluid as demonstrated in several studies (Cunningham et 
a/., 1985; Cunningham & Merigan, 1984; Torseth & Merigan, 1986). IFN- Y can 
restore MHC class I expression on the epidermal surface and increase the cellular 
production of TAP leading to MHC class II expression. Cells expressing MHC class 
II can be recognised by specific activated CD4 resulting in the increased prod~ction of 
IFN- y mediated by CD8 cells (Cunnigham & Noble, 1989) (Figure 1.6). MHC class I 
expression allows recognition by CD8 cells which destroy virus infected cells 
(Mikloska et a/., 1996). 
Cytokine production within herpetic lesions are critical for controlling HSV-2. 
Similarly, the role of CD8 cells in controlling HSV-l infection in the trigeminal 
ganglia has been reported (Decman et a/., 2005; Liu et a/., 2001; Khanna et a/., 2004). 
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Elevated levels of IFN-y and TNF-a transcripts in latently infected trigeminal ganglia 
has shown TNF-C\' to synergize with IFN-7 in controlling HSV- I replication in vitro 
and in vivo (Theil et al., 2003 ; Feduchi et al. , 1989; Paludan et al., 200 t). It is thought 
that HSV glycoprotein gD induces TNF-;x. secretion in macrophages and that po t-
entry events are required for full induction (Paludan et al., 200 1). 
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followed by transportation through the Golgi appara tus to the endo orne for further 
fragmentation . Association of exogenous peptide fragments with cia s 11 MH 
molecules and their transportation to the cell surface. 
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1.5.2 Immune pathways and HIV-l 
In order for a virus to establish an infection in a host, a series of coordinated events 
are required to circumvent specific and non-specific host defences. Upon infection 
among healthy individuals CD4 lymphocytes secrete cytokines either via a Th 1 or 
Th2 pathway. The Thl pathway involves interleukin-12 (IL-12), tumour necrosis 
factor (TNF) or IFN-y. The Th2 pathway comprises neutralising antibody secreted by 
B cells, or by both. The Th 1 pattern activates CD8 cells through interleukin-12 (IL-
12) and IFN-y. This is an important controlling factor since T-cells may eradicate 
infected cells. IFN-y has a critical role in up-regUlating MHC class I and II on infected 
cells and activating macrophages. Hallmarks of this pathway are prominent in 
herpetic lesions, with the induction of MHC class II (Cunningham et al., 1985). A 
recent study in the USA investigating HSV -specific immune response in subjects with 
no reported history of genital herpes found 25% of HSV -seronegative persons to have 
HSV -specific CD4 and CD8 T cells (Posavad et al., 2003). Clinical and experimental 
data have shown HSV -2-specific CD8 lymphocytes to localize at the site of recurrent 
HSV -2 genital lesions (Koelle et al., 1993; Koelle et al., 1994). The clearance of 
infectious virus from lesions has shown to be temporally correlated with the 
infiltration of CD8 T cells and HSV -specific lymphocytes (Koelle et al., 1998). 
Similar observations on the inhibition of HSV -1 replication in latently infected cells 
of the trigeminal ganglia in murine models have also been documented (Decman et 
al., 2005; Liu et al., 2000). 
HIV -1 curtails the immune system, by destroying CD4 infected and uninfected 
bystander cells. In the first few weeks after HIV -1 infection, the numbers of CD4 cells 
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decline while those of CD8 rise sharply (Pattanapanyasat & Thakar, 2005). The half-
life of most HIV-l infected T cells in vivo is 12-36 hours (Ho et a/., 1995). The 
decline in immune function governed by the loss of CD4 cells is thought to make the 
host susceptible for opportunistic infections, although the specific mechanisms 
underlying the loss of CD4 cells and the varied susceptibility of HIV -1 infected 
individuals to HSV-2 infections still remains unclear (Pattanapanyasat & Thakar, 
2005). Apoptosis is thought to contribute towards T-cell destruction, as elevated 
levels of apoptosis have been found to correlate directly with disease progression and 
inversely with Th cell counts (Gougeon et a/., 1996). HIV proteins gp120, Tat, Nef 
and Vpu have been shown to induce cell, death in uninfected CD4 cells (Paranjape, 
2005). Syncytium formation of infected and uninfected cells stimulated by gp 120 can 
also contribute to cell death (Alimonti et a/., 2003). In addition, continuous budding 
of viruses from infected cells may cause membrane disruption and increased 
permeability leading to the death of the cell. 
HIV -1 infection and subsequent immunosuppression in individuals provide a unique 
model system to study critical immune functions necessary for control and resolution 
of human HSV infections. One hypothesis is that quantitative differences in specific T 
cell responses to HSV -2 may determine the development of genital herpes (Posavad et 
a/., 1997). In a cross-sectional study of individuals co-infected with HIV-l and HSV-2 
in Washington, USA, the frequency of HSV-specific CD8 cells was correlated 
inversely with the severity of recurrent anogenital HSV-2 infection (Posavad et a/., 
1997). Another study documented T cell activity to be low among cells derived from 
early culture-positive lesions, than those at later stages. In addition, viral clearance 
from the lesion was associated with a high level of local cytolytic activity (Koelle et 
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at., 1998). The data generated from this study was limited by technical differences. 
Sampling only a portion of the herpes lesion may have missed T cells that localized to 
a fine region, and that some cells present in biopsies may have failed to expand within 
the culture conditions used in the study. 
Several studies have demonstrated HIV-I positive individuals have significantly 
lower HSV -specific proliferative responses compared to HIV -I negative HSV 
seropositive patients (Hersh et at., 1985; Wainberg et at., 1987). This observation has 
been correlated with absolute CD4+ lymphocyte counts (Hersh et al., 1985; Carrega et 
at., 1995). A study in Washington, USA showed the frequency of HSV -specific CD8 
lymphocyte precursors in HSV-HIV-I co-infected individuals to be significantly 
lower than in HIV -1 negative HSV seropositive individuals (P = .0005) (Posavad et 
at., 1997). In the same study, HIV-l infected patients who suffered more severe 
genital herpes recurrences had significantly lower HSV -specific CD8 lymphocyte 
precursor frequencies than those patients with mild recurrences (P = 0.03). 
Data on highly active antiretroviral therapy (HAART) in HIV-I infected persons has 
demonstrated suppression of HIV -I replication, with subsequent increases in memory 
and naive CD4 lymphocyte responses (Posavad et a/., 2004). There is very limited 
data on the effect of HAART on the host immune responses to HSV-2, and its 
association with HSV-2 reactivation and shedding. Recent data has shown HAART 
does not significantly reduce the frequency of mucosal HSV shedding in HIV-I 
infected persons however, it does improve clinical HSV disease by reducing the 
percentage of days HSV lesions were presented (Posavad et a/., 2004). A key to 
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understanding the immune mediators of infection among both these viruses may assist 
in guiding potential preventive strategies. 
1.6 ANTIVIRAL MANAGEMENT OF HSV-2 INFECTIONS 
Antiviral therapy has shown to decrease viral shedding and symptoms associated with 
HSV infection. Nucleoside analogues such as acyclovir are mono-phosphorylated by 
viral thymidine kinase (TK) and subsequently converted to di and triphosphate forms 
by host enzymes. Acyclovir triphosphate can then compete with the substrate for 
HSV-encoded DNA polymerase causing termination of HSV DNA replication. 
Acyclovir has been shown to reduce HSV-2 asymptomatic shedding. In a double-
blind placebo-controlled trial of women with a history of genital herpes for <2 years, 
acyclovir at 400mg administered twice daily for 70 days was shown to reduce HSV-2 
sub-clinical shedding (Wald et al., 1996). Similarly, val acyclovir has shown to reduce 
sub-clinical shedding from 15.3% of days to 0.7% days in men and women (Wald et 
al., 1996). Famicyclovir has shown to suppress asymptomatic shedding in women 
with a history of genital herpes (Sacks, 2004). 
The transmission of HIV-l and HSV-2 may be possibly reduced by antiviral agents 
which decrease virus shedding and virus load (Celum, 2004). A meta-analysis of 8 
controlled trials showed acyclovir offered substantial survival benefit in HIV-l 
infected patients (Ioannidis et al., 1998). It has been suggested that a reduction in 
HSV infection may lead to suppression of HIV -1 replication (Severson & Tyring, 
1999). The suppression of HSV by acyclovir may also reduce HIV-l RNA levels 
(Schacker et al., 1998a). Data assessing the impact of highly active anti-retroviral 
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therapy (HAART) on HSV-2 shedding is limited. One recent study demonstrated that 
HIV-I infected individuals on HAART to have significantly fewer days with HSV 
lesions compared to un-treated individuals (Posavad et al., 2004). The possible use of 
anti-viral treatment in conjunction with improved STI management provides a viable 
strategy in controlling the HIV-l and genital herpes epidemic. 
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2. Chapter 2. Materials and Methods 
2.1. SPECIMENS 
2.1.1 Genital swabs 
Genital swabs were collected from GUM patients with suspected genital herpes 
attending Kings College Hospital, London and placed in 2.5 ml of virus transport 
medium (VTM) containing minimal essential medium (MEM). MEM constitutes 
Earle's salts and 25 mM Hepes buffer containing 2 mM L-glutamine, penicillin (l00 
U/ml), streptomycin (100 Ilg/ml) (BioWhittaker Europe, Berkshire, UK) and 10% 
(v/v) heat inactivated foetal bovine serum (FBS) (Sigma Aldrich, Dorset, UK). The 
VTM was balanced with 25 mM Hepes (BioWhittaker Europe, Berkshire, UK) 
supplemented with 10% bovine serum albumin (BSA), 7.5% sodium bicarbonate, 
penicillin (500 U/ml), streptomycin (1 mg/ml) and amphotericin B (5 Ilg/ml). After 
collection, the samples were vortexed for 30 seconds and aliquots of 500 III were 
either used immediately for virus isolation or stored at -80°C for PCR and sequencing. 
2.1.2 Serum samples 
Blood specimens (7.5 ml) were collected in serum collection tubes (Sarstedt, 
Leicester, UK) from HIV -1 infected and uninfected individuals attending the Royal 
Free Hospital, London. Whole blood samples were centrifuged at 1500 x g for 15 
min, serum isolated and stored at -20"C. 
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2.1.3 PBMC 
Blood samples (15 ml) were collected in preservative-free sodium heparin tubes 
(Sarstedt, Leicester, UK) for the isolation of PBMC from HIV -1 negative volunteers 
and HIV -1 infected individuals at different stages of HIV -1 disease from the Royal 
Free Hospital, London: long-term non progressors, recently diagnosed HIV -1 patients 
prior and following HAART and HIV-l patients already on HAART. Isolation of 
PBMC was performed as described (Section 2.7.1). 
2.2 VIRUS ISOLATION IN CELL CULTURE 
African green monkey kidney (VERO) cells were used for HSV isolation in cell 
culture. Vero cells were grown in MEM growth medium in a humidified atmosphere 
of 5% CO2 at 3TC and were passaged twice weekly prior to reaching confluency. 
Passaging was performed by rinsing the cell monolayers with sterile phosphate 
buffered saline (PBS) followed by trypsinisation for 5 min with 5 ml of Trypsin 
(0.05%)/EDTA (0.01%) solution (Gibco BRL, Paisley, UK). Upon detachment of 
cells from the flask surface, the cells were re-suspended in MEM/I0% FBS at a ratio 
of 1:2 or 1:3. 
Cells were inoculated with 200 III of specimen and monitored daily for the 
development of cytopathic effect (CPE). Cultures were maintained for 10 days. CPE 
was characterised by the presence of syncytia and formation of giant cells visualised 
through a light microscope. 
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2.2.1 Direct Immunofluorescence Test 
HSV-l and HSV-2 infected cell cultures were examined for CPE. Upon observation 
of a CPE, the infected Vero cells were washed with PBS, scraped off the culture flask 
and dried on to a Teflon coated slide and air-dried. The slide was then fixed in cold 
acetone for 10 min at 4°C, and 15 J.ll of fluorescein-labelled purified murine 
monoclonal antibodies against HSV-l and HSV-2 (Syva Microtak, Palo Alto, USA) 
were added to each well of the slide. Antibody incubation was carried out in a 
humidified chamber for 15 min, and excessive reagents were washed off by rinsing 
with PBS for 10 sec. The slides were air-dried and mounted with buffered glycerol 
and examined under a fluorescent microscope. Positive staining for HSV was 
identified by green fluorescent staining in the cells. No blind or direct staining on 
patient specimens was performed. 
2.3 PREPARATION OF VIRAL LYSATES 
HSV-l (Maclntyre strain) and HSV-2 (MS strain) (Microbix Biosystems Inc, Ontario, 
Canada) strains were grown in Vero cells with MEM/I0% FBS. Culture supernatants 
were clarified by centrifugation at 500 x g for 15 min. The pellet of infected vero cells 
were mechanically disrupted, rinsed with sterile PBS, and suspended in detergent 1 % 
Triton X-I 0011 mM phenylmethylsulfonylfluoride (PMSF)/O.1 % sodium dodecyl 
sulphate/50mM Tris (pH 8.0). Concentrations of lysates were determined by a protein 
assay based on bicinchoninic acid (BCA) (Pierce Biotechnology, Illinois, USA). The 
protein assay was performed using a series of dilutions of known concentrations of a 
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common protein such as Bovine serum albumin (BSA). Dilutions of stock BSA (2 
mg/ml in 0.9% saline and 0.05% sodium azide) were made at 0, 25, 125, 250, 500, 
750, 1000, 1500 and 2000 Ilg/ml according to manufacturer's instructions. Working 
Reagent was also prepared by mixing 50 parts ofBCA Reagent A (500 ml containing 
sodium carbonate, sodium bicarbonate, binchoninic acid and sodium tartrate in 0.1 M 
sodium hydroxide) to 1 part of Reagent B (25 ml containing 4% cupric sulphate) 
according to manufacturer's instructions. BSA standard, HSV-1 and 2 lysates (25 Ill) 
and working reagent (200 Ill) were added to individual wells of a microplate. The 
plate was mixed thoroughly on a shaker for 30 sec, covered, incubated at 3 TC for 30 
min and cooled at room temperature. The absorbance was measured at 562 nm on a 
plate reader. A standard curve was plotted using the average blank corrected 
measurements for each BSA standard versus its concentration in mg/ml, and this was 
used to determine the concentration ofHSV-1 and 2 lysates. Virus lysates were stored 
at 1 mg/ml at _80 DC until further use. 
2.4 DETECTION OF HSV ANTIBODIES 
2.4.1 Enzyme immunoassay (EIA) 
The HSV-1 and HSV-2 antibody status of individuals was determined using a 
modified HSV type-specific IgG EIA (Focus Technologies, Cypress, USA). The 
reagents were brought to room temperature prior to use. The pre-coated polystyrene 
plate containing glycoprotein G antigen, was soaked with 100 III of IX wash buffer 
solution (lOX solution containing PBS with 0.01% thimerosal) for 5 min and then 
decanted. Serum samples, controls (negative sera, low positive sera, high positive sera 
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and a cut-off calibrator provided by the manufacturer) were diluted 1: 101 using 
sample diluent (surfactant in protein-based PBS with 0.001 % gentamicin and 0.01 % 
thimerosal). A blank containing sample diluent alone was used. To appropriate wells, 
100 J.lI of sample diluent and 100 J.lI of diluted serum samples and controls were 
added. The plate was covered, incubated at 25°C for 60 min to allow specific antigen-
antibody binding and washed three times with 100 J.lI of 1 X wash buffer to remove 
non-specific reactants. To each well, 100 J.lI of IgG conjugate (affinity-purified 
peroxidase-conjugated goat anti-human IgG, with 0.05% thimerosal) was added to 
react with specific IgG. The plate was covered, incubated at 25°C for 30 min and 
washed a further 3 times with IX wash buffer as previously described. To each well, 
100 J.l1 of substrate reagent (tetramethylbenzidine and hydrogen peroxide in buffer) 
was added and the plate incubated at 25°C for 10 min for colour development. The 
reaction was stopped after by adding 100 J.lI of 1 M SUlphuric acid. The absorbance 
was read at 450 nm by a microwell spectrophotometer and index values calculated by 
dividing the optical density of the specimen by the optical density of the cut-off 
calibrator. The cut-off for a positive result was raised from 1.1 (recommended by the 
manufacturer) to 3.1 to increase specificity. Samples with index values between 0.9 
and 3.0 were scored as equivocal. 
2.4.2 HSV avidity assay 
Frozen sera were thawed and sera were tested using a modified protocol of the HSV-2 
type-specific IgG EIA (Focus Technologies, Cypress, USA) as described above 
(Section 2.4.1). Once all the reagents were brought to room temperature, serum 
samples were vortexed and 2.5 J.lI of each serum sample was diluted 1: 101 with 250 
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III of sample diluent, provided in the HSV-2 EIA kit. Diluted sera (100 Ill) were 
added to duplicate wells of the plate. The plate was incubated as described above, and 
processed with an additional wash step before the addition of the conjugate. The plate 
was washed with IX wash buffer (200 Ill) to one set of duplicate wells, and 200 III of 
Urea buffer [Tris (50 mM/L), urea (6M/L), sodium azide (0.9g/L); pH 7.4] was added 
to the other wells. After 5 min, the wells were washed twice with 1 X wash buffer, 
conjugate and substrate added, and the plate read as described above (Section 2.4.1). 
Each sample had 2 optical density values: one from the untreated specimen and one 
from the urea buffer treated specimen. Index values for the untreated specimens were 
obtained by dividing their optical density value by the optical density mean of the cut-
off calibrator. To obtain the avidity value, the optical density of the treated specimen 
was divided by the optical density of the untreated specimen and multiplied by 100. 
HSV -2 index values were established using a previously published avidity assay 
based on the HerpeSelect HSV-2 EIA (Morrow et a/., 2004). Samples with HSV-2 
index values> 3 were considered positive, and those with index values between 0.9 
and 3.0 were scored as equivocal. 
2.4.3 HSV -2 Inhibition EIA 
Prior to the EIA, the sera was diluted 1 :50 and 1 :200 using HerpeSelect sample 
diluent (surfactant in protein-based PBS with 0.001% gentamicin and 0.01% 
thimerosal) and then diluted with an equal volume of either HSV-l or HSV-2 lysates 
(1 mg/mt) (Section 2.3). The samples were incubated for 60 min on a shaker at room 
temperature. The samples were then added to the wells of the HSV -2 EIA, incubated 
for 60 min at room temperature followed by the addition of conjugate and substrate. 
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The plate was read at 450 nm and index values calculated as previously described. 
Percent inhibition due to pre-incubation with HSV-2 lysate was determined by the 
formula [1 - (index of HSV-2 lysate well/index of HSV-l well)] X 100. Samples 
showing inhibition ::::60% with HSV-2 but not with HSV-l lysates in two independent 
assays were scored as HSV-2 positive. 
2.4.4 Immunoblot 
The HerpeSelect Immunoblot (Focus Technologies, Cypress, USA) was used to 
confirm positive and equivocal results generated by the HSV -lor HSV -2 EIA. The 
assay employs the use of individual nitrocellulose membrane strips immobilised with 
native HSV gG-1 or gG-2. All reagents were brought to room temperature before use. 
A IX wash buffer solution was prepared from a lOX concentrate (surfactant in PBS 
with 0.1% azide). This was used to make the specimen buffer, by adding 100 ml of 
IX wash buffer to 4 grams of blotting powder (non-fat dry milk). Each strip was 
washed in 2 ml of IX wash buffer for 5 min on a shaker. To each strip, 2000 III of 
specimen buffer and 20 III of specimen or control were added. The strips were 
incubated at room temperature for 60 min on a shaker to allow antigen-antibody 
binding. Following decantation, the strips were washed using 2000 III of IX wash 
buffer for 3 min on a shaker. To each well, 2000 III of IgG conjugate (alkaline 
phosphatase-conjugated goat anti-human JgG, with 0.1 % azide) was added, incubated 
for 30 min at room temperature on a shaker, decanted and washed thrice with IX 
wash buffer as previously described. Band formation was observed upon addition of 
2000 III of substrate reagent (bromo-chloro-indolyl phosphate and nitroblue 
tetrazolium) to each strip on a shaker for 30 min. Colour development was stopped by 
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decanting the substrate solution and rinsing the strips five times with de-ionised 
water. Strips were then dried on filter paper. Reactivity was interpreted as gG-l gG-
2, HSV common antigen and anti-human serum bands (Figure 2.1). 
Anti-human serum band 
HSV common antigen band 
gG-I band 
gG-2 band 
Figure 2.1. Band interpretation of HerpeSelect 1 and 2 immunoblot IgG 
2.4.5 gG-2 monoclonal antibody blocking EIA 
To further validate our assay, a random subset of 50 sera was sent to the Health 
Protection Agency (HPA) (Colindale, London, UK) for HSV -2 testing by an in-hou e 
gG-2 monoclonal antibody (mAb)-blocking ErA. Briefly, wells of the plate were 
coated with HSV-2 extracts in PBS (\ :25 dilution) for 12 hours at 4° . Plates were 
washed with detergent (1.5% Triton X-IOO and 0.5% Nonidet P-40 in PBS) for 30 
min at 25°C followed by incubation with 10% FCSIPBS for 2 hour at 37°C. The 
plate was further incubated for 1 h at 37° with 10% FCSIPBS and 0.2% Tween 20. 
Dilutions of controls and test sera were as follows: a 1:4 dilution of te t era, a 
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1:16000 dilution of HSV-2-specific monoclonal antibody, and a 1:1,000 dilution of 
horseradish peroxidase-conjugated anti-mouse monoclonal antibody. Plates were 
washed three times between each stage using 0.05% Tween 20 in PBS for 30 min at 
25°C. Colorimetric detection was done using TMB substrate at room temperature in 
the dark. Colorimetric reaction was stopped after 20 min by the addition of 2M 
sulphuric acid. The OD was measured at 450 nml620 nm for reference. The percent 
blocking of each serum was calculated by comparison with controls and with the 
mean OD450/62o of four wells containing a positive control serum as described in a 
previously published protocol (Gopal et ai., 2000). Sera were considered positive for 
HSV-2 antibody if they gave a blocking value of~50%. 
2.5 HSV DETECTION BY PCR 
2.5.1 Specimen preparation 
For the detection of HSV DNA in genital swabs, three different techniques for 
specimen preparation were employed prior to polymerase chain reaction (peR). 
2.5.1.1 Manual DNA extraction 
The QIAamp DNA mini kit (Qiagen, West Sussex, UK) was used to extract HSV 
DNA from genital specimens, following a modified protocol. To a 200 III aliquot of 
genital specimen, 20 III of Qiagen Protease, and 200 III lysis Buffer AL were added 
and vortexed for 15 sec. To improve extraction in samples with low DNA copy 
numbers, an aqueous solution of 1 III of poly dA (5 Ilg/1 Ill) (Amersham Biosciences, 
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Buckinghamshire, UK) was added during lysis. Following incubation at 56°C for 10 
min, lysed samples were centrifuged briefly at 150x g for 2 min and 230 J.lI of 99% 
ethanol added to the pellet to improve extraction. The lysed specimens were pulse-
vortexed for 15 sec, further centrifuged at 150 x g for 2 min and carefully applied to 
the QIAamp spin column. The collection tubes containing the filtrate were discarded. 
To the column, 500 J-ll of buffer AWl was added, and the column centrifuged at 6000 
x g for 1 min. Filtrate in the collection tubes was discarded, and 500J-ll of buffer AW2 
was added. The columns were centrifuged at 20000 x g for 3 min, and the filtrate 
discarded. DNA from the column was eluted in 60 J.lI of de ionised water (Sigma, 
Dorset, UK), incubated at room temperature for 5 min, and centrifuged at 6000 x g for 
1 min. The DNA filtrate was stored at -80°C. 
2.5.1.2 Automated DNA extraction 
The MagNA Pure LC (Roche Diagnostics, East Sussex, UK) is a robotic DNA 
extraction system involving magnetic glass particle technology. Automated pipetting 
of samples (200 J-lI) was carried out by the MagNA Pure LC Total Nucleic Acid 
Isolation kit (Roche Diagnostics, East Sussex, UK). Each run had 4 negative controls 
and DNA was eluted in 100 J-li of deionised water and stored at -80°C. 
2.5.1.3 Virus precipitation 
Virus precipitation was performed by adding 200 J.lI of the genital specimen in VTM 
to a mixture of 2.5M NaCI (25 J.lI) and 20% PEG 8000 (25 J-lI). The mixture was 
vortex ed, incubated on ice for 30 min, and centrifuged at 11,000 x g for 20 minutes at 
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4°C. The supernatant was aspirated, pellet re-centrifuged at 4°C for 5 minutes. The 
supernatant was aspirated and the pellet was re-suspended in 20 /-11 of de-ionised water 
and stored at -80°C. 
2.5.2 Real-time PCR 
Real-time PCR by LightCycler technology (Roche Diagnostics, East Sussex, UK) was 
used to type HSV isolates by PCR amplification of the DNA polymerase gene. This 
method used high temperature transition rates (20°C/sec) in specially designed glass 
capillary reaction vessels. Real-time monitoring of amplified product was performed 
using a pair of fluorescently labelled hybridisation probes in close proximity « 5 
nucleotides separation) results in fluorescence resonance energy transfer (FRET) 
between the fluorophores. The amount of fluorescence measured was proportional to 
the amount of specific PCR product in the reaction mix. PCR quantification can be 
performed by determining the crossing point value. The crossing point is the cycle at 
which PCR amplification begins its exponential phase and is proportional to the 
logarithm of the initial concentration. As the crossing-point value increases, the 
starting concentration of sample target sequence decreases. Typing was characterised 
by melting curve analysis. 
2.5.2.1 PCR preparation and amplification 
HSV DNA from genital swabs was used as a template for PCR amplification 
reactions using primers specific for the 215 base pair region of the DNA polymerase 
gene. The PCR protocol was modified from a previously described method (Burrows 
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et a/., 2002; Espy et a!., 2000). Amplification was performed using the Roche LC Fast 
Start DNA Master Hybridisation Probe kit (Roche Diagnostics, East Sussex, UK). 
Briefly, 60 III of LightCycler FastStart Reaction Mix Hybridisation Probes was added 
to the vial containing LightCycler FastStart enzyme (HotStart reaction mix 
containing Taq DNA polymerase, reaction buffer, DNTP mix with dUTP instead of 
dTTP and lOmM magnesium chloride) followed by gentle mixmg. To this, 
magnesmm chloride (4 mM), forward (HSV POL F 5'-
GCTCGAGTGCGAAAAAACGTTC-3') and reverse primers (HSV POL A 5'-
TGCGGTTGATAAACGCGCAGT-3') (5 flM) and two fluorescently labelled 
hybridisation probes HSV-2 FLU (5'-gCgCACCAgATCCACgCCCTTgATgAgC-
FAM-3') and HSV-2 LCR (5'-LC Red 640-CTTgCCCCCgCAgATgACgCC-
phosphate-3') (1 flM) were added (Table 2.1). A total volume of 20 fll was obtained 
by adding 5 fll of DNA or precipitated virus to a PCR reaction mix in glass 
capillaries. 
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Table 2.1. Reaction components and volumes for DNA amplification by the 
LightCycler 
Components 
FastStart DNA Master Hybridisation Probe 
HSV forward primer (5/lM) 
HSV reverse primer (5 /lM) 
HSV FLU Probe (1 /lM) 
HSV LCR probe (1 /lM) 
Magnesium chloride (4mM) supplied in the LC FastStart DNA 
Master Hybridisation Probe kit 
De-ionised water supplied in the LC FastStart DNA Master 
Hybridisation Probe kit 
DNA 
Total volume 
- 64-
Volume btl) 
2.0 
2.0 
2.0 
2.0 
2.0 
2.4 
2.6 
5 
20 
The RealArtTM HSV1I2 LC PCR kit (Artus Biotech, Hamburg, Germany) was also 
used to process specimens for LightCycler PCR. Briefly, to 5 III of specimen DNA, 
15 III of RealArt HSV 112 Mastermix was added to LightCycler capillaries at 4°C and 
centrifuged at 150 x g for 10 sec. In addition, a quantification standard for HSV-l and 
HSV-2 were processed along with a negative control with DNA substituted with de-
ionised water. 
Reactions were performed under the following conditions: one I cycle of initial 
denaturation at 95°C for 10 min (temperature transition rate of 20°C/sec) to activate 
DNA Taq polymerase, followed by 50 cycles of denaturation at 95°C for 5 sec 
(20°C/sec transition), annealing at 50°C for 5 sec (20°C/sec transition) with single 
fluorescence acquisition, and extension at 72°C for 5 sec (20°C/sec transition). 
Melting curve analysis was performed as follows: annealing at 40°C for 30 sec 
(20°C/sec transition) followed by an increase to 80°C for 0 sec (0. 1°C/sec transition) 
with continuous fluorescence acquisition, and cooling to 40°C for 30 sec (20°C/sec 
transition). The Tm of DNA fragments and hybridisation probes was used to 
differentiate between HSV types. The probe Tm was 59°C for HSV-I and 64°C 
and/or 71°C for HSV -2. 
2.5.2.2 Cloning and PCR quantification 
The HSV-I and HSV-2 DNA polymerase gene amplified by real time LightCycler 
PCR was used as a control for quantification. After PCR amplification, 
electrophoretic separation of peR products (10 Ill) was performed on 2% agarose gels 
in 0.5 x Tris-borate-EDTA buffer, stained with ethidium bromide, and visualized by 
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UV illumination. Purification of HSV DNA from the agarose gel was performed with 
the QIAquick Gel Extraction Kit (Qiagen, West Sussex, UK). Briefly, the DNA band 
on the gel was excised and weighed. Two volumes of diffusion buffer were added to 
1 volume of gel followed by 30 min incubation at 50°C. The sample was centrifuged 
at 11000 x g for 1 min, supernatant removed and filtered through a column containing 
Whatman GF/C filter to remove residual polyacrylamide. Three times the volume of 
buffer QG was added to one volume of the supernatant and mixed. The suspension 
was filtered through the QIAQuick Spin column, centrifuged at 10000 x g for 1 min, 
and the filtrate disc'arded. To the column, 750 III of Buffer PE was added and the 
column centrifuged at 10000 x g for 1 min. The filtrate was discarded and the column 
centrifuged at 20000 x g for 3 min. DNA from the column was eluted in 50 Jll of 
deionised water (Sigma, Dorset, UK), incubated at room temperature for 5 min, and 
centrifuged at 6000 x g for 1 min. 
The amplicon was cloned directly into pGEM®-T easy vector using the pGEM®-T 
Easy Vector System (Promega, Southampton, UK). Briefly, the pGEM T easy vector 
and control insert DNA tubes were centrifuged. Ligation reactions were set up using 5 
III 2X rapid ligation buffer, 1 III pGEM®-T easy vector (50 ng/Ill), 1 Jll of PCR 
product, 1 III T4 DNA Ligase (3 Weiss units/ill) and deionised water to make a total 
volume of 10 Ill. Reactions were mixed and incubated at 25°C for 60 min. 
Transformation were performed using JM 1 09 competent cells provided in the kit. 
Briefly, 50 Jll of competent cells were incubated with 5 Jll of the ligation reaction on 
ice for 20 minutes and heat shocked at 42°C for 45 seconds to allow uptake of the 
ligated insert-vector. Reactions were incubated on ice for 2 min followed by a further 
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incubation at 37°C for 90 min in 950 III of 2 x Luria-Bertani (LB) medium (Sigma, 
Dorset, UK) with gentle agitation in a shaking incubator. LB agar plates containing 
ampicillin (100 Ilg/ml) were spread with 100 III of 100mM isopropyl-p-D-
thiogalactopyranoside (lPTG) and 20 III of 50 mg/ml 5-bromo-4-chloro-3-indolyl-P-
D-galactosidase, (X-Gal). Plates were incubated at 37°C to facilitate the screening of 
blue and white colonies and stored at 4°C. The transformation suspension was 
centrifuged at 6000 x g for 1 min and 900 III of the supernatant was removed. The 
cells were re-suspended in the remaining 100 III of medium, spread onto the plates 
and incubated at 37°C for 16-24 hours. Plasmid DNA was extracted from 
recombinant colonies using a WizardR Plus SV Minipreps DNA Purification System 
kit (Promega, Southampton, UK) kit. Briefly, single, well-isolated recombinant 
colonies were selected and grown in 5 mls ofLB and incubated at 37°C overnight in a 
shaking incubator at 250 rpm. Cells (4 ml) were harvested by centrifugation and re-
suspended in a Tris-EDTA-RNase A solution (50mM-lOmM-100 Ilg/ml). After 
alkaline lysis at room temperature, the cells were neutralised (4.09M guanidine 
hydrochloride, 0.759M potassium acetate, 2.l2M glacial acetic acid) and passed 
through a spin column comprised of a resin matrix to which the DNA selectively 
binds. Contaminants were removed by applying high salt-ethanol washes to the 
column (60mM potassium acetate, 8.3mM Tris-Hel, 0.04mM EDTA and 60% 
ethanol). Purified DNA was eluted from the resin matrix with 100 III nuclease free 
water. The identity of individual clones was confirmed by sequencing both strands of 
the viral DNA insert. 
Restriction digests of the recombinant plasmid DNA were carried out in a total 
volume of 30 III as described in the manufacturer's protocol (Promega, Southampton, 
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UK). DNA (10 Ill) was incubated for 90 minutes at 37°e with Pst I as described 
recently (Burrows et ai., 2002) to linearise plasmid DNA. DNA purification from the 
agarose gel was performed using the QIAquick Gel Extraction kit (Qiagen, West 
Sussex, UK). The concentration and purity of the DNA was determined by UV 
spectrophotometry. DNA was diluted (1:200) and measured at 260/280 nm in a quartz 
cuvette (Spectronic® GenesysTM 5, Spectronic Instruments, Leeds, UK). A series of 
dilutions (101, 102, 103 and 104 copies/reaction) of the purified linearised HSV clones 
were used to evaluate assay sensitivity. Briefly, a standard curve was used to calculate 
the copy number of the unknown HSV DNA samples. Ten HSV DNA negative 
samples were tested for peR inhibition using HSV -1 and HSV -2 positive DNA and 
primers. Briefly, test samples were 'spiked' into a peR reaction containing HSV 
DNA. The performance of the peR was monitored by quantitative real-time peR. 
The mean cycle threshold (et) and the standard deviation of the controls were 
calculated. Samples, in which the mean e t of the test sample fell outside the mean et 
plus three standard deviations of the controls, were considered to be inhibitory. 
2.6 DNA SEQUENCING 
2.6.1 Target regions of the HSV genome 
Sequencing was performed on two regions of the HSV genome. Target regions 
included the DNA polymerase and the HSV-2 UL14 gene. 
2.6.1.1 DNA Polymerase gene 
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Genital swabs taken from patients with a clinical diagnosis of genital herpes were 
processed and stored as previously described (Section 2.1.1). DNA extraction was 
performed using QIAamp DNA mini kit (Qiagen, West Sussex, UK) as mentioned 
earlier (Section 2.5.1.1). Samples were prepared for the LightCycler PCR as described 
above but in the absence of hybridisation probes HSV -2 FLU and LCR. The final 
volume of 20 JlI was made up with deionised water. Following PCR amplification, the 
DNA was purified for sequencing using the QIAquick PCR Purification kit (Qiagen, 
West Sussex, UK). The procedure entailed adding 5 volumes of buffer PB to 1 
volume of the PCR mix, applying this to the QIAquick spin column and centrifuging 
the column at 20000 x g for 1 min. The filtrate was discarded, 750 JlI of buffer PE 
was added and the column and the column centrifuged at 20000 x g for 1 min. DNA 
was eluted by adding 50 JlI of de-ionised water to the column, incubating at room 
temperature for 1 min, followed by a centrifugation at 20000 x g for 1 min. 
2.6.1.2 HSV-2 UL14 gene 
HSV-2 positive genital swabs confirmed through virus culture and PCR (as described 
earlier) were used to extract HSV-2 DNA using the QIAamp DNA mini kit (Qiagen, 
West Sussex, UK) as previously described (Section 2.5.1.1). DNA extracts were 
stored at _80°C and processed using the HotStarTaq DNA polymerase kit (Qiagen, 
West Sussex, UK). Briefly, 5 JlI of lOX PCR buffer, 5 JlI 25mM MgCh, 2 JlI of dNTP 
mix (lOmM each), 5 JlI of forward (GCTCACTCGCCATCGGGACAGT) and reverse 
primers (GCCGAGGTGTACAGGGACCAGACC) (l JlM each) (Sigma-Genosys 
Ltd, Dorset, UK), 0.25 JlI of HotStar Taq DNA polymerase (2.5 unitslreaction), and 5 
JlI DNA were added to make a total reaction volume of 50 JlI containing de-ionised 
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water. Prior to sequencing, the DNA products were purified using the QIAquick PCR 
Purification kit (Qiagen, West Sussex, UK) as previously described (Section 2.6.1.1) 
and eluted in 50 ~l of de-ionised water. 
2.6.2 Sequencing reactions 
Sequencing reactions for the DNA polymerase gene were performed using the Sanger 
dideoxy chain termination method with the ThermoSequenase DYEnamic Direct 
Cycle sequencing kit (Amersham Pharmacia Biotech Inc, Buckinghamshire, UK), 
using 3 ~l of extracted DNA, 1 ~l of each A, C, G, T reagent mix, 1 ~l of 0.5 ~M 
HSV forward and reverse primers (as described earlier) labelled with CY5.5 and CY5 
respectively (Sigma-Genosys Ltd, Dorset, UK). Reactions were performed on a 
GeneAmp 9700 thermocycler (PerkinElmer Applied Biosystems, Beaconsfield, UK) 
under the following conditions: 25 cycles of denaturation at 94°C for 5 min, followed 
by further denaturation at 94°C for 30 sec, annealing at 50°C for 30 sec and extension 
at 70°C for 1 min. Formamide loading dye (7 ~l) was added, and the DNA denatured 
at 80°C for 2 min. Sequencing reactions (2 ~l) were run on a Open Gene sequencing 
system (Visible Genetics, Ontario, Canada) using version 3.16 software as described 
by the manufacturer. 
For the HSV-2 UL14 gene, PCR reactions were performed in a Hybaid Multiblock 
System (0.5 MBS) (Hybaid GmbH, Heidelberg, Germany) under the following 
conditions: 1 cycle of denaturation at 95°C for 15 min followed by 40 cycles of 
denaturation at 95°C for 30 sec, annealing at 62°C for 30 sec, extension at 72°C for 1 
min and a final extension step at 72°C for 7 min. For negative controls, DNA 
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specimens were replaced with de-ionised water. When the PCR program was 
completed, 5JlI of each PCR mixture was mixed with I JlI of loading dye (Bioline, 
London, UK) and run on a 1.5% agaorose gel in TBE buffer and visualised by 
ethidium bromide staining. A I kb DNA ladder (Bioline, London, UK) was used as a 
reference to estimate the size of DNA products. Amplicons that were 500 base pairs 
in size were sequenced. 
2.6.3 Sequence analysis 
Sequences generated from the HSV DNA polymerase gene were aligned and 
compared to other HSV sequences (HSV-I GenBank Accession no. AB070847; 
HSV-2 GenBank Accession no. AY038367) sequences in the GenBank database to 
confirm HSV type using BLAST. For the HSV-2 ULI4 gene, sequences were 
analysed using chromas software version 1.45. HSV-2 ULI4 sequences were 
compared to other known HSV-2 ULI4 sequences (GenBank Accession no. 
CAB06774) and aligned using ClustalW software version 1.82 
(http://clustalw.genome.ad.jp) and submitted to the Genbank database. 
2.7 T-LYMPHOCYTE ASSAYS 
2.7.1 Lymphocyte isolation from whole blood 
Peripheral blood mononuclear cells (PBMC) were obtained from by density gradient 
centrifugation using Ficoll-Plaque (Amersham Biosciences, Buckinghamshire, UK) 
and collected in preservative-free sodium heparin tubes (Sarstedt, Leicester, UK). 
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Each tube of 7.5 ml whole blood was under layered with 15 ml of Ficoll in a 50 ml 
polypropylene tube. The tube was centrifuged at 400 x g for 20 min. PBMC were 
removed from the lymphocyte layer at the interface just below the plasma layer, and 
harvested into a new 50 ml tube, which was diluted with RPMI 1640 containing 2 
mM L-glutamine, penicillin and streptomycin (Sigma, Dorset, UK) to make 50 ml. 
Cells were centrifuged twice at 150 x g for 15 min. The supernatant was discarded 
and the pellet retained. Before the third wash step, the pellet was re-suspended in 50 
ml RPMI 1640 containing 2mM L-glutamine, penicillin and streptomycin (Sigma, 
Dorset, UK) and counted by mixing 50 III of diluted PBMC and 50 III of trypan blue 
solution (Sigma, Dorset, UK). The cell suspension (10 Ill) was transferred to a 
disposable counting chamber and phase microscopy was used to distinguish live cells 
from dead cells. 
Following cell counts (x 106), the required volume of cells were transferred to a fresh 
50 ml tube and diluted with RPMI 1640 up to 50 ml. The cells were spun at 150 x g 
for 10 min. Supernatant was discarded and the pellet was processed for 
cryopreservation and the enzyme linked immunospot (ELI SPOT) assay. 
2.7.1.1 Cryopreservation of lymphocytes 
Cells were cryopreserved on the day PBMC were isolated from blood. Cells were 
processed as described previously (Section 2.7.1), and the pellet re-suspended at 6 x 
106 cells/ml in a freezing solution consisting of 90% FBS and 10% 
dimethylsulphoxide (DMSO) (Sigma, Dorset, UK) which was pre-cooled to 4°C. The 
cell suspension was then transferred to 2 ml cryogenic vials (Alpha Laboratories, 
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Hampshire, UK) in 1 ml aliquots. The vials were placed in freezing containers 
containing isopropanaol (Nalgene, New York, USA) at room temperature, and then 
transferred to at -80DC. Stocks of cells were transferred to liquid nitrogen chambers at 
-192DC the following day. 
2.7.2 Enzyme linked immunospot (ELISPOT) assay 
The IFN- Y ELISPOT was used to measure T-cell immune responses against HSV 
among HIV-l infected and uninfected individuals. Fresh PBMC were used for this 
assay. 
2.7.2.1 Plate coating and antigen stimulation 
96 well multi screen filter plates (Millipore, Gloucestershire, UK) were coated with 
100 J.lI of 1 J.lg/ml primary anti-IFN-y antibody (IDIK) (Mabtech, Nacka Strand, 
Sweden) and incubated overnight at 4 DC. The antibody was diluted at a ratio of 1: 100 
using sterile filtered PBS. The following day, the plates were washed 6 times with 200 
J.lI of filtered sterile PBS containing 0.05% Tween (Sigma, Dorset, UK). Excess wash 
solution was removed by tapping the plate onto paper towels soaked with 70% 
ethanol to minimise contamination. Following the wash step, 100 J.lI of filtered sterile 
PBS containing 10% Human AB serum (Sigma, Dorset, UK) was added, and the plate 
incubated at room temperature for 60 min. PBMC in RPMl 1640 containing 20% 
Human AB serum were added at a concentration of 3 x 105 cells/well. HSV -1 and 
HSV-2 lysates (Section 2.3) were diluted in RPMI 1640 to make several 
concentrations (1 J.lg/ml, 5 J.lg/ml and 10 J.lg/ml) of which 100 J.lI were added to 
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respective wells of the plate. In addition, 5 JlI of phytohaemoglutinin (PHA) (Sigma, 
Dorset, UK) at 5 Jlg/ml and 100 JlI of tissue culture medium were added to 
appropriate wells to serve as positive and negative controls respectively. All samples 
were run in triplicates. The plate was incubated overnight in a humidified atmosphere 
of 5% CO2 at 3 TC. 
2.7.2.2 Colour development 
The plate was decanted and washed six times as previously described with 200 JlI of 
filtered sterile PBS containing 0.05% Tween (Sigma, Dorset, UK). Secondary anti-
IFN-y biotynlated antibody (7-B6-I-Biotin) (Mabtech, Nacka Strand, Sweden) was 
diluted at a ratio of 1: 1000 in sterile filtered PBS, 100 JlI of the diluted antibody 
solution was added to respective wells of the plate and incubated at room temperature 
for 3 hours. The plate was washed with 200 JlI of filtered sterile PBS containing 
0.05% Tween as before, and 100 JlI of the diluted streptavidin alkaline phosphatase 
(streptavidin-ALP) (Mabtech, Nacka Strand, Sweden) was added to the wells of the 
plate. The streptavidin-ALP was diluted in sterile filtered PBS at a ratio of 1: 1 000. 
The plate was incubated for 2 hours at room temperature, washed with sterile 
PBS/O.05% Tween 6 times before 100 JlI of substrate (Biorad, Hertfordshire, UK) was 
added. The substrate was supplied in a kit and was used according to manufacturer's 
instructions. The plate was left in the dark for colour development to occur (10-30 
min) and the reaction was stopped by washing the wells with water. The plate was left 
to dry at room temperature overnight before spots were counted using a Nikon 
stereomicroscope and an automated ELISPOT reader (Karl Zeiss-Imaging 
Associates, Germany). 
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2.7.3 Intracellular cytokine staining assay using flow cytoruetry 
Fresh blood was used to isolate PBMC from healthy HSV seropositive and 
seronegative donors as described earlier (Section 2.7.1). PBMC (1 x 106 cells in 1 rul 
RPMI 1640 medium containing 10% FCS) were stimulated with 500 III of infected 
cell lysate preparations of HSV-l (1 Ilg/ml) and HSV-2 (1 Ilg/ml). To positive and 
negative controls, 5 III of staphylococcal enterotoxin B (1 Ilg/ml) (Sigma, Dorset, 
UK) and 200 III of uninfected vero cell extracts were added respectively. Incubation 
was performed in the presence of 10 III of anti-CD28 antibody (0.5 Ilg/ml) (BD 
Biosciences, Oxford, UK) for co-stimulation. After a 2 hour incubation at 3TC, 1 III 
of GolgiPlug (1 Ilg/ml) (BD Biosciences, Oxford, UK) containing brefeldin A was 
added to block the transport of cytokines to the cell surface. Following 14 hour 
incubation at 3 TC, the reaction was quenched by washing cells with 2 ml PBS/O.O 1 % 
azide/0.5% bovine serum albumin. 
Centrifugation was performed at 1500 rpm for 5 min, supernatant discarded and pellet 
re-suspended in 1 III anti CD3 APC (BD Biosciences, Oxford, UK) 5 III of cytokine 
and cell surface marker CD4-peridinin chlorophyll A protein (PerCP) (BD 
Biosciences, Oxford, UK). The cell suspension was vortexed and stained in the dark 
for 15 min at 25°C. Cells were washed as before, fixed with 100111 F ACS 
permeabilisation buffer Reagent B and incubated for 15 min at 25°C in the dark. 
Following permeabilisation, cells were vortexed, 5 III anti CD69 PE (BD Biosciences, 
Oxford, UK) and 5 III anti-human IFN y-FITC (BD Biosciences, Oxford, UK) was 
added to detect activated T-cells. Cells were washed as described earlier, fixed in 4% 
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paraformaldehyde (BD Biosciences, Oxford, UK) and stored in the dark at 4°C before 
use. 
Samples were analysed by a F ACScan flow cytometer (Becton Dickinson). Dead cells 
and debris was excluded by forward and side scatter gating. In the flow cytometry 
analysis, the CD4 expression of T-cell activation marker CD69 was calculated by 
gating around the CD3+CD4+ cell population on a forward versus side scatter dot plot 
and 10,000 events were collected for each sample. Dead cells and debris was 
excluded by forward and side scatter gating. Data was analysed using CellQuest 
software (Beckton Dickinson, Oxford, UK) and Flow Jo software (Tree Star, 
Californa, USA). 
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3. Chapter 3a. The establishment of optimal diagnostic methods 
for genital herpes: Direct Virus Detection Methods 
3.1 INTRODUCTION 
In 2004, over 18,500 new cases of genital herpes were reported from GUM clinics in 
the UK, a 15% increase compared to 1995. These figures underestimate the true 
prevalence of symptomatic infections as atypical presentations are common and often 
misdiagnosed (Corey, 1994). Clinical history alone may not be sufficient to provide 
an accurate diagnosis of genital herpes and laboratory confirmation is required to both 
confirm and exclude the diagnosis (Mullan & Munday 2003; Cowan et al., 1994). The 
laboratory diagnosis of genital herpes relies on both direct and indirect virus detection 
techniques. The main direct methods include virus isolation in cell culture and 
detection of the viral nucleic acid by molecular methods. Methods based on the 
demonstration of viral antigens by immunoassays are also available. Indirect methods 
are based on the detection of virus-specific antibodies. 
3.1.2 Virus culture 
HSV isolation in cell culture can be performed in a variety of cell lines, including 
Vero, Hep-2, human diploid, rabbit kidney, and human amnion. HSV positive cultures 
demonstrate a cytopathic effect (CPE) characterised by cytopathological changes such 
as syncytia and multinucleated giant cell formation (Usta~elebi, 200 I). Appearance of 
a characteristic CPE usually takes 3-4 days but may take up to 7-10 days. HSV 
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isolates obtained by VIruS culture can be typed as HSV-l or HSV-2 by 
immunofluorescence (IF), which utilises fluorescent antibodies directed to HSV type-
specific antigens. Virus isolation in cell culture is used routinely for the laboratory 
diagnosis of HSV infection and is considered the gold diagnostic standard (Ashley, 
1993). According to a survey of GUM consultants, in 1999 virus culture was the 
diagnostic method of choice for genital herpes in the UK (Scoular & Kinghorn, 1999). 
A more recent survey conducted in 2003 among 25 diagnostic laboratories in 
England, Wales, Scotland and Northern Ireland showed that virus culture remains the 
diagnostic method of choice in the large majority of laboratories in the UK (Geretti & 
Brown, 2005). 
Virus culture has several drawbacks. It is slow, labour intensive, and requires up to 7-
10 days for the appearance of cytopathic changes in cultured cells or the release of a 
negative result. Although specificity of cell culture is virtually 100%, levels of virus 
shedding, quality of specimen and transport conditions influence its sensitivity (Wald 
et ai., 2003; Corey et aI., 1983; Scoular, 2002). The rate of virus recovery has been 
shown to decline significantly with time since the onset of lesions, from 52-93% for 
vesicles to 41-72% for ulcers and 19-27% for crusted lesions (Corey et al., 1983; 
Scoular, 2002). The lack of specimen refrigeration after collection and during 
transport markedly reduces virus viability. This is supported by evidence indicating a 
50% reduction in HSV isolation rates during summer months (Wald et al., 2003). 
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3.1.3 HSV DNA detection by peR 
Molecular techniques can directly detect and type HSV in a wide variety of clinical 
samples (Volpi & Pica, 1998). The introduction of PCR represented a major 
breakthrough in the diagnosis of HSV infections of the central nervous system. In 
patients with HSV encephalitis (HSE), virus isolation from brain biopsies was 
required for a definitive diagnosis, as cultures of cerebrospinal fluid were positive in 
only 4% of adult patients (DeBiasi & Tyler, 1999). In a landmark study, CSF was 
obtained from patients with clinical disease indicative of HSE who underwent 
diagnostic brain biopsy. HSV DNA was detected by PCR in CSF of 53 (98%) of 54 
patients with biopsy-proven HSE. In addition, positive PCR results were found in 3 
(6%) of 47 patients whose brain tissue was culture-negative (Lakeman & Whitley, 
1995). As a result, HSV DNA detection by PCR supplanted brain biopsy as the 
modality of choice for diagnosing neurological HSV disease, becoming the current 
diagnostic method of choice (Cinque et al., 1996). 
Although the traditional PCR methodology has previously been applied to the 
detection of HSV in various clinical specimens, the technique is relatively 
cumbersome and prone to contamination (Aldea et al., 2002). Recently, real-time 
PCR assays have been developed for the detection of viruses in clinical specimens. 
Real-time PCR assays allow rapid virus detection in a closed amplification and 
detection system, with high sensitivity, low risk of contamination, and no post-
amplification steps. Among available assays, the LightCycler PCR technology (Roche 
Diagnostics, UK) uses two specially designed sequence-specific oligonucleotide 
probes labelled with fluorescent dyes. One probe carries a fluorescein label (FLU) at 
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its 3' end and the other a LC Red (LCR) label at its 5' end and a phosphate at its 
3 'end. Both probes hybridise to the amplicon in close proximity allowing energy 
transfer to occur between fluorophores (Fluorescence Resonance Energy Transfer) 
resulting in light emission, measured by the LightCycler. The amount of fluorescence 
measured is proportional to the amount of specific amplicon generated during the 
ongoing PCR process. 
The melting temperature (Tm) is defined as the temperature at which 50% of the 
DNA is single-stranded. The most important criteria that determine the Tm are the 
G+C content and the length of the amplified DNA. The LightCycler monitors the 
fluorescence continuously, while raising the temperature gradually. When the 
temperature in the capillary reaches the Tm of the amplified DNA, a sharp decrease in 
fluorescence occurs as one of the two hybridisation probes can no longer bind to the 
target sequence. When the method is applied to the detection of HSV DNA, melting 
curve analysis demonstrates a different Tm for HSV -1 and HSV -2, allowing direct 
typing of the amplified product. 
3.1.4 Study objectives 
In order to develop the optimal tools to investigate the epidemiological features of 
genital herpes, we established and evaluated the performance of a real-time PCR 
assay on a LightCycler platform for HSV detection in genital swabs. As specimen 
preparation is a time-consuming process in PCR, evaluation of different specimen 
preparation methods was necessary in terms of cost, labour and performance. Assay 
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reliability was evaluated by repeat testing, comparison with other PCR assays and 
HSV sequence analysis. 
3.2 METHODS 
3.2.1 Study population and sampling 
Genital swabs were collected from 233 GUM clinic attendees from Kings College 
Hospital, London who presented with clinical features suggestive of genital herpes. 
The first part of the study comprised genital swabs from 145 consecutive patients. The 
patients' demographic and clinical data were recorded, including swab site, type of 
presentation (first or recurrent episode), duration of onset «5 days or ~5 days), 
presence of genital ulceration, administration of antiviral drugs before disease onset 
(acyclovir, val acyclovir, or famcyc10vir), and HIV status. In the second part of the 
study, 88 additional genital swabs from GUM patients from Kings College Hospital, 
London were tested to provide a validation group for the larger subset. Swabs were 
placed in 2.5 m1 of supplemented VTM (Section 2.1.1) 
3.2.2 Virus culture 
Swabs in VTM were vortexed and 200 ~1 were inoculated in two tubes containing 
Vero cells. Cultures were maintained as described earlier and examined daily for the 
appearance of a CPE (Section 2.2). The infected cells were harvested and HSV was 
typed by direct immunofluorescence (Section 2.2.1). 
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3.2.3 Specimen preparation for peR 
With a subset of 140 samples, three different methods were used to prepare DNA 
from 200 1-11 of specimen in VTM: (1) manual DNA extraction with the QIAamp 
DNA Mini Kit (Qiagen, West Sussex, UK); (2) automated DNA extraction with the 
MagNA Pure LC (Roche Diagnostics, East Sussex, UK), and (3) DNA precipitation 
with polyethylene glycol (PEG) and sodium chloride (NaCl). The QIAamp DNA Mini 
Kit, MagNA Pure LC instrument, and PEG precipitation methods were employed as 
described earlier (Section 2.5.1.1, Section 2.5.1.2, Section 2.5.1.3). 
Real time PCR was performed with the LightCycler (Roche Diagnostics, East Sussex, 
UK) using previously described HSV forward and reverse primers and two 
fluorescently labelled hybridization probes (Section 2.5.2.1). For the PCR, primers 
were chosen within a highly conserved region of the DNA polymerase gene, yielding 
a 215 base-pair fragment from each of the HSV-l and HSV-2 DNA polymerase 
genes. Following PCR amplification (Section 2.5.2.1), the Tm of DNA fragments and 
hybridisation probes was used to differentiate between HSV types. The probe Tm was 
59°C for HSV-l and 64°C and/or 71°C for HSV-2. The commercially available 
RealArt HSV1/2 LC PCR kit (Artus Biotech, Hamburg, Germany) was used to 
compare the results of 15 specimens. 
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3.2.4 DNA sequencing 
Samples were prepared for LightCycler PCR as described earlier but in the absence of 
hybridisation probes HSV-2 FLU and LCR (Section 2.6.1.1). Following 
amplification, the DNA was purified using QIAquick PCR Purification. DNA 
sequencing was performed by the Sanger dideoxy chain termination method as 
described earlier using extracted DNA, A, C, G, T reagent mix, HSV forward and 
reverse primers labelled with CYS.S and CYS respectively as described previously 
(Section 2.6.2). Reactions were performed on a thermocycler and automated DNA 
sequencing reactions were run on a sequencing system. Sequence data were compared 
to other HSV sequences present in the GenBank database to confirm HSV type using 
BLAST followed by sequence alignment using ClustalW version 1.81. 
3.2.5 Data analysis 
The HSV detection rates for virus culture versus PCR according to clinical 
characteristics were compared by the X2 or Fisher's exact test. To evaluate and 
compare the three PCR specimen preparation methods, a definition of "true positive" 
specimen was required. True positive specimens were considered as those that were 
either positive in both virus culture and PCR, or were virus culture negative but PCR 
positive in >2 separate assays and by >2 specimen preparation methods. To determine 
the level of agreement between the three specimen preparation assays, Kappa values 
were calculated. 
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3.3 RESULTS 
3.3.1 Establishment of HSV Real-time PCR on a LightCycier platform 
The PCR method selected amplified a 215 bp product of HSV DNA polymerase gene 
and allowed its qualitative detection and typing. HSV-I and HSV-2 positive DNA and 
deionised water were used as positive and negative controls respectively. 
Quantification of 5 specimens was carried out by the amplification and purification of 
known HSV positive DNA from agarose gels using the QIAquick Gel Extraction Kit 
(Qiagen, West Sussex, UK). The target gene was directly cloned into the pGEM T 
easy vector and transformed into JMI09 competent cells using the PGEM®-T Easy 
Vector System (Promega, Southampton, UK) cloning kit (Promega, Southampton, 
UK). The plasmid DNA was extracted from transformed cells using WizardR Plus SV 
Miniprep DNA Purification System kit (Promega, Southampton, UK). A series of 
dilutions (101, 102, 103 and 104 copies/reaction) of the plasmid standards was used to 
determine assay sensitivity. Briefly, a standard graph comprising the Ct values from 
the serial dilutions of the plasmid and the Ct values from unknown samples were 
plotted to calculate the number of HSV genomes per miIIilitre. The LightCycIer 
Quantitation Analysis software provided the crossing point (Cp) (i.e. cycle number at 
which reactions enter the log/linear phase) to determine the initial target 
concentration. 
Standards were tested in duplicate in 10 separate runs to determine the threshold and 
d 
·bl·ll·ty of the real-time PCR assay. As 10 copies per reaction were 
repro UCI 
consistently detected in all of the runs for both HSV-l and HSV-2, this was 
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considered to be the lowest limit of quantification (data not shown). To check for 
inhibition, experiments were conducted where 10 HSV negative clinical specimens 
were spiked with HSV-l and HSV-2 DNA (5 HSV-l and 5 HSV-2) and subjected to 
multiple specimen preparation methods (see below). No significant inhibition was 
detected in these experiments. To check for assay reproducibility, experiments were 
performed in triplicates. Results revealed the assay to be highly reproducible with all 
three specimen preparation methods accurately exhibiting equivalent typing 
sensitivity in all 10 specimens. 
3.3.2 Comparison of specimen preparation methods 
Three specimen preparation methods using manual DNA extraction with the QIAamp 
DNA mini kit, automated DNA extraction with MagNA Pure LC, and virus 
precipitation with PEG were compared to determine assay performance, labour 
intensity and reagent cost. Of 140 specimens being compared, 120/140 (86%) were 
either HSV negative or positive by all three methods, 12/140 (8%) were positive by 
two methods and 8/140 (6%) were positive by only one method. In addition, mean 
crossing point values were highly concordant in HSV positive specimens between the 
three PCR preparatory methods. Of the 8 specimens that were positive by only one 
method, three were also virus culture positive and therefore scored as true positive. 
According to the definition of true positive given above, HSV detection rate was PEG 
precipitation> MagNA Pure LC > QIAamp DNA mini kit (Table 3.1). A high level of 
agreement was observed between the three preparatory assays, with Kappa values 
~0.84. 
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HSV was detected in 65/72 (90%) true positive specimens by PEG precipitation, 
including three specimens that were positive by culture but negative by QIAamp 
DNA mini kit and MagNA Pure Le. In comparison to the other preparation methods, 
PEG precipitation was also faster and least expensive (Table 3.1). 
Table 3.1 Comparison of detection rate, duration and cost of three specimen 
preparation methods with virus culture 
DNA extraction Virus 
Virus culture 
Manual Automated precipitation 
Relative detection 61172 62/72 65/72 
42/72 (58%) 
ratea (85%) (86%) (90%) 
Duration 
Specimen 
90m 120 m 60m 
preparation 
peR 81 m 101m 81m 
TotalC 171m 221m 141m 2-10 days 
Negative sample: 
Reagent cost per test 1.00 
3.99 9.27 2.44 
(£): Positive sampleb: 
1.55 
arrue positive: specimens that had tested HSV positive in both virus culture and peR, 
or if virus culture negative, positive in ~2 separate peR assay and by ~2 specimen 
preparation methods; bTyped by direct immunofluorescence; cTime taken to process 1 
sample. 
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3.3.3 HSV typing 
HSV typing was performed using LightCycler melting curve analysis to differentiate 
between HSV types. Melting curve analysis was based on base-pair (bp) differences 
between HSV-l and HSV-2 amplicons in the probe-binding region of the DNA 
polymerase gene. The probe melting temperature was 59°C for HSV -1 and 64°C 
and/or 71°C for HSV-2 (Figure 3.1). Among 132 HSV-positive swabs, 106/132 
(80%) were typed as HSV-2 and 12/l32 (9%) as HSV-l. Results were all confirmed 
by repeated testing. Samples that yielded an isolate in virus culture also showed 
consistent results of HSV typing by Immunofluorescence. In addition, 15 specimens 
were tested with a commercial assay with identical HSV typing results. A further 
14/l32 HSV positive swabs showed atypical melting curves with Tm >60°C (Table 
3.2). 
3.3.4 Characterisation of specimens with atypical melting curves 
Overall 6/14 (43%) specimens showed 2:2°C variation from the HSV-2 reference Tm 
(64°C and/or 71°C) (Table 3.2). The most problematic samples to interpret were those 
with a Tm below 64°C and close to the reference Tm for HSV-l (59°C). To determine 
whether atypical melting curves were a result of target sequence variation, the 
corresponding DNA polymerase region was sequenced. All 14 samples were typed as 
HSV -2 following DNA polymerase gene sequence alignment. In addition they were 
typed as HSV-2 by immunofluorescence testing of virus isolates. Sequence variation 
in the 100 bp region of the FLU probe binding site of the DNA polymerase gene was 
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evident in 4/14 specimens with Tm ranging between 61 ·C - 66·C (Table 3.2). No 
sequence variation was observed in the target HSV -2 sequence among the 10 
remaining specimens. 
Table 3.2 Nucleotide sequences of HSV positive specimens with Tm >60oC 
Specimen HSV -2 Sequence 
HSV -2 Control CGGCGTCATCTGCGGGGG AAGATGCTr-ATCAAGGGCGTG-GATCTG-GTG G AAAAAC 
Probe LCR iGGCGTCAT TGCGGGGGCAAGi 
Probe FLU IGCTCATCAAGGGCGTG-GATCTG-GTGCGg 
1 CGGCGTCATCTGCGGGGGCAAGATGCTCA AGGGCGT GA CTG-GTGCG AAAAAC 
2 CGGCGTCATCTGCGGGGG AAGA TGCT A TCAAGGGCGTG-GA TCTG-GTG G AAAAAC 
3 CGGCGTCATCTGCGGGGG AAGA TGCTCA TCAAGGGCGTG-GA TCTG-GTGCGCAAAAA 
4 CGGCGTCA TCTGCGGGGG AAGA TGCTCA TCAAGGGCGTG-GA T TG-GTG G AAAAAC 
5 CGGCGTCATCTGCGGGGGCAAGATGCTCATCAAGGGCGTG-GA TCTG-GTG GCAAAAA 
6 CGGCGTCA TCTGCGGGGGCAAGA TGCT A TCAAGGGCGTG-GA T TG-GTG G AAAAA 
7 CGGCGTCA TCTGCGGGGGCAAGA TG TCA TCAAGGGCGTG-GA TCTG-GTG G AAAAA 
8 CGGCGTCATCTGCGGGGG AAGATGCTCATCAAGGGCGTG-GATCTG-GTG G AAAA 
9 CGGCGTCATCTGCGGGGGCAAGATG T ATCAAGGG GTG-GAT TG-GTG G AAAAA 
10 CGGCGTCATCTGCGGGGGCAAGATGCTCA GGG GT -GA TG-GTG GCAAAAA 
11 CGGCGTCATCTGCGGGGGCAAGATGCTCATCAAGGGCGTG-GAT TG-GTG G A AAA 
12 CGGCGTCATCTGCGGGGGCAAGATGCTCATCAAGGG GTG-GAT TG-GTG G AAAAA 
13 CGGCGTCATCTGCGGGGGCAAGATGCT ATCAAGGGCGTG 
14 CGGCGTCATCTGCGGGGGCAAGATG T ATCAAGGG 
Probes are boxed and nucleotide differences are shaded. 
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To determine whether different specimen preparation methods might influence the 
outcome of the HSV melting curve, the 14 specimens were re-processed with 
QIAamp DNA mini kit, automated DNA extraction with the MagNA Pure LC and 
viral precipitation with PEG. Repeat testing with 6/14 samples showed reproducible 
Tm values with the three specimen preparation methods (Table 3.3). Of samples with 
~2°C variation from the reference Tm, identical Tm were observed in 4 QIAamp 
DNA mini kit and MagNA Pure LC, 1 in QIAamp DNA mini kit and PEG, and 1 in 
MagNA Pure LC and PEG preparations. Overall, discrepancies were fewer in 
specimens processed by MagNA Pure LC or PEG precipitation compared with the 
QIAamp DNA mini kit. Overall, between all three specimen preparation methods, 7 
samples had atypical Tms, of which 5 specimens had conserved sequences and 2 had 
sequence differences at the probe binding site. 
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Table 3.3 Comparison of melting temperatures (Tm,OC) of HSV-2 positive swabs 
following three specimen preparation methods and parallel testing in the same 
LightCycier PCR assay. The reference Tm for HSV-2 was 64°C and/or 71°C 
Manual DNA extraction: 
QIAamp DNA mini kit 
61*t 
62* 
65* 
65 t 
66*t 
66 
66 
66t 
65, 71 t 
72t 
72 
72 
72 
72 
14 
6/14 
Specimen preparation methods 
Automated DNA extraction: 
MagNA Pure LC 
60t 
61 
64 
63 t 
66t 
66 
66 
66t 
66, 71 t 
71t 
71 
71 
71 
72 
Total samples with Tm variation 
9 
Total samples with Tm variation ~2°C 
6/9 
Virus precipitation: 
Polyethylene glycollNaCI 
61 
61 
65 
68t 
64t 
66 
71 
65 t 
62,72 t 
65 t 
71 
71 
71 
66 
9 
5/9 
fThe Tm value was replicated in 6 independent experiments for each specimen 
preparation method; * sequence variation in probe binding region of the DNA 
polymerase gene 
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0.011-
0.010-
0.009-
0.008-
0.007 -
0.006-
0.005-
0.004-
0.003-
0.002-
·0.001-
·0.002 -I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
42.0 44.0 ~.o 48.0 50.0 52.0 54.0 56.0 58.0 60.0 62.0 64.0 66.0 68.0 70.0 72.0 74.0 76.0 78.0 
Temperature eC) 
Figure 3.1. Typing of HSV-l and HSV-2 by melting curve analysis. 
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3.3.5 Comparison of virus culture and PCR 
We tested genital swabs from 145 patients with a clinical diagnosis of genital herpes 
using virus culture and PCR. The most common swab sites were the penile skin in 
males (63/85, 74%) and the vulva in females (48/60, 80%) (Table 3.4). Among 
patients with visible genital ulceration, a significant difference in detection rate was 
observed by both virus culture and PCR (34% vs. 64%). However in the absence of 
visible ulceration no significant differences between virus culture and PCR were 
observed (25% vs. 31%). By virus culture and PCR, 45/145 (31%) and 771145 (53%) 
specimens were HSV positive respectively. All HSV negative specimens by culture 
(n=32) were confirmed HSV PCR positive upon retesting in ~2 independent replicate 
PCR assays (mean 2.75 assays per sample). In addition a random subset of 15 
samples, were also confirmed HSV positive by The RealArt™ HSV1I2 LC PCR kit 
(Artus Biotech, Hamburg, Germany). Real-time PCR was shown to increase HSV 
detection by 71% (32/45). No patient with positive culture had a negative PCR. A 
positive virus culture result was obtained in 3 days (range 2-10 days) with negative 
results being available in 10 days, compared to less than 4 hours for PCR results. 
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Table 3.4 Comparison of virus culture and PCR for the detection of HSV in 
different clinical presentations of genital herpes 
HSV positive n (%) 
Total 
Virus culture peR 
First episode 83 26 (31) 41 (49) 
Recurrent episode 62 19 (31) 36 (58) 
Onset < 5 days 64 27 (42) 38 (59) 
Onset ~ 5 days 81 18 (22) 39 (48) 
Visible ulceration 97 33 (34) 62 (64) 
No visible ulceration 48 12 (25) 15 (31) 
HIV positive 17 7 (41) 12 (71) 
HIV negative 58 20 (34) 32 (55) 
HIV status unknown 70 18 (26) 33 (47) 
Males 85 24 (28) 43 (51) 
Females 60 21 (35) 34 (57) 
Total 145 45 (31) 77 (53) 
3.3.6 Performance of virus culture according to demographic and clinical 
characteristics 
Virus culture was more frequently positive in patients presenting <5 days of onset of 
symptoms (27/64, 42%) than in those who presented later (18/81,22%, p=O.OI). The 
proportion of patients with a positive culture was similar in first episode and recurrent 
disease. 
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3.3.7 Performance of HSV peR according to demographic and clinical 
characteristics 
HSV detection rates were similar among both sexes, with peR increasing detection 
by 79% (19/24) and 62% (13/21) in men and women respectively (Table 3.4). No 
significant differences were observed among patients who presented < 5 days or ~ 5 
days of onset of symptoms with a positive peR result (38/64, 59% vs. 39/81, 48%, 
p=O.2). As a result, peR increased HSV detection by 41 % (11/27) in early disease 
and 116% (21118) in late disease. peR increased HSV detection by 58% (15126) in 
first disease and 89% (17/19) in recurrent disease. Detection of HSV in the presence 
of f genital ulcers was also enhanced by peR (Table 3.4). Improved detection by peR 
was seen regardless of HIV status. 
3.3.8 Validation study 
To validate the previous results, the study was further extended to include an 
additional 88 consecutive genital swabs from patients with suspected genital herpes. 
Of these, 34/88 (39%) were virus culture positive and 55/88 (63%) were peR 
positive. In this additional subset of specimens, peR increased HSV detection rate by 
62% (21134) validating the data from the larger subset. Overall in our entire cohort, 
34% (79/233) of swabs were HSV positive by culture and 132/233 (57%) were 
positive by peR. 
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3.4 DISCUSSION 
Virus culture remains the reference method for the laboratory diagnosis of genital 
herpes in the UK (Geretti & Brown, 2005) despite its limitations (Scoular, 2002; 
Wald et al., 2003). Virus culture is a labour-intensive and time consuming 
methodology requiring stringent conditions for specimen transport and storage 
conditions to preserve virus viability (Wald et al., 2003). 
In this study we demonstrated that real-time peR significantly increased the rate of 
HSV detection in genital swabs by 61-71 % compared to virus culture. Among 
patients with visible genital ulcerations, 88% more infections were detected by peR 
than virus culture. This might be due to replicating virus on the mucosa. During HSV 
reactivation, the virus is released from the nerve endings in the sub-mucosa. Therefore 
breakages in the epithelial barrier would result in virus transfer from the sub-mucosa 
to the mucosa (Wald et al., 2003), leading to increased detection sensitivity. A recent 
study and 12 patients (10%) among In the absence of peR testing, 53/233 of the 
symptomatic patients would have received a negative result, thus preventing 
appropriate counselling on prognosis and risk of transmission and possibly triggering 
additional clinic visits and investigations. Real time peR exhibited increased 
sensitivity for the detection of both HSV-l and HSV-2 relative to virus culture. 
Detection sensitivity of 10 copies/reaction in the proficiency evaluation along with the 
high concordance in replicate tests confirmed the high sensitivity and specificity of 
the assay. 
- 95-
The performance, labour and cost of HSV PCR for HSV detection in genital swabs 
was also investigated by comparing three specimen preparation methods. Kappa 
values of 2:0.84 indicated a high level of agreement between the three preparatory 
assays. Virus precipitation by PEG, although not previously used for LightCyc1er 
PCR, had the highest detection rates, was the least expensive and required the shortest 
preparation time, thus providing a valid option for specimen processing prior to PCR. 
This study led to the first published evidence that PEG precipitation offers a valid 
method for specimen preparation from genital swabs prior to PCR. 
Even though PCR shows increased sensitivity over virus culture, its implementation 
may be limited by concerns of contamination. The advantages of real-time PCR are 
that it allows direct quantification of the target and avoids post-PCR handling, 
leading to minimal contamination risk with PCR products. Retesting of HSV positive 
specimens yielded reproducible results validating the assay to be reliable. In addition, 
the high prevalence of HSV disease in our cohort could have contributed to assay 
reproducibility (Van Doornum et a/. J 2003). Although the costs of consumables for 
PCR (£2.44-£9.27) were higher than those for virus culture (£1.00-£1.55), real-time 
PCR proved cost-efficient by significantly reducing labour cost per sample. 
Melting curve analysis allows the differentiation between HSV types, characterised 
by different Tm values for HSV -1 and HSV -2 specific probes. Real-time PCR 
allowed for the typing of HSV without additional, time consuming post-PCR steps. 
Sequencing of a subset of HSV -2 positive samples showed a low prevalence of 
sequence variation indicating robustness and reliability of the assay. In a subset of 
samples, atypical melting curves were observed that did not conform to the expected 
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Tm for HSV-l and HSV-2. Atypical melting curves have been previously reported as 
a result of sequence variation causing base-pair mismatches over the probe sites 
(Anderson et al., 2003; Issa et al., 2005). In our study, of the 14 specimens sequenced, 
4/14 (29%) showed sequence variation in the FLU probe-binding site whereas 10114 
(71 %) specimens did not reveal sequence differences. Differences in Tm were shown 
to arise from different specimen preparation methods. Fewer discrepancies were 
observed in specimens prepared by the MagNA Pure LC or the PEG precipitation 
compared with the QIAamp DNA mini kit. This suggested that atypical melting 
curves may occur as a result of factors other than sequence variation. These may 
include carryover of contaminants, such as salts during purification, which may 
influence the annealing stringency of the probe/target complex. Thus multiple factors 
including, but not limited to sequence variation may complicate melting curve 
analysis, following real-time LightCycler PCR. These findings indicated that 
differentiation between HSV types may require alternative typing procedures for a 
small subset of samples with atypical melting curves. 
In this study, the increased HSV detection by PCR was observed in different clinical 
presentations. Previous reports have shown virus culture to yield a significant higher 
HSV detection rate among patients with first episode disease (84%) compared to 
those with HSV recurrences (42%) (Corey & Holmes, 1983). In contrast, no 
difference in HSV detection rate by virus culture was observed in first (26/83, 31 %) 
and recurrent disease (19/62, 31 %) in this study. However, HSV detection rates were 
higher in persons who presented < 5 days onset of symptoms (27/64, 42%) than in 
those who presented later (18/81, 22%), indicating an effect of declining virus 
shedding on assay sensitivity. HSV detection by PCR was higher than virus culture 
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(18/81, 22% vs. 39/81, 48%) among patients who presented late after the onset of 
symptoms (2: 5 days). This finding suggests that declining levels of virus shedding in 
older lesions favour PCR as the more the sensitive method. Even among patients who 
presented <5 days of onset of symptoms, detection was significantly increased by 
PCR (38/64, 59%) compared with virus culture (27/64, 42%). As our study was 
performed during the summer months, warm conditions may have affected HSV 
viability and influenced on the sensitivity of virus culture. This explanation is 
consistent with findings from a recent study which showed virus viability in 2116 
genital swabs to decrease by approximately half in summer compared to winter (Wald 
et ai., 2003). 
Previous studies that investigated over 60000 mucocutaneous swabs by virus culture 
and PCR have also reported increased sensitivity of PCR over virus culture (Table 
3.5). Overall, PCR has shown to be 25-89% more sensitive than virus culture (Scoular 
et al., 2002; Burrows et al., 2002; Aldea et al., 2002; Van Doornum et al., 2003; Wald 
et al., 2003; Schmutzhard et ai., 2004). 
Only a small proportion of laboratories in the UK were shown to use PCR for 
processing genital swabs, despite the wide availability of PCR for HSV DNA 
detection in CSF. A survey of diagnostic methods for HSV detection demonstrated 
17/25 (68%) laboratories used HSV PCR for processing of CSF specimens (Geretti & 
Brown, 2005). This contrasted with only 5/25 (20%) providing HSV PCR for genital 
swabs. The findings presented here, together with evidence from other investigators, 
provide strong support to the use of PCR for the diagnosis of genital HSV infections. 
Laboratory investigations provide important guidance for the management of patients 
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with suspected genital herpes. Although virus culture continues to be the reference 
diagnostic test, our results showed that its ability to detect HSV in a large proportion 
of infected individuals was clearly deficient compared to PCR. The findings strongly 
supported the implementation of PCR to investigate the epidemiological features of 
genital herpes. 
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Table 3.5 Overview of studies that compared the diagnostic yield of virus culture 
and peR for HSV detection in mucocutaneous swabs 
Swab type No % 
% Specimen PCR Typing VC+ PCR+ £re£aration method 
Reference 
Genital 236 37 41 Manual Real-time RFLP Scoular et 01 .• 2002 
Genital, 668 11 14 Automated Real-time Yes Van Doomum dermal et 01 .• 2003 
Genital 28 64 100 Manual Real-time Yes Aldea et 01 .• 2002 
Genital 63 57 99 Manual Real-time Yes Burrows et 01 .• 2002 
Genital 372 35 48 Manual Real-time Yes Bruisten et 01 .• 2001 
Genital, 88 78 100 Manual Real-time Yes Espy et 01 .• dermal 2000 
Genital 36471 3 12 Manual Real-time No Wald et 01 .• 2003 
Genital 100 32 36 Manual 
Real-time 
Yes Marshall et 01.. Multiplex 2001 
Genital, 110 49 62 Manual Real-time Yes Schmutzhard dermal et 01 .• 2004 
Genital 194 48 59 Manual Gel-based RFLP Slomka et 01 .• 1998 
Genital, 89 50 64 Manual Real-time Yes Filen et 01 .• dermal 2004 
Cutaneous 246 47 60 Manual PCR-EIA Yes Safrin et 01 .• 1997 
Genital, 479 45 45 Automated Real-time Yes Namvar et 01 .• dermal 2005 
Genital 24345 2 13 Manual 
Real-time 
Yes Corey et 01 .• Multiplex 2005 
Genital, 226 9 14 Automated Real-time Yes Mengelle et dermal 01 .• 2004 
Genital, 182 27 39 Automated Real-time Yes Stninska et 01 .• dermal 2004 
Manual 
Genital, 198 35 48 and Real-time Yes Espy et 01 .• dermal Automated 2001 
Genital, 104 41 53 Manual Real-time Yes Koenig et 01 .• dermal 2001 
Manual 
Genital 233 34 57 and Real-time Yes Ramaswamy 
Automated et 01 .• 2005 
Total 64432 704 964 
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Chapter 3b. The establishment of optimal diagnostic methods for 
genital herpes: Antibody detection 
3.5 INTRODUCTION 
Infection with HSV-l and HSV-2 can be classified into primary, initial and recurrent 
on the basis of antibody results. Primary infections with either virus type occur in the 
absence of pre-existing antibodies to HSV -lor HSV -2. Initial infections with one 
virus type occur in the presence of antibodies to the other type. Although the initial 
immune response to HSV is complex and not completely understood, the first 
antibodies to be detected are IgM followed by IgG. Several of the viral envelope 
proteins of HSV-2 (gG, gB, gO, VP5, VP16, ICP35) have been shown to be 
immunogenic, eliciting an antibody response in humans (Gorander et al., 2003; 
Ashley et al., 1994; Straus et al., 1997; Bellner et al., 2005; Ho et al., 1993). Due to a 
high degree of genetic similarity between HSV-l and HSV-2, most viral proteins 
induce a cross-reactive antibody response. Glycoprotein G of HSV-l (gG-l) and 
HSV-2 (gG-2) are the only known viral envelope protein which elicits a type-specific 
antibody response. 
The time required for the development of IgG antibodies following HSV infection 
varies between 21-42 days, although detectable IgG has been demonstrated among 
several individuals 21-28 days from the onset of symptoms (Ashley et a/., 1998; 
Slomka et al., 1995; Ho et a/., 1993; Page et a/., 2003). IgM antibodies are usually 
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detectable 9-10 days after exposure and last 7-14 days, but may remain detectable for 
up to 6 weeks in some individuals (Ho et al., 1992; Ho et al., 1993; Ashley, 1998). 
Therefore, serological testing soon after the first development of symptoms may help 
to determine if an HSV infection is recently acquired (IgM antibody positive, IgG 
antibody negative), or pre-existing (IgG antibody positive). 
Both HSV-l and HSV-2 are closely related, with an overall homology of 50% 
(Dowbenko & Lasky, 1984; Levi et al., 1996). The HSV virion contains 7 
glycoproteins (B, C, D, E, G H, and I). There is extensive antibody cross-reactivity 
between the glycoproteins. However the glycoprotein G (gG) is HSV type-specific 
(Ashley & Wald, 1999; Levi et al., 1996; Morrow et al., 2004; Liljeqvist et al., 2002). 
The US4 gene encoding gG is located in the unique short region of the HSV genome. 
The percentage of HSV-l and HSV-2 homology in the C terminal region of the 
protein is higher than that observed in the N terminal region (Levi et al., 1996). In 
addition, the gG protein of HSV-2 (gG-2) is 460 amino acids longer than its HSV-l 
counterpart (gG-l) (McGeoch et al., 1987). 
Definitive diagnosis of genital herpes is essential for the management of patients and 
transmission prevention strategies. In the past, accurate serologic diagnosis of HSV 
infection was hampered by inaccurate commercial tests that failed to distinguish 
between HSV -1 and HSV -2 antibodies.· The development of IgG and IgM type 
specific serological tests have aided in the diagnosis, treatment, and counselling of 
patients presenting with primary genital HSV infection. The western blot assay 
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remains the current gold-standard test, due to its high specificity and sensitivity. 
However, this assay is expensive and cumbersome, requiring high expertise, and is 
thus not widely used. Commercial assays, based on type-specific gG antigens of 
HSV-l and HSV-2 have become recently available (Table 3.6). Most of these tests 
use colorimetric end points based on enzyme-substrate reactions (EIA), although one 
lmmunblot assay is also available. The recently FDA approved HerpeSelect HSV gG 
diagnostic kits (HerpeSelect 1 EIA, HerpeSelect 2 EIA, HerpeSelect lmmunoblot, 
Focus Technologies, California, USA) have been demonstrated to be very sensitive 
and specific compared to the Western blot (96-100%), (Ashley, 2001) (Table 3.6). 
Table 3.6. Performance of some commercial serological assays based on HSV-2 
gG (gG-2) 
FDA 
HSV -2 serological test (Manufacturer) 
Sensitivity Specificity 
approved (%) (%) 
HSV-2 EIA IgG (Focus Technologies, USA) Yes 96-100 97-100 
HSV -1 and HSV -2 IgG differentiation 
Yes 97-100 98 
Immunoblot (Focus Technologies, USA) 
POCkit HSV-2 (Diagnology, Northern Ireland) Yes 93-100 94-97 
Cob as Core HSV -2 IgG EIA (Roche, 
No 93 98 
Switzerland) 
Captia Select HSV -2 EIA (Centecor, USA) No 90-92 91-99 
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The performance of HSV type specific IgG assays is not affected by HIV -I status 
(Laeyendecker et al., 2004). Although many studies from USA and Europe have 
shown a high degree of concordance for gG-based serologic assays, recent evidence 
has demonstrated that recombinant gG-2 (rgG-2) EIA (Focus Technologies, 
California, USA) may give false-positive results in certain African sera (Hogrefe et 
al.,2002). 
The primary objective of this chapter is to establish the use of HSV -type specific 
serology as a tool to study the epidemiology of genital herpes. As part of the 
evaluation, we investigated the use of commercially available HSV type-specific 
antibody tests in various clinical scenarios. We also evaluated the performance of a 
gG inhibition EIA assay with sera from sub-Sahara Africa. 
3.6 METHODS 
3.6.1 Antibody testing 
Patient sera were tested using the HerpeSelect IgG HSV-I and HSV-2 EIA (Focus 
Technologies, Cypress, California, USA) according to manufacturer's instructions. 
The sample ODs were compared with the reference cut-off readings to determine the 
index values, which were reported according to the formula [Specimen OD/mean 00 
of cut-off calibrator]. 
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Samples were also tested by the HerpeSelect lmmunoblot IgG (Focus Technologies, 
Cypress, California, USA) (Section 2.4.4), according to the manufacturer's 
instructions. Results were read visually as coloured precipitate at different positions 
for an anti-human serum band, HSV common antigen band, HSV gG-I band, and a 
HSV gG-2 band. 
To determine the specificity of the HSV-2 EIA, an inhibition-EIA was established, as 
described in Chapter 2 by pre-incubation patient sera withHSV-I (MacIntyre strain) 
and HSV -2 (MS strain) lysates (I mg/ml). Percent inhibition relative to untreated 
serum was determined by the formula [I - (index of HSV -2 lysate well/index of HSV-
I well)] X 100. Samples showing inhibition 2::60% with HSV-2 but not with HSV-I 
lysates in two independent assays were scored as HSV-2 positive. 
3.7 RESULTS 
3.7.1 Performance of the EIA and Immunoblot 
We tested 537 serum samples by HSV-2 EIA. Using the manufacturer's 
recommended cut-off of 1.1 for a positive result and >0.9 to 1.0 for an equivocal 
result, 316 samples were scored as positive, 79 as equivocal and 142 as negative. 
Equivocal (>0.9 to 1.0) and positive (> 1.1) samples were retested by lmmunoblot. 
51160 (85%) EIA positive samples with index values between 0.9 and 3.0 were 
confirmed positive by the Immunoblot and 9/60 (15%) were negative. Of the 205 
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serum samples with index value >3.0, 186/205 (91%) were positive by Immunoblot 
and 19/205 (9%) were negative. The median EIA index value was 3.9 (range 1.2-
14.4) for samples that tested positive by Immunoblot, and 1.1 (0.9-4.7) for those that 
tested negative. Based on these results, we increased the EIA cut-off value for a 
positive result from 1.1 to 3.1. 
3.7.2 Inhibition EIA 
Previous studies have highlighted problems of specificity associated with the use of 
the HerpeSelect EIA with samples from patients from Uganda and Kenya, when using 
a cut-off of 1.1 for the screening EIA (Hogrefe et a/., 2002; Laeyendecker et a/., 
2004). To address this issue 32 samples that had tested positive by routine EIA (>1.1) 
were retested using an inhibition-EIA, as described earlier (Section 2.4.3). By 
inhibition EIA, 20/32 (63%) Ugandan samples and 2/6 (33%) Kenyan samples 
showed inhibitions levels 2:60%. The median EIA index value for samples that 
showed inhibition values 2:60% was 8.1 (7.2-17.2) whereas that for samples that 
showed lower inhibition levels was 2.2 (1.1-3.8). This confirmed that the use of a 
higher cut-off for the HSV -2 EIA than that recommended by the manufacturers can 
be used to increase specificity without compromising sensitivity of the assay. 
3.7.3 Prospective evaluation of nSV-2 antibody seroconversion 
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The first set of prospective serum samples was obtained from a woman who 
developed a first episode of laboratory-confirmed genital HSV -2 infection during 
pregnancy and transmitted the HSV-2 infection to the neonate. Stored serum samples 
collected at week 12 of pregnancy and 1 week after delivery were tested 
retrospectively by the Focus HSV type-specific EIA. No HSV-l and HSV-2 
antibodies were detected in maternal sera at 12 weeks of pregnancy and 1 week after 
delivery. However, HSV-2 antibodies were detected 6 weeks after delivery, 
indicating a newly acquired primary HSV-2 infection (Table 3.7). Paternal sera 
collected 1 week after delivery was HSV -1 seronegative and HSV -2 seropositive, 
suggesting that the father was the source of the maternal infection. Both parents 
denied a clinical history of genital herpes. 
Table 3.7. HSV type-specific serological follow-up in a couple implicated in the 
neonatal transmission of genital HSV -2 infection 
Time from conception Maternal HSV antibody Paternal HSV antibody 
in weeks statusa statusat 
HSV-l HSV-2 HSV-l HSV-2 
12 0.29 0.46 NO NO 
42 0.55 0.42 0.77 7.47 
47 0.65 10.82 NO NO 
a HSV EIA index values; tNO, no data 
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A second set of samples was obtained from a woman who developed brain stem 
encephalitis associated with HSV -2 detection in CSF by PCR, and evidence of 
intrathecal synthesis of HSV IgG antibodies (Tang et al., 2003) (Table 3.8). 
Sequential serum samples from the patient showed that she remained HSV -1 antibody 
negative throughout the serological follow-up period of 60 days. The patient was 
initially HSV -2 seronegative on day 5 of onset, and seroconverted to being HSV-2 
positive on day 28. Samples taken on days 45, and 60 were HSV-2 antibody positive 
with increasing EIA OD values (Table 3.8). Immunoblot analysis on 4 samples (days 
5-40) revealed the presence of bands on the positions for anti human serum, HSV 
common antigen, and gG-2. No band for gG-l was seen. These findings indicated that 
the brain stem encephalitis was associated with a primary HSV-2 infection, as 
indicated by seroconversion to HSV -2 antibodies in the absence of antibodies to 
HSV-1. 
Table 3.8. HSV serological follow-up in a patient with acute HSV encephalitis 
HSV EIAt 
HSV serological follow up since onset of symptoms in days 
5 28 45 60 
HSV-l 0.17 0.31 0.42 0.64 
HSV-2 0.39 4.78 8.91 11.63 
fHSV EIA index values over the 60 days follow-up period 
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3.7.4 Evaluation in patients with a diagnosis of genital herpes 
Serum samples were collected from 70 GUM clinic attendees with suspected genital 
herpes. Serological testing was performed by the Focus EIA with equivocal results 
confIrmed by an Immunoblot IgG (Focus Technology, USA) (Section 2.4.1, Section 
2.4.4). Based on the clinical history and result of HSV -2 peR of the genital swab, 
serum samples were classifIed as either (1) fIrst-episode genital disease and positive 
HSV -2 peR, (2) a history of recurrent genital disease and positive HSV -2 peR, and 
(3) a history of recurrent genital disease and negative HSV peR. In total, 32 samples 
were HSV -2 antibody positive, including four that were equivocal by EIA but 
positive by immunoblot. 
Among patients with fIrst-episode genital disease and a positive HSV-2 peR, 26/42 
(62%) were HSV-2 antibody negative. This fInding was consistent with a newly 
acquired infection. A follow-up to demonstrate seroconversion in these patients was 
not performed due to the blinded nature of antibody testing. The presence of HSV-2 
specifIc antibodies at the time of presentation in the remaining 16/42 (38%) patients 
with a positive HSV-2 peR indicated that the infection was established than a newly 
acquired infection (Figure 3.2). Among patients with recurrent genital disease and a 
positive HSV-2 peR, 9/9 (100%) tested positive for HSV-2 antibodies. This was 
consistent with the clinical diagnosis of recurrent disease. Among patients with a 
history of recurrent genital disease but negative HSV peR, 7/19 (37%) had HSV-2 
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antibodies, indicating that genital herpes was the likely cause of recurrent symptoms 
(Figure 3.2). 
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Figure 3.2. Detection of HSV-2 specific antibodies in patients with first-episode 
and recurrent genital disease, stratified according to the results of HSV-2 DNA 
detection in genital swabs using polymerase chain reaction (peR). There were 42 
patients with first-episode disease and positive HSV peR, 9 patients with recurrent 
genital disease and positive HSV peR, and 19 patients with a history of recurrent 
genital disease but negative HSV peR. 
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3.8 DISCUSSION 
We evaluated the performance of 2 commercial serological assays (HerpeSelect EIA 
and HerpeSelect Immunoblot), and an in-house inhibition EIA. Overall there was 
excellent concordance between the EIA and Immunoblot results, which is to be 
expected given that tests employ a similar antigenic format. One study which 
compared and evaluated the performance of the HerpeSelect Immunoblot reported 
that the HerpeSelect Immunoblot had specificity, sensitivity, negative and positive 
predictive values of 94%, 98%, 97% and 96.5% respectively (Ribes et al., 2002). 
Another study demonstrated 100% concordance between the HerpeSelect 
Immunoblot and the HerpeSelect EIA in a study of 506/532 concordant specimens 
(Ribes et al., 2002). Nonetheless optimal correlation was found when the cut-off was 
raised from 1.1 to >3.0, which was associated with a confirmed Immunoblot 
reactivity in 91 % of samples. Since the median EIA index value was 3.9 (range 1.2-
14.4) for samples that tested positive by Immunoblot, and 1.1 (0.9-4.7) for those that 
tested negative, a cut-off value of 3.1 was chosen in order to improve specificity 
while preserving good sensitivity. 
When using an inhibition EIA, discrepant results were obtained with specimens from 
patients from Uganda and to a lesser extent Kenya. The evaluation clearly indicated 
that the positive cut-off value for the EIA should be raised from the 1.1 recommended 
by the manufacturer. The median EIA index value for samples that tested positive by 
inhibition EIA was 8.1 (7.2-17.2) whereas that for samples that tested negative was 
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2.2 (0.9-3.8). Thus a cut-off >3.8 may be considered to ensure optimal specificity of 
the assay with some samples from Kenya and Uganda. To ensure no loss of 
sensitivity and given that the origin of samples was not always available, in 
subsequent studies we adopted the same cut-off of 3.1 for all samples. This is in line 
with recent recommendations (Laeyendecker et al., 2004). 
One study that investigated the performance of the HSV-2 EIA on Ugandan sera, 
reported an increase in the index cut-off value to 3.4 improved the specificity of the 
assay (Laeyendecker et al., 2004). It has been suggested that antibodies may exist in 
African sera which react to the gG-2 protein on the HSV -2 EIA, either due to genetic 
reasons or as result of a reaction to other endemic infections in the region 
(Laeyendecker et al., 2004). Another explanation for potential anomalies could be 
that African cohort may be infected with a more heterogeneous population of viruses 
or have a different affinity to HSV-2 as measured by the present assay. Although the 
role of biological contaminants in affecting the assay's fidelity remains unknown, it 
may be possible that certain contaminating proteins may be more prevalent in some 
parts of Africa. 
To asses the evolution of HSV type-specific antibodies in persons with newly 
acquired HSV -2 infection we tested prospective samples from two patients. In the 
first case, we used the HSV type-specific EIA to trace retrospectively the timing of 
HSV -2 infection in a mother who had transmitted HSV -2 to her neonate. In this case 
we demonstrated that no HSV -1 and HSV -2 antibodies were present during 
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pregnancy and immediately after delivery, whereas seroconversion for HSV-2 
antibodies in the absence of HSV -1 antibodies was demonstrated during further 
follow-up. These findings demonstrated a primary HSV -2 infection acquired during 
pregnancy, possibly in the last part of pregnancy, and that delivery occurred before 
the maternal development and possible transplacental transfer of HSV-2 type-specific 
antibodies. This scenario has shown to carry the highest risk of neonatal morbidity 
(Brown, 2004). 
We reviewed a recent clinical case of a 27 year old woman diagnosed with primary 
HSV-2 infection with encephalitis (data not shown), admitted to Kings College 
Hospital (London, UK). Serological testing demonstrated an absence of HSV -2 type-
specific antibodies at the onset of symptoms which however became detectable 
within 4 weeks of onset. The absence of HSV-l antibodies in this case indicated that 
HSV-2 infection was primary. These findings were consistent with previous 
observations indicating that in persons with recently acquired genital herpes, the 
median time to the development of HSV -2 antibodies from the onset of symptoms is 
21-23 days as determined by the HerpeSelect HSV-2 EIA (Ashley-Morrow et af .• 
2003). One study used the HerpeSelect EIA to determine seroconversion times in 113 
patients (413 sera) with recently acquired genital herpes. Of the 113 patients, 31 had 
primary genital HSV-l, 56 had primary HSV-2 and 26 were HSV-l antibody positive 
and newly acquired HSV -2. The median interval from onset of symptoms to 
seroconversion was 25 days, 21 days and 23 days respectively. In addition, the 
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HerpeSelect E1A was able to detect the HSV -2 seroconversion rate faster than the 
western blot assay (Morrow et al .• 2003). 
We also tested the performance of the HSV-2 antibody assay in a population of GUM 
attendees with known HSV PCR results from genital swabs. HSV-2 antibodies were 
detected in all patients with a history of recurrent genital herpes and a HSV -2 positive 
genital swab. Among patients with first-episode genital herpes and a HSV -2 positive 
HSV -2 swab, 62% lacked HSV -2 antibodies consistent with a newly acquired 
infection. Conversely, 38% of first-episodes were in fact established and recurrent 
HSV -2 infections. These data confirmed that differentiation between primary and 
recurrent infections based on clinical history alone can be inaccurate and that type-
specific serology can improve diagnosis by correctly classifying the infection. One 
limitation of this study was that antibody testing was anonymised. Hence serological 
follow-up was not possible to demonstrate seroconversion in patients with a newly 
acquired HSV -2 infection. Among patients with a history of recurrent genital herpes 
but with a negative HSV PCR, 37% were HSV-2 antibody positive, confirming that 
HSV -2 type specific serology can be used to identify patients who lack a definitive 
diagnosis of genital herpes by HSV detection methods. This finding also 
demonstrates that although PCR significantly improves HSV detection, the combined 
use of PCR and serology can provide the most sensitive tool for the diagnosis of 
patients with recurrent genital disease of unknown aetiology. 
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With the recent advent of HSV type-specific serological tests, it has become possible 
to use HSV -type specific serology in sexual health settings. Several applications are 
currently being evaluated including the management of individuals with features 
suggestive of genital herpes where culture and/or peR are repeatedly negative. In this 
context a positive HSV-2 antibody result is consistent with genital HSV-2 infection 
and may therefore provide the diagnosis. The detection ofHSV-l antibodies however 
would not differentiate between a genital and an oropharyngeal HSV infection 
(Ashley & Wald, 1999). Potential applications include management and risk-
reduction counseling of patients with/without partners diagnosed with genital herpes. 
In addition, determining whether HSV infection is new or established in pregnant 
women with first-episode genital herpes would provide valuable information on the 
risk of vertical infection in the neonate (Ashley, 1998). HSV-2 type-specific antibody 
testing may be proposed as a screening tool to diagnose genital herpes in 
asymptomatic persons and identify those at risk of transmitting the infection to sexual 
partners or neonates (Wald, 2002; Kimberlin, 2004). This however remains currently 
controversial. 
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4. Chapter 4. The clinical epidemiology of genital herpes in 
genitourinary clinic attendees 
4.1 INTRODUCTION 
Genital herpes has traditionally been associated with HSV -2 infection. In recent 
years however, HSV-1 has increasingly been recognised as a common cause of 
genital herpes. In several cohorts in Europe and the USA (Smith & Robinson, 
2002) HSV-1 has accounted for over 50% of first presentations. Among GUM 
clinic attendees in England and Scotland, 22-71 % of genital herpes cases were due 
to HSV-1 (Woolley & Kudesia, 1990; Ross et ai., 1993; Tayal & Pattman, 1994; 
Scoular et ai., 2002), 
It is important to determine the HSV type in genital infections, as knowledge of 
the infecting HSV type provides additional information for management and 
counselling. The natural history of genital infection differs significantly according 
to whether HSV-1 or HSV-2 is implicated. Although the duration of HSV-1 and 
HSV-2 episodes is similar, infection with HSV-1 is milder with fewer recurrences 
(Engelberg et ai., 2003; Benedetti et ai., 1994). The risk of a symptomatic 
recurrence is 50-57% for HSV-1 and 89% for HSV-2 within the first 12 months 
after first episode disease. For HSV-1 and HSV-2 infections, the average annual 
recurrence rates are 1.3 and 4 episodes per year respectively (Corey & Holmes, 
1983; Engelberg et ai., 2003; Benedetti et ai., 1994). Although the rates of HSV 
recurrences decline over time for both viruses, HSV -1 recurrences decline by 50% 
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within the second year of infection, whereas an appreciable decline in the 
recurrence rate is not observed with HSV-2 until 3 to 5 years after the first episode 
(Wald et al., 2000; Benedetti et al., 1999). Sub-clinical shedding is also less 
frequent with HSV-l (Koelle & Wald, 2000). Given the important role that sub-
clinical shedding plays in transmission, this observation suggests that transmission 
may occur less easily than transmission of HSV-2. 
In the previous chapter we demonstrated that real-time PCR is a sensitive 
technique for HSV detection in genital swabs. Using this method, we investigated 
the epidemiological and clinical features of genital herpes in an ethnically diverse 
population of GUM attendees. 
4.2 METHODS 
The cohort included 186 consecutive GUM clinic attendees from Kings College 
Hospital, London who underwent swabbing for suspected genital herpes. The 
genital swabs were tested by real-time LightCycler PCR and typed as described in 
the previous chapter. Statistical analyses were performed using SAS version 8; X2 
or Fisher's exact tests were used for qualitative variables, Mann-Whitney U tests 
for quantitative variables. 
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4.3 RESULTS 
4.3.1 Study population 
The demographic characteristics of our study population are summarised in Table 
4.1. We investigated 186 consecutive individuals presenting to the GUM clinic in 
Kings College Hospital, London with suspected genital herpes. There were 104 
males and 82 females, and the median age was 29 years (range 16-67 years). 
Sexual orientation was predominantly heterosexual (1761186, 95%). A large 
proportion of the cohort comprised of persons of black-Caribbean ethnicity 
(76/185, 41%) followed by white (65/186, 35.5%) and black-African ethnicity 
(44/186, 22%). Of the 76 patients of black-Caribbean ethnicity, 39176 (51%) 
patients immigrated to the UK from Jamaica and 37176 (49%) were born in the 
UK. Of the 65 patients of white ethnicity, most were born in the UK (56/65,86%), 
and the remaining 9/65 (14%) were born in other European countries (n=6) or 
America (n=3). Of the 41 patients of black-African ethnicity, 29/41 (71%) had 
immigrated to the UK from Sub-Saharan Africa and 12/41 (29%) were born in the 
UK (n= 11) or France (n= 1). The most common countries of origin in Sub-Saharan 
Africa were Zimbabwe (7/29), Nigeria (7129), Ghana (5/29), Zambia (3/29), 
Uganda (2129), Gambia (1/29), Eritrea (1/29), Ethiopia (1/29) and Kenya (1129). 
Finally, there were three patients from the Indian subcontinent and one from the 
Middle East. 
- 118 -
Table 4.1. Demographic and clinical characteristics of patients with suspected 
genital herpes stratified by gender 
Men Women 
n(%) n(%) pI 
Number 104 82 
UK 53 (51) 52 (63) 
Country of birth Jamaica 26 (25) 13 (16) 
Other 25 (24) 17 (21) 0.19 
Black-Caribbean 41 (39) 35 (43) 
Ethnic group 
White 35 (34) 30 (37) 
Black-African 24 (23) 17 (21) 
Other 4 (4) 0 (-) 0.37 
Median 30 29 0.37 
Age (years) 
Range 17-67 16-61 
First-episode 60 (58) 54 (66) 
Disease Recurrent 44 (42) 28 (34) 0.33 
Penis 85 (82) 
Perineum 9 (9) 9 (11) 
Urethra 6 (6) 
Swab site Scrotum 4 (4) 
Vulva 63 (77) 
Vagina 9 (11) 
Buttock 1 (1) nla 
Onset 
<5 days 43 (41) 51 (62) 
~5 days 61 (59) 31 (38) 0.008 
Ulceration 72 (69) 62 (76) 0.42 
Negative 53 (51) 31 (38) 
HIV status Positive 11 (11) 8 (10) 
Not known 40 (39) 43 (52) 0.15 
IP-value obtained from xi, Fisher's exact or Mann-Whitney U tests. 
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4.3.2 Clinical features of infection 
Lesions most commonly occurred in the penile skin in men (85/104,82%) and the 
vulva in women (63/82, 77%). Other lesion sites included the perineum, urethra, 
and scrotum in men, and the vagina and buttocks in women (Table 4.1). Women 
were significantly more likely than men to present <5 days of the onset of 
symptoms (51182, 62% versus 43/104,41 %; P=0.008) (Table 4.1). There were no 
other significant differences between men and women, except that the 10 
homosexual patients were all men. A clinical diagnosis of first episode disease 
was made in 114/186 (61%) of patients. The remaining 72/186 (39%) reported a 
history of recurrent genital herpes. No significant differences were seen between 
first and recurrent episodes in the time of presentation (P=0.10), the presence of 
visible ulceration on examination (P= 0.48), and the site of presentation in men 
(P=0.45) and women (P=0.58) (Table 4.2). 
Analysis of demographic and clinical features according to ethnic background 
showed that all men of homosexual orientation were of white ethnicity (P=0.0002) 
(Table 4.3). Patients of black-African ethnic origin were older than those from 
other ethnicities (P=0.03). Patients of white ethnicity (38/65, 59%) were the most 
likely to present ~5 days of the onset of symptoms, whereas those of black-
Caribbean ethnicity (29176, 38%) were the least likely (P=0.04) (Table 4.3). In the 
entire cohort, HIV-l status was negative in 84/186 (45%) and positive in 19/186 
(10%) patients. A large proportion of patients declined HIV testing (83/186, 45%). 
A large proportion of persons of black-Caribbean origin declined HIV testing 
compared with other ethnicities (P=0.03) (Table 4.3). 
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Table 4.2. Comparison of clinical characteristics among patients "ith 
suspected genital herpes, stratified by first episode and recurrent disease 
presentations 
Clinical characteristics First episode Recurrent pI 
episode 
S' 2 Ite among men : 
Penis 51 (85.0) 34 (77.3) 
Perineum 4 (6.7) 5 (11.4) 
Urethra 2 (3.3) 4(9.1) 
Scrotum 3 (5.0) 1 (2.3) 0.45 
S" 2 Ite In women: 
Vulva 43 (79.6) 20 (71.4) 
Perineum 5 (9.3) 4 (14.3) 
Vagina 6(11.1) 3 (10.7) 
Buttock 0(-) 1 (3.6) 0.58 
Onset 
<5 days 63 (55.3) 31 (43.1) 
>5 days 51 (44.7) 41 (56.9) 0.10 
Ulceration: 80 (70.2) 54 (75.0) 0.48 
HSV-2Ab 
Number tested 42 28 
n (%) positive 16(38.1) 19(67.9) 0.03 
IP-value obtained from Chi-squared tests, Fisher's exact tests or Mann-Whitney U 
tests, 2Comparisons of site of swab are performed after combining the three 
smallest groups in each case. Therefore, in men the comparison is between the 
penis and other sites, and in women it is between the vulva and other sites. 
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Table 4.3. Demographic and clinical characteristics of patients presenting 
with suspected genital herpes, stratified by ethnic group) 
Black- White Black-Caribbean African 
n(%) n (%) n(%) p2 
Number 76 65 41 
Gender Male 41 (54) 35 (54) 24 (59) 
Female 35 (46) 30 (46) 17 (42) 0.87 
Sexual Heterosexual 76 (100) 56 (86) 41 (100) 
orientation Homosexual o (-) 9 (14) 0(-) 0.0002 
Age Median 28 29 33 0.03 
Range 16-57 17-61 18-67 
Disease First-episode 51 (67) 38 (59) 22 (54) 
Recurrent 25 (33) 27 (42) 19 (46) 0.32 
Swab site Penis 34 (45) 29 (47) 18 (44) 
Perineum 6 (8) 7 (11) 5 (12) 
Urethra 2 (3) (1.5) 3 (7) 
Scrotum 3 (4) 1 (2) 
Vulva 27 (36) 22 (34) 14 (34) 
Vagina 4 (5) 5 (8) 
Buttock 1 (1.5) nla 
Onset <5 days 47 (62) 27 (42) 19 (46) 
~5 days 29 (38) 38 (59) 22 (54) 0.04 
Ulceration 57 (75) 43 (66) 32 (78) 0.34 
HIV status Negative 30 (40 34 (52) 18 (44) 
Positive 6 (8) 4 (6) 9 (22) 
Not known 40 (53) 27 (42) 14 (34) 0.03 
(Four patients with other ethnicities were excluded, 2P-value obtained from '1.2-
squared tests, Fisher's exact tests or Mann-Whitney U tests. 
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4.3.3 Detection of HSV in genital swabs by real-time peR 
Real-time PCR detected HSV DNA in 108/186 (58%) genital swabs (Table 4.4). 
The majority of HSV positive patients were infected with HSV-2 (1011108, 
93.5%), and only a small proportion with HSV-I (7/108, 6.5%). Typing results 
were confirmed as described in chapter 3. The proportion of HSV-1 positive 
swabs was 4/58 (7%) in men, 3/51 (6%) in women, 5/62 (8%) in first-episode 
presentations and 2/46 (4%) in recurrent disease. 
Statistical analysis by univariable analysis revealed a positive HSV PCR to be 
associated with heterosexual risk group, <5 days of onset and presence of genital 
ulceration (Table 4.4). Multivariable analysis confirmed all three factors to be 
independently associated with a positive HSV PCR after adjustment (Table 4.4). 
No significant differences were evident in HSV detection rates between men and 
women (P=0.31), first and recurrent episodes (P=0.26), and HIV status (P=O.lS). 
Analysis by ethnic origin showed that a similar proportion in each group tested 
positive for HSV (P=0.24). Of those who tested positive for HSV, HSV-1 was 
significantly associated with white ethnicity, whereas HSV-2 was common in 
persons of black-African and black-Caribbean ethnicity (P=0.006) (Figure 4.1). 
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Table 4.4. Characteristics of patients whose genital swabs tested positive for 
HSV. 
HSV PCR positive) Multivariable Analysis 
n (%) p2 OR (95% CI)3 P 
Male 57 (55) 
Gender 
Female 51 (62) 0.31 
Black-Caribbean 49 (65) 
White 33(51) 
Ethnic group Black-African 25 (61) 
Other 1 (25) 0.20 
Sexual Heterosexual 106 (60) 
orientation Homosexual 2 (20) 0.02 0.16 (0.03-0.83) 0.03 
First-episode 62 (54) 
Disease Recurrent 46 (64) 0.26 
<5 days 62 (66) 2.00 (1.04-3.81) 0.04 
Onset ~5 days 46 (50) 0.04 
No 15 (29) 
Ulceration Yes 93 (69) 0.0001 5.63 (2.73-11.61) 0.0001 
Negative 51 (61) 
HIV status Positive 14 (74) 
Not known 43 (52) 0.18 
Those with negative 29 (16-54) 
PCR 
Age 
Those with positive 30 (17-67) 0.84 
PCR 
lHSY positive results included both HSY-l and HSV-2 positive swabs, iP-value 
obtained from x2-squared tests, Fisher's exact tests or Mann-Whitney U tests, 
395% Confidence Interval. 
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Figure 4.1. Contribution of HSV-l and HSV-2 to genital herpes, by ethnicity. 
Among persons whose genital swabs tested HSV positive, HSV-l was detected 
more commonly in those who were white, while HSV -2 was more common in 
those of black-African and black-Caribbean ethnicity (P=O.006). 
4.4 DISCUSSION 
The results presented in this chapter indicated that epidemiological trends in 
genital herpes due to HSV-l or HSV-2 vary between ethnicities in the UK. 
Ethnicity did not predict the likelihood of a HSV positive genital swab and did not 
modify the clinical features of the infection; however, it significantly influenced 
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the type of HSV associated with the infection and the delay between onset of 
symptoms and presentation. Early studies in UK (Sheffield, Newcastle upon Tyne, 
and Watford) and Scotland (Edinburgh, Fife and Glasgow) have shown HSV-l to 
account for 22-71 % of cases of genital herpes, with a higher prevalence among 
young women with first-episode disease (Woolley & Kudesia, 1990; Ross et al., 
2003; Tayal & Pattman, 1994; Slomka et aI., 1998; Thompson, 2000; Scoular et 
al., 2002). 
Among GUM attendees in Edinburgh, HSV -1 was more commonly reported as 
the cause of genital herpes in patients born in the UK than HSV -2 (Ross et al., 
1993). The results from this study are in contrast with other studies done in the 
UK. HSV-2 was the most prevalent cause of genital herpes in our ethnically 
diverse population. A significant association was found between black ethnicity 
and HSV-2 infection. To explain this observation, one could propose that 
childhood acquisition of HSV -1 among those of lower socioeconomic status could 
render them less susceptible to genital HSV -1 infection during adulthood. One 
could also speculate that persons of black ethnicity were less likely than patients 
of white ethnicity to attend the GUM clinic if infected with HSV -1. 
HSV -1 oropharyngeal transmission occurs commonly in children, and may 
influence the risk of genital HSV -1 acquisition in later life. Epidemiological 
surveys in England and Wales, including a small proportion (2%) of persons from 
London, indicated that currently HSV -1 acquisition occurs less commonly in 
children, leaving large numbers of sexually active adults susceptible to genital 
HSV -1 infection as they lack protective antibodies (Vyse et aI., 2000). In contrast, 
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HSV -1 seropositivity rates remain >91 % in children in several African countries 
(Smith & Robinson, 2002). In the UK and the USA, the seroprevalence of HSV-l 
is higher in persons of black ethnicity compared to those of white ethnicity 
(Gibson et al., 1990; Breinig et al., 1990). In a study of 3533 pregnant women 
attending an antenatal clinic in London, HSV -1 seroprevalences were 75%, 96% 
and 92% among black women born in the UK, Africa and the Caribbean 
respectively, compared to 80% of women born in the UK of white ethnicity (Ades 
et al., 1989). The population-based AIDS in multiethnic neighbourhoods study 
among 1770 individuals in the USA, revealed 61 % and 46% of persons of black 
and white race respectively to be HSV -1 seropositive (Siegel et al., 1992). 
Another important contributing factor is that the GUM clinic in Kings College 
Hospital (London, UK) serves a socio-economically disadvantaged population, 
which may be more likely to acquire oropharyngeal HSV -1 infection in childhood 
(Cowan et al., 2002; Barlow et al., 1997; Narouz et al., 2003). This may explain 
the relatively low prevalence of HSV-l in women of white ethnicity, with 2/9 
(22%) first-episode diseases and 117 (14%) recurrences due to HSV-l, which is in 
contrast with the recognised strong association between genital HSV-l and female 
gender (Scoular et al., 2002). 
An increase in oral sex practices is thought to be a contributory factor to the 
increasing prevalence of genital HSV -1 infections, resulting from transmission 
from persons infected with HSV -1 oropharyngeally. There is limited evidence to 
indicate that oral sex practices vary among patients of different ethnicity. Surveys 
conducted among GUM attendees in London between 1993-1994, indicated 
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women of white origin were more likely to have practiced fellatio than women of 
black-Caribbean ethnicity, and that both fellatio and cunnilingus were practised 
more frequently by men of white ethnicity than men of black ethnicity (Radcliffe 
et al., 1993; Evans et al., 1998). One study conducted among students in the USA, 
revealed that persons of white ethnicity were significantly more likely to engage 
in oral sex than those of black ethnicity (Johnson et al., 1994). In contrast, another 
study reported the proportion of black American teenage men who engaged in oral 
sex to have more than doubled between 1988 - 1995, an increase that brought 
them in line with levels of oral sex reported by white and Hispanic adolescent 
males (Gates & Sonenstein, 2000). However, findings from this study must be 
interpreted with caution as population demographics was lacking. As the 
prevalence of genital HSV-l infections increases in the community, genital 
transmission of HSV -1 also becomes more likely. In this context assortative (like 
with like) sexual mixing may contribute to maintaining the differences in 
prevalence of genital HSV -1 among ethnic groups. 
Independent predictors of a positive HSV PCR were early presentation after the 
onset of symptoms, heterosexual risk group and presence of visible genital 
ulceration on examination. Women were more likely than men to present early 
after the onset of symptoms. An additional interesting finding was that patients of 
black-Caribbean ethnicity presented earlier than other groups. A large proportion 
of patients of black-Caribbean ethnicity also declined HIV testing compared to 
patients of other ethnicity. HIV infection rates are estimated to be significant in 
this group, ranging from 0.6-0.7% among heterosexuals to over 10% among male 
homosexuals (Dougan et al., 2004). Our findings support results from the 
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Unlinked Anonymous Prevalence Monitoring Programme which showed 50-73% 
of black-Carribean persons in the UK left the GUM clinic unaware of their HIV 
infection (Dougan et at., 2004). 
In summary, this study highlighted differences in genital HSV -1 and HSV-2 
i~fection trends between different ethnicities in the UK. HSV PCR was used for 
the virological diagnosis of genital herpes, due to its increased sensitivity, as 
demonstrated in the previous chapter. The prevalence of HSV-2 infection was 
high among the cohort, with a higher prevalence in patients of black ethnicity. 
These findings have important implications for strategies to prevent the 
transmission of genital herpes. 
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Chapter 5. Sequence analysis of the HSV-2 UL14 gene in clinical isolates 
from an ethnically diverse population with genital herpes 
5.1 INTRODUCTION 
The genome of Herpes simplex virus (HSV) contains at least 74 genes, many of which 
have unknown function. The UL 14 gene is a core gene of herpesviruses. It is conserved 
among all alpha herpesviruses and homologues are found in beta and gamma herpes 
viruses. UL 14 encodes a 219 amino acid protein with a 32kDa molecular mass, which is a 
minor component of the viral tegument produced late in the replication cycle (McGeoch 
et ai., 1988; Dolan et ai., 1998). The coding region overlaps substantially with that of the 
UL13 gene. 
The UL14 gene is dispensable for HSV replication in cultured cells and is therefore 
classified as an accessory gene. Nonetheless accessory genes appear to play essential 
roles in HSV replication and infectivity (Nishiyama, 2004). Consistent with this 
observation, a mutant with a 4 bp deletion in the central part of UL14 (amino acid 
position 96-98) showed an extended growth cycle in vitro and appeared compromised in 
efficient transit of virus particles from the infected cell (Cunningham et ai., 2000). In 
mice injected intracranially, the 50% lethal dose of the mutant virus was significantly 
reduced. In addition, recovery of the mutant virus from the sacral ganglia of mice injected 
peripherally was significantly reduced relative to that of wild-type virus, suggesting 
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defective establishment of latency or defective reactivation from latency (Cunningham et 
al.,2000). 
Although the function of the UL14 gene has not yet been fully characterised, HSV-l 
UL14 appears to function as a molecular chaperone and is involved in the translocation to 
the nucleus of the viral proteins VP26 (a minor capsid protein) and UL33 (a DNA 
cleavage/packaging protein) (Roizman, 1996; Yamauchi et al., 2001). The UL14 protein 
shares several properties of heat shock proteins (Hsp), including nuclear translocation 
upon heat shock, A TP deprivation and osmotic shock (Yamauchi et al., 2002a). The 
protein contains an amino acid sequence that is homologous to part of the substrate-
binding domain of the Hsp70 family. In HSV-2, the homologous region stretches a region 
beginning with Arg60 to Ala74. Two arginine residues in this region (Arg 60 and Arg64) 
have been found to be important for the translocation to the nucleus of VP26 (Yamauchi 
et al., 2002a). Further data have suggested that the UL14 protein plays an anti-apoptotic 
role, which is consistent with the role of other molecular chaperones such as Hsp27 and 
Hsp70 (Yamauchi et al., 2003). 
Although the UL region of the HSV-l strain 17 has been sequenced (McGeoch et al., 
1988; Dolan et al., 1998), there are no data currently on the degree of conservation of the 
UL 14 gene. Most studies on the molecular diversity of HSV -2 have focused on the DNA 
polymerase (Podzorski et al., 2000; Sun et al., 2003) or the thymidine kinase (TK) gene 
(Chibo et al., 2004; Nagamine et al., 2000). HSV genetic variability has been used to 
identify HSV genotypes associated with distinct anatomical sites (Buchman et al., 1978; 
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Chaney et al., 1983; Umene & Yoshida, 1993; Umene et al., 1996; Umene & Kawana, 
2000; Remeijer et al., 2002; Yoshida & Umene, 2003; Roest et al., 2004) and disease 
patterns (Yoshida & Umene, 2003; Buchman et al., 1978; Chaney et al., 1983; Umene & 
Yoshida, 1993; Umene & Kawana, 2000; Yoshida & Umene, 2003) and to investigate the 
molecular epidemiology of HSV infections (Sakaoka et al., 1985; Sakaoka et al., 1987; 
Umene & Sakaoka, 1991; Sakaoka et al., 1995; Maertzdorf et al., 1999; Sakulwira et al., 
2003; Norberg et al., 2004; Bowden et al., 2004). These studies have most commonly 
employed restriction fragment length polymorphism (RFLP) to investigate HSV 
variability. Although geographical clustering of HSV-2 strains has been suggested 
(Sakaoka et al., 1987; Sakaoka et al., 1995), there remains limited information on the 
variability of HSV -2 sequences. 
The aim of this study was to characterise sequence variability of the HSV-2 UL14 gene in 
clinical isolates obtained from an ethnically diverse cohort of patients with genital herpes. 
5.2 METHODS 
Genital swabs (Section 2.1.1) from 26 GUM clinic attendees from Kings College 
Hospital, London who presented with clinical symptoms of genital herpes and had a 
HSV -2 positive swab by real-time LightCycler PCR (Section 2.5.1.1, Section 2.5.2.1) 
were processed. The viral DNA was extracted using the QIAamp DNA mini kit (Qiagen, 
UK) as previously described (Section 2.5.1.1, Section 2.6.1.2). PCR amplification of the 
659 bp spanning position from 28229 to 28888 of the HSV-2 UL14 gene was performed 
- 132-
with dNTPs, forward and reverse primers as described earlier (Section 2.6.1.2). For 
negative controls, DNA specimens were replaced with deionised water. Positive controls 
included previously known clinical specimens that were typed HSV -2 positive by both 
virus culture and PCR. Amplicons of 500 bp were identified by ethidium bromide 
staining and the UL14 protein region was sequenced (spanning amino acids 1-137) using 
identical forward and reverse primers on an ABI 3100 analyser, under conditions 
previously described (Section 2.6.2, Section 2.6.3). Sequence analysis was performed 
using Chromas software version 1.45 and confirmed HSV-2 using BLAST. Sequence 
alignment was performed using ClustalW software version 1.82. 
(http://www.ncbi.nlm.nih.gov/BLAST). Only one entry for the HSV-2 UL14 nucleotide 
sequence was found in the Genbank database (Accession no: CAB06774). Sequence 
alignment was performed using ClustalW software version 1.82 
(http://clustalw.genome.jp). The 26 nucleotide sequences were submitted to GenBank and 
assigned accession numbers (Table 5.3). 
5.3 RESULTS 
5.3.1 Study population 
The cohort included 26 GUM attendees (13 men and 13 women) from Kings College 
Hospital, London who were diagnosed with HSV -2 infection. The demographic 
characteristics of the study population are summarised in Table 5.1. Our cohort was 
ethnically diverse and included 8/26 (31 %) black-African patients of which 5/8 were born 
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in Nigeria (n=3) or Zimbabwe (n=2) and migrated to the UK in adult life, and 3/8 were 
born in the UK. Among the 13/26 black-Caribbean patients, 5/13 (39%) were born in 
Jamaica and migrated to the UK in adult life, and 8/13 (61%) were born in the UK. 
Among those of white ethnicity, 5/26 (19%), all were born in the UK. Genital lesions 
were seen most commonly in the penile skin of males (12/13, 92%) and in the vulva of 
females (9/13, 69%). Other sites of presentation included the perineum and the buttock. 
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Table 5.1. Demographic characteristics of GUM attendees with genital herpes 
Characteristics n(%) 
Gender Male 13 (50) 
Female 13 (50) 
Age (median, range in years) 32 (17-60) 
Sexual orientation Heterosexual 25 (96) 
Homosexual 1 (4) 
Ethnicity Black-Caribbean 13 (35) 
Black-African 8 (31) 
White 5 (19) 
Clinical Episode First 15 (58) 
Recurrent 11 (42) 
Onset of symptoms < 5 days 17 (65) 
~ 5 days 9 (35) 
HIV status Positive 4 (15) 
Negative 10 (38) 
Unknown 12 (46) 
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5.3.2 Nucleotide differences of the HSV-2 UL14 gene among individuals diagnosed 
with genital herpes 
HSV -2 UL14 sequences were conserved and no differences were observed in the 
nucleotide sequences of 18/26 (69%) samples. The 8/26 (31 %) individuals with variant 
nucleotide sequences included 4 white patients all born in the UK, 2 black-African (one 
born in the UK and one from Zimbabwe) and 2 black-Caribbean persons from Jamaica. 
There were equal proportions of men and women and 4/8 patients presented with first-
episode disease. 
Sequence alignment revealed that sequence differences evident in the 8 patients were 
primarily nucleotide substitutions. These were scattered across 8 different regions of the 
UL14 gene (Table 5.2) at positions 28237 bp, 28347 bp, 28362 bp, 28469 bp, 28601 bp, 
28603 bp, 28606 bp and 28617 bp. One patient showed a single insertion at position 
28636 bp. 
Among the patients with variant sequences, 7/8 showed a single nucleotide substitution, 
whereas one 39 year old black-African male patient born in the UK showed a more 
divergent sequence with 4 nucleotide substitutions. The sequence variation in the 8 
patients included two silent or synonymous substitutions and 8 non-synonymous 
nucleotide substitutions (Table 5.2) that translated into single point mutations at amino 
acid positions 3, 40, 45, 125, 126 and 130 of the UL14 protein. One black-Caribbean 
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patient from Jamaica showed a single nucleotide insertion at bp position 28636, which 
translated into 7 point mutations spanning amino acid positions 129-136. All 26 
nucleotide sequences were submitted to the GenBank database (Table 5.3). 
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Table 5.2. Demographic characteristics and nucleotide sequence differences in patients 
infected with variant strains of HSV-2 
Country of Ethnic Clinical Nucleotide Nucleotide variationC Amino acid 
Patient8 
birth groupb episode position (bp) changed 
F 19 UK W Recurrent 28237 G-C SS NSy R3P 
M20 UK W First 28237 G-C SS NSy R3P 
F 21 Zimbabwe BA Recurrent 28237 G-C SS NSy R3P 
M22 UK BA Recurrent 28347 G-A SS NSy D40N 
28603 C-T SS NSy A125V 
28606 A-C SS NSy N126T 
28617 T-C SS NSy W130R 
M23 UK W First 28362 G-T SS NSy G45C 
M24 UK W Recurrent 28469 C-A SS Sy 
F 25 Jamaica BC First 28601 G-T SS Sy 
L129P, W130V, 
F 26 Jamaica BC First 28636 +C SI NSy D132G, G133R, o 134R, L135P, 
A136G 
aM= male; F= female; bW= white, BA= black African, BC= black-Caribbean; Nucleotide 
variation from consensus, whereby the first letter denotes the consensus nucleotide and 
the second letter denotes the change; SS= single substitution, SI= single insertion; Sy= 
synonymous NSy= non syno nymous; d Amino acid change from consensus sequence, 
whereby the first letter denotes the amino acid consensus and the second letter denotes 
the base change 
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Table 5.3. HSV-2 UL14 amino acid sequences (amino acids 1 to 137) in 26 patients infected with HSV-2. 
Position 10 20 30 40 50 60 70 80 90 100 11 0 120 130 137 
Control s e que nce MSRDASHAALRRRLAETHLRAEVYRDQTLQLHREGVSTQDPRFVGAFMAAKAAHLELEARLKSRARLEMMRQRATCVKIRVEEQAARRDFLTAHRRYLDPALSERLDAADDRLADQEEQLEEAAANASLWGDGDLAD 
1- 18 : 
DQ22 4079 - DQ224081 
DQ231011 - DQ231025 MSRDASHAALRRRLAETHLRAEVYRDQTLQLHREGVSTQDPRFVGAFMAAKAAHLELEARLKSRARLEMMRQRATCVKIRVEEQAARRDFLTAHRRYLDPALSERLDAADDRLADQEEQLEEAAANASLWGDGDLAD 
24 : DQ223892 
25 : DQ223893 
F19: DQ222885 MSPDASHAALRRRLAETHLRAEVYRDQTLQLHREGVSTQDPRFVGAFMAAKAAHLELEARLKSRARLEMMRQRATCVKIRVEEQAARRDFLTAHRRYLDPALSERLDAADDRLADQEEQLEEAAANASLWGDGDLAD 
M20: DQ223889 MSBDASHAALRRRLAETHLRAEVYRDQTLQLHREGVSTQDPRFVGAFMAAKAAHLELEARLKSRARLEMMRQRATCVKIRVEEQAARRDFLTAHRRYLDPALSERLDAADDRLADQEEQLEEAAANASLWGDGDLAD 
F21 : DQ223890 MS~PASHAALRRRLAETHLRAEVYRDQTLQLHREGVSTQDPRFVGAFMAAKAAHLELEARLKSRARLEMMRQRATCVKIRVEEQAARRDFLTAHRRYLDPALSERLDAADDRLADQEEQLEEAAANASLWGDGDLAD 
M23 : DQ223891 MSRDASHAALRRRLAETHLRAEVYRDQTLQLHREGVSTQDPRFVQAFMAAKAAHLELEARLKSRARLEMMRQRATCVKIRVEEQAARRDFLTAHRRYLDPALSERLDAADDRLADQEEQLEEAAANASLWGDGDLAD 
1122: DQ222886 MSRDASHAALRRRLAETHLRAEVYRDQTLQLHREGVSTQ~PRFVGAFMAAKAAHLELEARLKSRARLEMMRQRATCVKIRVEEQAARRDFLTAHRRYLDPALSERLDAADDRLADQEEQLEE 
F26: DQ223894 MSRDASHAALRRRLAETHLRAEVYRDQTLQLHREGVSTQDPRFVGAFMAAKAAHLELEARLKSRARLEMMRQRATCVKIRVEEQAARRDFLTAHRRYLDPALSERLDAADDRLADQEEQLEEAAANAS"2llG] D 
·Point mutations are shaded. The HSV-2 UL14 control sequence was derived from the GenBank database (Accession no: CAB06774). 
GenBank accession numbers for the 26 nucleotide sequences are denoted alongside patient identifiers; ·Amino acid position calculated 
from start of the 219 amino acid UL14 protein. 
- 139 -
5.4 DISCUSSION 
In this study we demonstrated a high degree of conservation of the HSV -2 ULl4 gene 
among HSV-2 infected GUM attendees in London. RFLP analysis has demonstrated the 
presence of genomic polymorphism among strains of the same HSV type (Umene & 
Yoshida, 1993; Umene & Sakaoka, 1991; Sakulwira et al., 2003). Several 
epidemiological studies have used this approach to genetically characterise HSV 
infections, with particular emphasis on HSV -1 (Maertzdorf et al., 1999; Roest et al., 
2004; Umene et al., 2003; Yoshida & Umene, 2003). Molecular epidemiological studies 
demonstrated that HSV -1 RFLP patterns show geographical clustering (Sakaoka et al., 
1985). There is limited information available for HSV -2 (Sakaoka et al., 1995; Norberg et 
al., 2004; Bowden et al., 2004). Early studies on 123 unrelated HSV-2 isolates from 
Japan and Sweden showed distinct cleavage site distributions (Sakaoka et al., 1987). This 
finding is consistent with data from a study of 307 HV -2 isolates from four countries 
(Japan, Korea, Sweden and USA) which similarly showed geographical clustering of 
HSV-2 strains (Sakaoka et al., 1995). 
Association between HSV genotypes and both anatomical site of infection and disease 
patterns have been proposed. Early studies that analysed HSV-l DNA variation using 
RFLP analysis identified 35 HSV-l genotypes, of which Fl and F35 were predominant 
(Umene & Yoshida, 1993). The Fl genotype was associated with multiple clinical 
patterns. In contrast, the F35 genotype showed a characteristic association with eczema 
herpeticum (Umene et al., 1996). Genotypic variation has also been observed among 
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sequential isolates of 11130 (37%) patients with recurrent epithelial keratitis (Remeijer et 
al., 2002). HSV-l genotypes can also be specifically isolated from primary or recurrent 
genital lesions and the HSV-l Fl genotype has been shown to be closely associated with 
recurrent infections (Umene & Kawana, 2000). 
There are no data available on the sequence variability of the HSV -2 UL 14 gene. Our 
findings demonstrated that the gene sequence if conserved, with nucleotide changes 
occurring in 8126 (31 %) patients. The substitutions translated into amino acid changes in 
6 of the 8 patients. There were no consistent substitution patterns, as changes involved 
amino acid position 3 in three patients, 45 in one patient, and 40, 125, 126 and 130 in 
another patient. There was a high degree of conservation of the protein region spanning 
amino acids 46 to 124. One black Caribbean female showed a single nucleotide insertion 
which resulted in multiple amino acid changes between positions 129-136. To determine 
whether the nucleotide insertion and the amino acid changes represented a new allele 
polymorphism or a result from a typing or sequencing error, patient specimens underwent 
virus culture, PCR and sequencing. Reproducible results were obtained, suggesting the 
above were not due to sequencing artefacts. In addition, no trends in HSV variability 
were observed according to ethnic background or clinical presentation. 
Previous data indicate that the amino acid sequences in the N-terminal region (residues 
60-74) of HSV -2 UL14 protein sequence shares homologies with the C-terminal region of 
the substrate recognition domain of Hsp70 (Yamauchi et al .. 2002a). Interestingly no 
changes were observed in the Hsp homologous region containing the two arginine 
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residues important for the translocation to the nucleus of VP26. A study of BALB/c mice 
injected intracranially with a HSV-I mutant containing a 4 bp deletion (spanning amino 
acid 96-98) demonstrated that 50% lethal dose of the mutant was reduced by more than 
30,OOO-fold and that recovery of the mutant from the latently infected sacral ganglia of 
mice injected peripherally was significantly less than that of wild-type virus (Cunningham 
et a/., 2000). The region identified as important in attenuating pathogenicity and latency 
was similarly conserved in the isolates we sequenced. These observations are consistent 
with the proposed function ofUL14 as an Hsp-like molecular chaperone and an important 
role in virus replication and infectivity. 
The observation that a truncated mutant carrying a deletion of 81 amino acids at the N-
terminus of the UL14 protein can traffic a fused peptide of at least 13 amino acids 
intracellularly (Yamauchi et a/., 2002b) has led to the speculation that the mutant UL 14 
may provide a novel strategy for increasing the distribution of physiologically active 
substances in gene therapy (Nishiyama, 2004). Defining the degree of variation of the 
protein may help the development of such treatment strategies. 
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6. Chapter 6. The epidemiology of HSV -1 and HSV -2 infection in 
HIV-l infected individuals 
6.1 INTRODUCTION 
6.1.1 HSV-1 seroprevalence 
HSV -I seroprevalence varies by country and type of population. The National Health and 
Nutrition Surveys (NHANES II, 1976-80; NHANES III, 1988-94) conducted in the 
general population in the USA, reported 68% of persons aged 12 years and over to be 
HSV-I seropositive (Schillinger et al., 2004). In the UK, HSV-I seroprevalence in the 
general population has been shown to be 50% among individuals up to 30 years of age 
(Vyse et al., 2000) (Table 6.11). A recent cross-sectional survey taken among eight 
European countries showed the highest age standardised HSV -I seroprevalence among 
the general population to be 84% in Bulgaria, 81 % in the Czech Republic, 67% in 
Belgium, 57% in the Netherlands and 52% in Finland (Pebody et al., 2004). The median 
age of HSV -I acquisition ranged from 5-9 years in the Czech Republic and Bulgaria to > 
25 years in England & Wales, Finland and the Netherlands. 
Among high-risk populations, HSV-l antibody rates may be higher (Table 6.12). Among 
HIV-I positive persons attending a GUM clinic in Coventry, 86% of men and 97% of 
women (p = 0.14) were HSV-l antibody positive (Allan & Das, 2004). Similar rates 
(94%) have been observed among female commercial sex workers in Mexico (Conde-
Glez et al., 1999) and STD clinic attendees (91 %) in Uganda (Wagner et al., 1994). 
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Table 6.1.1. HSV-l seroprevalence in the general population 
Country Total Year % Reference 
France 3192 1994-2002 66 Malvy et al., 2005 
1994-1995 24 
England and Wales 5430 Vyse et al., 2000 
1986-1987 34 
Germany 3792 1997-1998 83 Hellenbrand et al., 2005 
USA 13098 1988-1994 68 Schillinger et al., 2004 
Switzerland 3120 1992-1993 80 BUnzii et al., 2004 
1973 65 
Rural districts in Japan 614 Hashido et ai, 1999 
1993 70 
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Table 6.1.2. HSV-l seroprevalence in high-risk populations 
Country Setting Year n(%) Reference 
SID clinic attendees 
Washington, USA with positive genital 1993-1997 1145 (17) Lafferty et al., 2000 
cultures 
Cape town Johannesburg SID clinic attendees 
1993-1994 558(51) Chen et al., 2000 
and Durban, South Africa with GUD 
Ontario, Canada SID clinic attendees 1994-1995 6555 (56) Singh et al., 2005 
Marrazzo et al., 
Washington, USA Lesbian population 1998 392 (46) 
2003 
HIV-l positive and 
negative homosexuals 
Melbourne, Australia 1999-2000 
in a primary care 
300 (73) Russell et al., 2001 
setting 
1993 1024 (68) 
Rotterdam, Netherlands SID clinic attendees Roest et al., 2001 
1998 654 (59) 
Female commercial sex 
Mexico City, Mexico workers attending a 1992 
Conde-Glez et al., 
997 (94) 
1999 
SID clinic 
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6.1.2 HSV-2 seroprevalence 
The prevalence of HSV -2 infection varies among regions and populations. In the USA, a 
population-based seroprevalence survey conducted in 1990 detected HSV -2 antibodies in 
22% of persons aged 12 years and above (Johnson et al., 1989). HSV -2 seroprevalence 
increased from 16% to 22% between 1978 and 1990 (Janier et al., 1999). In Europe, 
HSV-2 seroprevalence in the general population ranges between 4% in England and 
Wales to 24% in Bulgaria (Pebody et al., 2004) (Table 6.2.1). Higher seroprevalence 
rates have been observed among high-risk populations (Table 6.2.2). In STD attendees, 
HSV-2 seroprevalence ranges between 22% and 55% in Western Europe (Janier et al., 
1999; Roest et al., 2001; Varela et al., 2001; Suligoi et al., 2002),30% and 64% in the 
US (Austin et al., 1999; Whittington et al., 2001; Koutsky et al., 1990), and 40% and 
65% in Australia (Cunningham et al., 1993; Bassett et al., 1994). In South-East Asia, 
HSV-2 seroprevalence rates range between 53% and 76% among commercial sex 
workers (CSW) (Nelson et al., 1997; Limpakarnjanarat et al., 1999). 
In Africa, HSV -2 prevalence rates of 40-50% are common in 20 year old persons (Kamya 
et al., 1995; Greenblatt et al., 1988). In the Mwanza region in Tanzania, a serological 
survey of a random sample of 259 women and 231 men in 12 rural communities showed 
that 75% of women ~ 25 years of age and 60% of men ~ 30 years of age were HSV-2 
antibody positive (Obasi et al., 1999). However, as with many serological assays, some 
uncertainty remains about borderline values. The authors reported a risk of 
overestimation in low prevalence subgroups as the cut-off estimated in the EIA was 
dependent on the overall prevalence of infection in the population. Similar prevalence 
rates (58%) have also been observed in a randomly selected population aged 15-54 years 
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in Uganda (Emonyi et al., 2000). Among high-risk populations, HSV -2 prevalence rates 
are higher. A multi-centre study involving sex workers in four different African cities 
reported HSV-2 prevalence rates of 91 % in Cotonou, 84% in Yaounde, 94% in Kisumu 
and 87% in Ndola (Lagarde et al., 2001). 
Table 6.2.1. HSV-2 seroprevalence in the general population 
Country Total (n) Year %' Reference 
USA 68000 1976-1994 22 Fleming et al., 1997 
3 (M) 
England and Wales 5430 1994-1995 Vyse et al., 2000 
5 (F) 
France 4410 1994-2002 15.5 Malvy et al., 2005 
Germany 3792 1997-1998 14 Hellenbrand et al., 2005 
Switzerland 3120 1992-1993 19 BUnzii et al., 2004 
GuanCaste, Costa Rica 10049 1993-1994 38.5 Rodriguez et al., 2003 
Spain 3974 1992-1993 4 Garcia-Corbeira et al., 1999 
Masaka, Uganda 294 1989-1990 68 Wagner et al., 1994 
Mwanza, Tanzania 490 1993 31 Obasi et ai, 1999 
1973 5.5 
Rural districts in Japan 614 Hashido et ai, 1999 
1993 6 
, 
(M) males, (F) females 
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Table 6.2.2. HSV-2 seroprevalence among high-risk populations 
Country 
Baltimore, USA 
Washington, USA 
Ontario, Canada 
Rotterdam, 
Netherlands 
Gijon, Spain 
Northern Italy 
Coventry, UK 
Oar-Es-Salaam, 
Tanzania 
Setting 
Intravenous drug users 
Lesbian population 
STO clinic attendees 
STO clinic attendees 
STO clinic attendees 
STO clinic attendees 
HIV-l infected GUM 
attendees 
STO clinic attendees 
Pondicherry, India STO clinic attendees 
STO clinic attendees Haifa, Israel 
Mexico 
Mexico 
Chiang 
Thailand 
City, Female commercial sex 
Rai, 
Dhaka, Bangladesh 
workers 
Sex workers 
Hotel-based 
workers 
sex 
Year n(%) 
1999-2002 543 (40) 
1998 392 (8) 
1994-1995 6555(19%) 
1993 1024 (30) 
1998 654 (22) 
1996-1997 374 (25) 
1997-1998 919(25) 
2000-2001 96 (20) 
1989-1993 294 (43) 
2001-2003 135 (85) 
1998-1999 472 (9) 
1992 747 (65) 
1991-1994 500 (76) 
Reference 
Plitt et al., 2005 
Marrazzo et al., 2003 
Singh et al., 2005 
Roest et al., 2001 
Varela et al., 2001 
Cusini et aI., 2000 
Allan & Oas, 2004 
Langeland et al., 1998 
Shivaswamy et aI., 
2005 
Feldman et al., 2003 
Uribe-Salas et al., 1999 
Limpakarnjanarat et 
al., 1999 
2002 400 (34.5) Nessa et aI., 2004 
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6.1.3 The relationship between HSV-l and HSV-2 seroprevalence 
A decrease in HSV-l acquisition during childhood is thought to have contributed to 
increased HSV -2 seroprevalence in the developed world (Kinghorn, 1994), suggesting a 
possible protective effect of HSV -I against HSV -2 acquisition. Studies have shown up to 
90% of adults in Africa to be infected with HSV-I (Whitley & Roizman, 2001). Prior 
HSV -1 infection may therefore provide little or no protection against HSV -2 acquisition, 
leading to increased numbers of asymptomatic HSV -2 seroconversions (Langenberg et 
al., 1999) and influence the clinical severity of disease (Corey et al., 1999; Brown et al., 
1997). This is consistent with recent findings from vaccine trials which have 
demonstrated an absence of cross-reactive immune protection (Stanberry, 2004; Aurelian, 
2004; Jones & Cunningham, 2004). 
The most recently studied subunit vaccine is from GlaxoSmithKline (GSK). Two phase 
III trials were conducted, one among HSV -I and HSV -2 seronegative individuals and the 
second among HSV-2 seronegative persons with or without HSV-I seronegativity. Both 
trials demonstrated a significant protective effect (73% efficacy) with reduced clinical 
symptoms of genital herpes among HSV -I and HSV -2 seronegative women (Stanberry et 
al., 2002). The second trial demonstrated no significant effects in HSV-I seropositive 
men and women. It has been postulated that previously established immunity might 
interfere with the vaccination and contribute to the lack of efficacy in HSV -1 seropositive 
women. An alternative explanation would be that the latter may not enhance levels of 
protection provided by earlier HSV -1 infection. In either case, a significant effect on the 
proportion of the disease is unlikely, because approximately 80 to 95% of adults are 
infected with HSV-I (Xu et al., 2002; Aurelian, 2004). 
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6.1.4 The relationship between IISV-2 seroprevalence and IIIV-l infection 
In recent years, a strong epidemiological association has emerged between HSV-2 and 
HIV-l infection (Severson et al., 1999; Hook et al., 1992; Celum et al., 2004). The strong 
epidemiological association between HIV-l and HSV-2 may reflect common risk factors 
for infection. Previous studies have documented an association between HSV -2 infection 
and sexual behaviour (Cowan et al., 1994; Johnson et al., 1989). A recent behavioural 
surveillance survey in 16 states in the USA, between 2000-2002 showed that 36% of 
HIV -1 positive MSM with non-steady partners did not know the serostatus of their most 
recent partner, with only a quarter of this population reporting condom use (CDC, 2004). 
There is also evidence for a more direct interaction between the two viruses. In 
prospective studies, HSV-2 has shown to increase the risk of HIV-l acquisition and 
transmission by approximately two-fold (Blower & Ma, 2004; Celum et al., 2004; Weiss, 
2004). 
A meta-analysis of 9 cohort and nested case-control studies (Table 6.3) showed that the 
population-attributable risk percentages for HIV -1 infection were 19% and 47% with a 
HSV-2 seroprevalence of 22% and 80% respectively (Wald & Link, 2002). Although 
these studies address heterosexual transmission, additional studies conducted in 47 HIV-I 
seroconverting homosexual men and 57 matched controls in San Francisco, USA, found 
that HSV-2 seropositive men were significantly more likely to acquire HIV-l than those 
that were seronegative for HSV -2 (Holmberg et al., 1988). A similar nested case-control 
study of homosexual men in Amsterdam also documented increased risk of HIV-l 
acquisition associated with HSV -2 seropositivity (Keet et al., 1990). 
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Table 6.3. Meta-analysis of 31 studies to assess risk estimates of HIV-l infection in 
HSV-2 infected individuals * 
Summary 
Study type and sub-group No of studies 95%Cl 
estimate •• 
Cohort and nested case-control 9 2.1 1.4 - 3.2 
Women 1 0.5 0.2 - 1.1 
Heterosexual men 4 2.2 1.3 - 3.8 
MSM 4 2.1 1.3 - 3.4 
Developing countries 5 2.1 1.0 - 4.2 
Developed countries 4 2.1 1.3-3.4 
Case-control and cross-sectional 22 3.9 3.1 - 5.1 
Women 13 3.9 2.7 -5.5 
Heterosexual men 9 4.1 2.9 - 5.8 
MSM 3 4.3 2.4 - 7.6 
Developing countries 15 4.6 3.5 - 5.9 
Developed countries 7 2.9 1.7 - 4.7 
• Adapted from Wald & link, 2002; "Summary estimates for cohort and nested case-
control studies, were calculated using relative risk and for case-control and cross-
sectional studies, odd ratios were used. 
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Extensive observational studies leave little doubt that STOs facilitate HIV transmission 
through direct biological mechanisms. Genital ulceration due to HSV -2 is thought to 
increase HIV -1 transmission by increasing the levels of HIV -1 shedding through genital 
lesions, and by providing a portal entry into the host (Mbopi-Keou et al., 2003). These 
findings have been supported by a study conducted in Rakai, Uganda, which indicated an 
increased risk of HIV-l transmission in persons with genital ulcer disease (Gray et al., 
2001). In addition, there is supporting evidence from studies that show HSV-2 and HIV-l 
to interact at a molecular level, and up-regulate HIV -1 replication through the long-
terminal repeat region (Golden et al., 1992; Mosca et al., 1987). In a transient co-
infection system, HSV immediate early regulatory proteins (ICPO, ICP4 but not ICP27) 
have shown to transactivate HIV -1 L TR, although the ability of these proteins to produce 
this effect depends on the cell-line used (Ostrove et al., 1987). Transfected ICPO was 
shown to activate HIV -1 L TR expression from an integrated chimeric HIV -I provirus 
(Chapman et al., 1991). In addition, interactions between ICPO and RNA binding protein 
Tat has shown to stimulate HIV -1 LTR-driven transcription (Schafer et al., 1996). 
Activated C04 cells recruited by inflammatory responses to HSV -2 to the site of herpetic 
lesions may provide an ideal target for HIV -1. These data indicate plausible biological 
interactions between the two viruses and suggest that genital herpes plays an important 
role in the dynamics of HIV-l infection. The objectives of the study were to determine 
the rates of HSV-l and HSV-2 seroprevalence in persons newly diagnosed with HIV-I 
infection and the associated risk factors. In addition, we wished to determine the role of 
HSV-2 seroconversion following HIV-l diagnosis. Among HSV-2 seropositive persons, 
we determined the clinical expression of genital herpes. 
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6.2 METHODS 
6.2.1 Study cohort 
Our cohort comprised of 850 newly diagnosed HIV -1 seropositive persons who attended 
the Caldecot Centre, King's College Hospital, between January 1986 and December 
2001, and were followed up for at least one year after HIV -1 diagnosis. HSV -type 
specific serology was performed on this study population using stored serum samples 
collected at the time of HIV -1 diagnosis (Section 2.1.2, Section 2.4.1, Section 2.4.3, 
Section 2.4.4). Of those individuals who initially tested as being HSV-2 seronegative, a 
subset of 200 persons was randomly selected. Persons with at least one year of follow-up 
were retained, leaving 123 patients who underwent HSV-2 serological testing at ~1 year 
after HIV -1 diagnosis. 
A review of patient's clinical and laboratory records was performed to collect 
demographic data, determine the occurrence of a clinical diagnosis of genital herpes. 
Information on a virological diagnosis of genital herpes by virus culture, and diagnosis of 
other STDs was also collected. When assigning risk group status, bisexual males were 
categorised under the homosexual risk group. Ethnicity was assigned according to UK 
Census categories. The clinical diagnosis of genital herpes was made by the observation 
of genital lesions suggestive of genital herpes and a history of symptoms consistent with 
the diagnosis. Virus culture was the routine diagnostic test used for virological 
confirmation. The diagnosis of syphilis was based on dark ground microscopy of ulcer 
exudate and serological testing by Treponema pal/idum EIA IgG and IgM, quantitative 
RPR, and fluorescent antibody absorbed test. Testing for other STDs included serological 
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assays for the diagnosis of hepatitis A and hepatitis B; culture, enzyme immunoassay 
(ErA), and molecular testing of urine and urethral, cervical and anal swabs for the 
diagnosis of Chlamydia infection; microscopic examination and culture of urethral, 
cervical, anal and throat swabs for the diagnosis of gonorrhoea, and microscopy and 
culture of vaginal swabs for the detection of Trichomonas vagina lis. The diagnosis of 
human papilloma virus (HPV) infection was based on either the clinical observation of 
genital warts or the detection of HPV-associated changes on cervical or anal cytology. 
The diagnosis of scabies was made clinically. 
6.2.2 HSV type-specific serology 
HSV-l and HSV-2 serology was performed using the HerpeSelect IgG EIA (Focus 
Technologies, Cypress, California, USA). Specificity was increased by raising the assay 
cut-off for a positive result to 3.1 as described in chapter 3b and by repeat testing of sera 
from Sub-Saharan Africa by inhibition EIA. 
6.2.3 Statistical Analysis 
Univariable comparisons were performed using X2 or Fisher's exact tests for qualitative 
variables and Mann-Whitney U tests for quantitative variables. Factors independently 
associated with i) the presence of HSV -2 antibodies, ii) a clinical diagnosis of genital 
herpes among those with HSV -2 antibodies, and iii) a positive HSV -2 swab in those with 
a clinical diagnosis of genital herpes were identified by multivariable logistic regression 
analysis. All statistical analyses were performed using Statistical Analysis System (SAS) 
version 8. 
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6.3 RESULTS 
6.3.1 Patient demographics 
Between 1986 and 2001,850 individuals (median age 33 years, range 17-71 years) were 
newly diagnosed with HIV-l infection. Of these, 534 (63%) were men (Table 6.4). Risk 
groups for HIV-l infection were heterosexual contact in 467 (55%), homosexual contact 
in 338 (40%) homosexuals, and less commonly other risk groups including intravenous 
drug use in 39 (4%). The cohort was ethnically diverse (Table 6.4). Among patients of 
black-African ethnicity, 3511385 (91 %) were born in sub-Saharan Africa (95 Uganda, 65 
Zimbabwe, 33 Zambia, 27 Nigeria, 23 Ivory Coast, 19 Ghana, 17 Kenya, 11 Ethiopia, 10 
Sierra Leone, 9 Tanzania, 7 Zaire, 6 Burundi, 6 Rwanda, 4 Malawi, 3 Somalia, 3 
Cameroon, 3 Congo, 2 Gambia, 2 Guinea, 2 Togo, 2 Eritrea, 1 Angola and 1 Benin), 
24/385 (6%) in the UK and 10/385 (3%) in other countries (6 South Africa, 3 France and 
1 USA). Among 83/850 (10%) patients of black-Caribbean ethnicity, 44/83 (53%) were 
born in the UK, 32/83 (39%) were born in Jamaica, and 7/83 (8%) were born in other 
areas of the Carribean Islands. Among patients of white ethnicity, 263/371 (71 %) were 
born in the UK, 82/371 (22%) in other areas within Europe (21 Italy, 15 Spain, 11 
Ireland, 10 Portugal, 10 France, 3 Germany, 3 Greece, 3 Cyprus, 2 Albania, 1 Belgium, 1 
Norway, 1 Poland and 1 Finland) 10/371 (3%) in the USA/Australia, and 16/371 (4%) 
born in other countries (7 Brazil, 2 Colombia, 2 South Africa, 1 St. Lucia, 1 Zimbabwe, 1 
China, 1 Russia and 1 Singapore) . Finally, there were 11 patients from other ethnicities 
(1 from South America, 1 from Asia, 2 from the Middle East and 7 from the Indian 
subcontinent). 
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Table 6.4. Demographic characteristics and predictors of HSV-2 serostatus in 850 
persons diagnosed HIV-l positive between 1986 and 2001. 
Number (% of total No. HSV-2 
Characteristics 
population) seropositive (%)d 
pa 
Gender Male 534 (63) 298 (56) 0.0001 
Female 316 (37) 239 (76) 
Risk group Heterosexual 467 (55) 351 (75) 0.0001 
Homosexual 338 (40) 167 (49) 
IVDUb 39 (4) 17 (44) 
OtherC 6 (1) 2 (33) 
Ethnicity Black-African 385 (45) 300 (78) 0.0001 
White 371 (44) 181 (49) 
Black-Caribbean 83 (10) 53 (64) 
Other 11 (1) 3 (27) 
HSV -1 serostatus Positive 752 (88) 479 (64) 0.45 
Negative 98 (12) 58 (59) 
ap value determined by univariable analyses; bIVDU: intravenous drug users; ':Other risk 
group: exposed to contaminated blood or blood products; d% value relates to the number 
HSV-2 seropositive and not to the total population tested. 
6.3.2 HSV-l seroprevalence at the time of HIV-l diagnosis 
At the time of HI V-I diagnosis, 752 (88.5%) patients were seropositive for HSV-1. HSV-
1 seropositivity was 289/752 (38%) among women and 463/752 (62%) among men (data 
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not shown). Seroprevalence was 369/372 (99%) in persons of black-African ethnicity, 
307/307 (100%) in persons of white ethnicity, and 45/67 (67%) in persons of black-
Caribbean ethnicity (data not shown). 
6.3.3 HSV-2 seroprevalence at the time of HIV-l diagnosis 
HSV-2 specific antibodies were detected in 537 (63%) of patients. Univariable analyses 
indicated that HSV-2 antibody positivity at the time of HIV-I diagnosis was associated 
with female gender (P=O.OOOI), heterosexual risk group (P=O.OOOI), black-African or 
black-Caribbean ethnicity (P=O.OOOI) and older age (P=O.OI) (Table 6.5). As most 
heterosexual persons were women, a possible confounding association between gender 
and risk group could not be excluded. To investigate further, two separate multivariable 
models were used for the two variables. In both models, a positive antibody result was 
strongly associated with black ethnicity and older age at the time of HIV-I infection 
(Table 6.6). After adjustment for these variables, female gender (P=0.03; OR 1.51; 95% 
CI [1.03-2.20]) and heterosexual risk group (P=0.04; OR 1.62; 95% CI [1.02-2.57]) were 
independently associated with a positive HSV -2 antibody result (Table 6.6). There was 
no association with HSV-I serostatus. 
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Table 6.5. HSV-2 seroprevalence among 850 HIV-l positive persons, stratified by 
age. 
Women Men 
No. HSV-2 positive No. HSV-2 
Age No Age No 
(%) positive (%) 
All ages (17-66) 316 239 (76) All ages (17-71) 534 298 (56) 
17-21 14 8 (57) 17-21 11 5 (45) 
22-26 65 49 (75) 22-26 42 13 (31) 
27-31 87 68 (78) 27-31 120 57 (48) 
32-36 74 51 (69) 32-36 162 95 (59) 
37-41 38 31 (82) 37-41 109 72 (66) 
42-46 23 19 (83) 42-46 52 28 (54) 
>46 15 13 (87) >46 38 28 (74) 
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Table 6.6. Predictive factors for HSV-2 seropositivity at the time of HIV-l diagnosis, 
identified by multivariable logistic regression analyses. 
Odds ratio 95% CIa p 
Modell: Including Gender 
Female 1.51 1.03-2.20 0.03 
White/other 1 NAb NAb 
Black-African 3.25 2.25-4.71 0.0001 
Black -Caribbean 1.84 1.12-3.04 0.02 
Age (per 5 years older) 1.18 1.08-1.30 0.0004 
Model 2: Including Risk group 
Heterosexual 1.62 1.02-2.57 0.04 
White/other NAb NAb 
Black-African 2.70 1.64-4.43 0.0001 
Black-Caribbean 1.66 0.98-2.81 0.06 
Age (per 5 years older) 1.16 1.06-1.27 0.001 
aCI: Confidence Interval; bNA not applicable 
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6.3.4 IISV -2 seroincidence after IIIV -1 diagnosis 
Following the diagnosis of HIV-l infection, 123 patients who were HSV-2 antibody 
negative at the time of HI V-I diagnosis and who remained in follow-up for? 1 year were 
tested at subsequent time points for the development of HSV -2 specific antibodies. The 
median HSV-2 EIA index value among the 123 HSV-2 seronegative patients was 0.28 
(range 0-0.87). Persons in the prospective cohort had a median age of 32 years (range 17-
70) at the time of HIV -1 diagnosis, which was made in 1990-2000 (median 1997). Over 
median 5 years follow-up (range 2-12 years) 12/123 patients (10%) seroconverted for 
HSV-2 antibodies. The median index value of the 12 patients before and after HSV-2 
seroconversion was 0.25 (range 0.08-0.74) and 4.54 (range 3.52-15.98) respectively. The 
cohort included 98/123 (80%) males, 80/123 (65%) homosexuals, 431123 (35%) 
heterosexuals, and 871123 (71%) white, 25/123 (20%) black-African and 111123 (9%) 
black-Caribbean patients. The incidence rate was 1.8 cases/l00 person-years (95% CI: 
0.8-2.8). Seroconversion occurred at a median of 4 years (range 2-11 years) after HIV-l 
diagnosis. 
Among the same 123 patients, 101 (82%) were tested for other STDs at a median of 2 
time-points (range 1-12) over median 5 years, according to standard clinical protocols. 
Overall, 54/123 (44%) received a diagnosis of one (n=38), two (n=15) or three (n=l) 
STDs. The diagnosed infections included HPV (45/123, 37%), gonorrhoea (131123, 
11 %), chlamydia (6/123, 5%), acute syphilis (3/123, 2%), and other infections (acute 
hepatitis B, n=2; acute hepatitis A, n= 1; scabies, n= 1) (Table 6.7). The diagnosis of HPV 
infection was based on the detection of genital warts in 39/45 (87%) patients and the 
detection of cytological abnormalities of cervical or anal smears in the absence of visible 
- 160-
genital warts in 6/45 (13%) patients. A significant association was found between HSV-2 
seroconversion after HIV-l diagnosis and a diagnosis of HPV infection (P=0.005), 
gonorrhoea (P=0.05) or other infections (acute hepatitis A, acute hepatitis B or scabies, 
P=O.OOOI). Other predictors of HSV-2 seroconversion could not be identified due to 
small numbers. Those who seroconverted included 11198 (11 %) males and 1/25 (4%) 
females, 7/80 (9%) homosexuals and 5/43 (12%) heterosexuals, and 9/87 (10%) white 
and 3/25 (12%) black-African patients. 
Table 6.7. Occurrence of sexually transmitted infections and HSV-2 seroconversion 
during median 5 years of clinical follow-up among 123 HIV-l positive persons, 
according to gender and sexual orientation. 
Population HPV
a Gonorrhoea Chlamydia Acute syphilis OtherG 
Total 45 13 6 3 4 
Males 37 13 2 2 4 
Gender 
Females 8 0 4 0 
Risk Homosexuals 31 13 1 1 3 
group Heterosexuals 14 0 5 2 
HSV -2 seroconversion 10 4 0 0 4 
aHPV: Human papilloma virus infection, including genital warts and HPY-related 
cytological abnormalities in cervical or anal smears; bOther: Hepatitis B (n=2), Hepatitis 
A (n=I), Scabies (n=l). 
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6.3.5 Clinical and virological diagnosis of genital herpes among HSV-2 
seropositive persons 
A clinical diagnosis of genital herpes was made in 116/549 (21 %) HSV -2 seropositive 
patients. None of the 12 HSV-2 seroconverters received a diagnosis of genital herpes. 
Predictive factors for a clinical diagnosis of genital herpes in univariable analyses were 
male gender, non heterosexual risk group and white ethnicity (Table 6.8). The year of 
HIV -1 diagnosis was significantly different in HSV -2 seropositive patients who received 
a clinical diagnosis of genital herpes (median 1997, range 1990-2001) compared to those 
who were clinically undiagnosed (median 2000, range 1986-2001) (P=O.OOO 1). Among 
individuals diagnosed HIV-l positive before 1997, 63/140 (45%) received a clinical 
diagnosis of genital herpes compared with 42/397 (11 %) patients diagnosed 1997 
onwards (P=O.OOOI). No association was found between the clinical diagnosis of genital 
herpes and HSV-l serostatus (Table 6.8). The median age at HIV-l diagnosis was 33 
years (range 18-70) in HSV -2 seropositive patients with a clinical diagnosis of genital 
herpes and 34 years (range 17-71) in those without a clinical diagnosis (P=0.79). 
Multivariable logistic regression analysis confirmed the strong correlation between pre-
1997 HIV-l diagnosis and a clinical diagnosis of genital herpes. The adjusted odds ratio 
(OR) was 5.11 (95% Confidence Interval, CI 3.28-7.98; P=O.OOOI). In addition, in 
multivariable analysis there remained a significant association between heterosexual risk 
group and a reduced likelihood of receiving a clinical diagnosis of genital herpes: OR 
0.55; 95% CI 0.35-0.86; P=O.OOOI. 
Of the 116 persons who were clinically diagnosed with genital herpes, 46 (40%) genital 
swabs yielded an HSV -2 positive result by virus culture (Table 6.8). In univariable 
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analyses, the year of HIV -1 diagnosis was the only significant predictor of a culture 
positive swab. The median year of HIV -1 diagnosis was 1996 (range 1990-2001) in 
patients with a positive swab and 1999 (range 1991-2001) in patients without a 
virological diagnosis by virus culture (P=0.0006). Those diagnosed prior to 1997 were 
four times more likely to have a positive HSV-2 swab than those diagnosed subsequently 
(OR 4.01; 95% CI 1.78-9.02; P=0.0008). Median age at HIV-l diagnosis was 31.5 years 
(range 18-70) in patients with a positive swab and 34 years (range 20-53) in those 
without a HSV positive culture result (P=0.10). There was no significant difference in 
the yield of a positive genital swab between heterosexuals and other risk groups (Table 
6.8). 
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Table 6.S. Predictive factors for a clinical and virological diagnosis of genital herpes 
among HSV-2 seropositive individuals, identified by univariable analyses 
No. with 
No. with clinical 
HSV-2 positive 
Factors diagnosis of genital P P 
swab by virus 
herpes (%)8 
culture (%)b 
Male 76 (25) 0.02 26 (34) 0.15 
Gender 
Female 40 (17) 20 (50) 
Homosexual 50 (30) 0.005 16 (32) 0.33 
Risk group Heterosexual 61 (17) 28 (46) 
Other 5 (26) 2 (50) 
White 54 (30) 0.003 18 (33) 0.43 
Ethnicity Black-African 55 (18) 25 (45) 
Other 7 (12) 3 (43) 
HSV-l Positive 101 (21) 0.51 41 (41) 0.80 
serostatus Negative 15 (26) 5 (33) 
a Among those who were HSV -2 seropositive; bamong those with a clinical diagnosis of 
genital herpes. 
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6.4 DISCUSSION 
HSV-2 seroprevalence was 63% among patients who received a diagnosis of HIV-l 
infection between 1986 and 2001, confirming the strong epidemiological association 
between the two infections. The prevalence was significantly higher than that observed in 
the general UK population. In adults in the general popUlation in England and Wales, the 
prevalence of HSV -2 antibodies is 4% in those aged> 12 years (Pebody et al., 2004) and 
10% among those aged >16 years (Morris-Cunnington et al., 2004). The absolute HSV-2 
seroprevalence figures presented in the latter study should be interpreted with care, since 
the Focus ElA test has shown to produce false positive results in African sera (Chapter 
3b). In many sub-Saharan African countries HSV -2 seropositivity rates are 40-50% or 
higher in the general population (Kamya et al., 1995; Greenblatt et al., 1988). In a 
random sample of individuals aged 15-54 years in Uganda, HSV-2 seropositivity was 
58% (Emonyi et ai., 2000). In rural communities in the Mwanza region of Tanzania, a 
random sample showed that 75% of women above 25 years of age and 60% of men above 
30 years of age had HSV -2 antibodies (Obasi et al., 1999). 
Earlier studies among STD clinic attendees in London have shown HSV -2 prevalence to 
range between 23 and 26% (Pebody et al., 2004; Evans et al., 2003). However, HSV-2 
prevalence data among HIV -1 positive persons in the UK are very limited. In one study, 
among 92 persons, HSV-2 seroprevalence was 50% among men and 94% among women 
and the rates of infection were higher in persons of black ethnicity than white ethnicity 
(Allan & Das, 2004). 
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Consistent with previous findings (Wald, 2004; Malkin, 2004; Weiss, 2004, Fleming et 
al., 1997) HSV-2 seropositivity increased with increasing age and was associated with 
female gender. Previous evidence has suggested HSV -2 seroprevalence to increase with 
age, and plateau at about 40 years in high prevalence regions such as sub-Saharan Africa 
(Smith & Robinson, 2002). Age-related risk factors are likely to reflect the cumulative 
number of sexual partners, age of initiation of sexual activity, and duration of sexual 
activity (Wald, 2004; Cowan et al., 1994). However, no information on sexual behaviour 
was available in this study. The high levels of HSV-2 seroprevalence in our cohort are 
consistent with findings of several previously reported studies. The population based 
AIDS in Multiethnic Neighbourhoods (AMEN) study, found highest HSV -2 seropositive 
rates in African-American women than Caucasian women and men (Siegel et al., 1992). 
The association with female gender is believed to reflect both biological and behavioural 
factors, including exposure to infection of a large mucosal area in vaginal intercourse and 
sexual contact with older partners who are more likely to be HSV-2 seropositive (Wald, 
2004). 
Among HIV-l infected individuals, HSV-2 seropositivity was also associated with black 
ethnicity. This finding is in line with previous studies in HIV-l negative cohorts, 
indicating that HSV -2 infection rates are generally higher in persons of black ethnicity 
than in those of white ethnicity (Wald, 2004, Fleming et al., 1997; Evans et al., 2003; 
Narouz et al., 2003). However, these studies may be limited by population size. In our 
cohort, a large proportion of persons of black ethnicity originated from sub-Saharan 
Africa and migrated to the UK in adult life. A smaller proportion of persons were of 
Caribbean origin, approximately half of whom emigrated from Jamaica to the UK in 
adult life. In African HIV-l positive populations, HSV-2 seroprevalence remains high 
- 166-
(Wald, 2002; Freedman & Mindel, 2004; Gwanzura et al., 1998; Mbopi-Keou et al., 
2000; Weiss et al., 2001) with rates >80% reported in selected cohorts in Zimbabwe 
(Gwanzura et al., 1998), Malawi (Sutcliffe et al., 2002), the Central African Republic 
(Wald, 2004), and Cameroon (Eis-Hubinger et al., 2002) (Table 6.9). Data from the 
Caribbean are limited, but in one study 77% of 107 HIV -1 positive adults in Barbados 
were HSV -2 seropositive (Levett, 2005). These data must be interpreted with care due to 
low population numbers. An increase in the number of participants may have led to more 
significant findings. The high rates of HSV-2 seropositivity found among persons of 
black-African and black-Caribbean ethnicity were in agreement with high HSV-2 
seroprevalences found in the respective countries of origin. Consistent with this 
observation, HSV-2 seroprevalence was significantly higher among persons born outside 
of the UK than in those born in the UK (data not shown). 
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Table 6.9. The seroprevalence of IISV-2 infection among IIIV-l positive individuals 
worldwide. 
Median age 
(Town), Country Year Gender/Setting Total (%HSV-2+) Reference 
(range) 
(Bangui), Central Mbopi-Keou 
1998-1999 Women 27 (15-48) 58 (91) 
African Republic et al., 2000 
(CapeTown, 
Durban, Chen et al .• 
1993-1994 Men/GUD 26 (15-65) 196 (63) 
Johannesburg), South 2000 
Africa 
(Greater Harare), Male/factory Gwanzura et 
Pre-1997 (::S25->45) 191 (83) 
Zimbabwe workers al .• 1998 
Boulos et al., 
(Cite Soleil), Haiti Pre-1992 Women 26 (15-40) 95 (88) 
1992 
Men and Allan & Das, 
(Coventry), UK 2000-2001 35 (21-80) 96 (67) 
women 2004 
(Seattle), Hitti et al., 
1989-1995 Women 27 60 (75) 
Washington 1997 
(Seattle), Koutskyet 
1983-1986 Homosexuals 28 100 (66) 
Washington al .• 1990 
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Heterosexual risk group was a strong predictor of HSV -2 seropositivity, although due to 
the relatively small number of heterosexual males a possible confounding association 
with gender could not be excluded. The relationship between HSV-2 seroprevalence and 
sexual orientation is not well established. In HIV -I negative cohorts, no difference in 
seropositivity was found according to gender or sexual orientation (Cusini et al., 2000). 
This might be explained by study limitations including reduced population size, and 
younger age of women at enrolment with reduced sexual exposure. Furthermore, 
discrepancies which exist between comparisons must take into account differences 
between serological tests. In a cross sectional study of 380 HIV-I positive individuals in 
Rome, Italy, 33% were HSV-2 seropositive, with higher rates in men (38%) than in 
women (17%) and in homosexuals (55%) than heterosexuals and IVnUs (15%) (Suligoi 
et al., 2002). The higher prevalence among men and homosexuals can be accounted by 
differences in the study population tested. These findings are in conflict with the large 
body of data indicating a higher prevalence of HSV-2 infection in women than in men 
and illustrate that the predictors ofHSV-2 serostatus are numerous and diverse. 
Studies in Europe have shown lower HSV -2 infection rates than those documented in 
sub-Saharan Africa. Studies among European HIV-I positive cohorts have shown HSV-2 
seroprevalence to be 40-54% in men who were either homosexuals (Bystricka et al., 
2000) or predominantly homosexuals (Wutzler et al., 2000; Rabenau et al., 2002) and 42-
66% in women (presumably predominantly heterosexuals) (Wutzler et al., 2000; Rabenau 
et al., 2002; Van Benthem et al., 2001). Among HIV-l positive persons in the USA, 
HSV -2 antibodies were reported in 63% of heterosexual males (Hook et al., 1992), 66% 
of homosexual males (Stamm et al., 1988) and 75-78% of heterosexual women (Hook et 
al., 1992; Hitti et al., 1997). These data suggest an association with female gender rather 
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than sexual orientation, although a direct comparison of a large number of homosexual 
and heterosexual males is lacking. 
The EIA assay used to determine HSV-2 serostatus shows a sensitivity of 96% and a 
specificity of 97% among sexually active adults relative to Western blot. The assay 
performance is not affected by HIV -1 status (Laeyendecker et ai., 2001). The threshold to 
calculate positive results was increased from 1.1 to 3.1 in order to improve specificity, as 
discussed in chapter 3. The HerpeSelect EIA has shown problems of specificity with 
samples from patients from Uganda and Kenya (Hogrefe et ai., 2002; Laeyendecker et 
ai., 2001). To address these problems, all samples with equivocal results and 38% of 
those with positive results by EIA were retested using an Immunoblot assay with 97% 
sensitivity and 98% specificity. Furthermore positive samples from patients from Uganda 
or Kenya were retested by inhibition-EIA. Despite these precautions, the absolute HSV-2 
seroprevalence figures should be interpreted with caution, because false-positive and 
false-negative results may have occurred, leading to a 2-3% error in the estimation of the 
HSV-2 seroprevalence. 
The prevalence of HSV -1 infection was high in the cohort. There is conflicting evidence 
concerning the association between HSV-l and HSV-2 serostatus, with some studies 
indicating a protective effect of HSV-l antibodies against the acquisition of HSV-2 
infection. The findings are in agreement with other studies (Cowan et ai., 1994; Pebody 
et al., 2004; Wutzler et ai., 2000; Suligoi et ai., 2002; Brown et ai., 1997; Langenberg et 
ai., 1999) where no association between HSV -2 and HSV -1 serostatus was demonstrated. 
Furthermore, in HSV -2 seropositive persons there was no association between HSV-l 
serostatus and the likelihood of receiving a diagnosis of genital herpes. 
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Genital herpes was under-diagnosed in the cohort, with only 22% of patients with HSV-2 
antibodies receiving a clinical diagnosis and an even smaller proportion having a virus 
positive swab. A similar finding has been described in other HIV -1 positive cohorts, with 
a history of genital herpes reported in 25% of HSV -2 seropositive women (Van Benthem 
et al., 2001) and 33% of homosexual males (Russell et al., 2001). As it occurs in HIV-l 
negative persons, the under-diagnosis may reflect the fact that HSV -2 clinical recurrence 
rates tend to decline with time, or that atypical clinical presentations escape recognition 
by patients or physicians (Wald, 2004). As shown in previous chapters, suboptimal 
sensitivity of virus culture may playa significant role, explaining the lack of a virological 
diagnosis in a large number of HSV-2 seropositive persons with clinical symptoms of 
genital herpes. Furthermore, the introduction of highly active antiretroviral therapy 
appeared to have a significant impact on the likelihood of developing symptoms of 
genital herpes. HSV -2 seropositive patients diagnosed from 1997 onwards were at least 
four times less likely to receive a clinical diagnosis of genital herpes than patients 
diagnosed earlier. Ihis is consistent with data showing that HIV-I positive persons on 
highly active anti-retroviral therapy reported significantly fewer days with HSV lesions 
than untreated subjects (Posavad et al., 2004) and that CD4 counts correlate with the 
clinical expression of genital herpes (Van Benthem et al., 2001). However, due to the 
unavailability ofCD4 counts for the HIV-l infected cohort, no correlation between HSV-
2 seropositivity and CD4 counts could be made. 
HIV -1 infected persons remained at risk of acquiring HSV -2 after being diagnosed HIV-l 
positive and this risk was associated with the acquisition of other SIDs. A diagnosis of 
HPV infection, gonorrhoea, hepatitis A or B and scabies were strongly associated with 
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HSV-2 acquisition. Thus HSV-2 seroconversion after HIV-l diagnosis can be considered 
as a strong marker of high risk sexual behaviour. A recent study in the UK has shown 
inconsistent condom use among 300 GUM attendees (Handy, 2004). This is consistent 
with other studies in Africa, which has shown occasional condom use in only 14% of 
men and 17% of women (Maharaj & Cleland, 2004). High risk taking behaviour has also 
been observed among HIV -1 infected homosexual men in the USA. Among 1918 HIV-l 
infected homosexual men across 4 cities in the USA, 59% reported having multiple 
partners, 16% engaged in unprotected anal sexual intercourse with partners who were 
either HIV-negative or whose serostatus was unknown, and an estimated 30 new 
infections (80% as a result of sexual interactions with MSM) would be expected among 
the sex partners of study participants during the 3-month reporting period (The National 
Institute of Mental Health Healthy Living Project Team, 2004). 
These findings indicate that persons diagnosed with HIV-l continue to be at risk of 
acquiring HSV-2 despite regular counselling on risk-reduction. There was a high 
incidence of genital warts and HPV-associated cytological abnormalities in cervical and 
anal smears among those who seroconverted for HSV-2 antibodies. In addition HSV-2 
seroconversion was significantly associated with cases of acute gonorrhoea, acute 
hepatitis A or hepatitis B, and scabies, all but one occurring among homosexual males. 
These findings indicate that HSV-2 seroconversion and HPV infection in HIV-l infected 
persons may be used as a surrogate marker for high risk sexual behaviour. With evidence 
for a bi-directional interaction between HIV-l and other STDs, there remains a need for 
HIV-l prevention strategies, education and counselling. 
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7. Chapter 7. T-cell mediated immune responses to HSV-2 infection in 
HIV-l positive individuals 
7.1 INTRODUCTION 
There is overwhelming evidence that T-cell mediated immunity is important in the 
control of HSV infection. The vast majority of investigations evaluated the protective role 
of T-cell mediated immunity in mouse models (Parr & Parr, 1998; Parr & Parr, 2003; 
Svensson et al., 2005). Early data had suggested that the majority of T-cell activity 
against HSV resides within the CD4 cell subset, although HSV -specific CD8 T -cells has 
also been detected (Koelle et al., 2000a; Koelle et al., 2000b; Koelle et a/., 1994). More 
recent studies have provided evidence that both CD4 and CD8 T-cell subsets play an 
important role in the host defence against HSV infection (Koelle et a/., 2005; Posavad et 
al., 2003; Barcy et a/., 2005). In particular, the ability of both CD4 and CD8 T-cells to 
secrete IFN- y upon activation has been proposed as a common protective mechanism 
against the infection (Ellerman-Eriksen, 2005). This is supported by the observation that 
in vivo reactivation of latent HSV can be promoted by anti-IFN-y treatment (Liu et a/., 
2001; Liu et a/., 2000). 
In patients with genital herpes lesions, mononuclear cell infiltrates composed of CD4 and 
CD8 T cells and macrophages have been demonstrated (Eriksson et a/., 2004; Cunnigham 
et a/., 1985; Aurelian et a/., 2003). CD4 cells are the first cells to infiltrate the site of 
infection, followed by CD8 cells 48 hours later (Cunningham et a/., 1985). HSV is a 
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strong inducer of IFN-a (GobI et al., 1988; Ankel et al., 1998; Honda et al., 2005) and 
the high concentrations of IFN- y detected within herpetic lesions (Koelle et al., 1998; 
Mikloska & Cunningham, 2001) are thought to induce up-regulation ofMHC class I and 
II on infected cells, thereby promoting T-cell recognition (Cunningham & Mikloska, 
2001). 
Within the ganglia where HSV latency is established, the control of infection appears to 
be dependent on the infiltration of CD8 T cells and expression of T-cell derived cytokines 
(Branco & Fraser, 2005; Simmons & Tscharke, 1992). The persistence of CD8 T cells 
and IFN-y in the ganglia suggests persistent HSV antigenic expression as a driver of 
antigen-specific T cells. In support of this hypothesis, limited transcription of immediate 
early (IE) and early (E) genes, in particular, the ICP4 and thymidine kinase has been 
documented (Shimeld et al., 1999; Kramer & Coen, 1995). Antigen presentation is 
thought to occur either through neurons expressing MHC class I, or through satellite cells 
expressing both MHC class I and II (Nash, 2000). Early studies involving mutant mice 
lacking CD8 T cells demonstrated impaired control of lytic virus infection and loss of 
neurons from sensory ganglia (Guidotti et al., 1996). These observations imply a role for 
CD8 T cells in containing actively replicating virus. One study examining the effect of 
CD8 cells on ganglionic cultures revealed that ganglionic CD8 T cells also effectively 
inhibited HSV reactivation during latent infection (Liu et al., 1996). More recently, 
evidence suggested that IFN-y can independently arrest HSV-l reactivation in latently 
infected neurons by inhibiting ICPO and gC promoter activity (Decman et al., 2005). 
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These findings imply that resident CD8 cells and/or lymphocyte-derived cytokines are 
important in both initial control and suppression of reactivation. 
Viral immune evasion strategies are important for establishment and maintenance of 
infections. HSV can evade immune functions in many ways. Dendritic cells (DC) 
expressing HSV receptors in the skin and the dermis can be productively infected with 
HSV (Salio et al., 1999) depending on the maturation status of the DC (Kruse et al., 
2000; Mikloska et al., 2001). There is documented evidence that the maturation, 
expression of co-stimulatory molecules, and antigen presenting capacity of DC can be 
reduced by HSV (Kruse et al., 2000; Salio et al., 1999). 
The virion host shutoff (vhs) protein, a component of the tegument has been shown to be 
released into the cytosol of infected cells and mediate the rapid shutoff of protein 
synthesis via degradation of both cellular and viral mRNAs (Everly et al., 2002). Vhs can 
down-regulate MHC class I and class II molecules (HillT et al., 1994; Tigges et al., 1996; 
Trgovcich et al., 2002) thereby avoiding T cell recognition of HSV-infected cells (Tigges 
et al., 1996). 
HSV can also inhibit antigen processmg and presentation In class I pathways by 
interaction of the US12 gene product, ICP47, with the transporter associated with antigen 
processing (TAP) (Hill et al., 1995; York et al., 1994). After primary penetration, HSV 
protein ICP47 binds to TAP and blocks peptide binding and peptide translocation by 
TAP. This therefore avoids the loading of peptide epitopes into the binding cleft ofMHC-
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I molecules. Alternatively, HSV can evade immune attack by inhibiting activities 
mediated by complement (C) components C3, C5, and properdin (P). HSV can also 
interfere with activities mediated by the Fc domain of immunoglobulin G (lgG) 
antibodies. HSV-l gE can bind to the JgG Fc domain and interfere with Clq binding and 
antibody-dependent cellular cytotoxicity (ADCC). HSV-l gC can also bind complement 
component C3 and its activation products, C3b, iC3b, and C3c, and accelerate the decay 
of the alternative complement pathway (Fries et a/., 1986; Kostavasili, et a/., 1997). The 
HSV non-essential glycoproteins gE and gJ can also together form a hetero-oligomer 
complex that functions as a Fc receptor for IgG. Bipolar bridging of the IgG antibody 
leads to the disruption of effector functions mediated by the Fc region, including binding 
of C 1 q which consequently inhibits the classical pathway for complement activation by 
blocking opsonization (Nagashunmugam, et a/., 1998). 
Contrastingly, there is convincing immunological data implicating T-cells in HSV 
epidermal damage (Aurelian et a/., 2003). Erythema multiforme (EM) refers to a broad 
morphological spectrum of lesions, of which a subset is caused by HSV (HAEM). 
Histopathological features include accumulation of mononuclear cells, endothelial 
swelling, and epidermal damage. Prospective studies have shown that the preponderance 
of cells infiltrating the dermis is primarily CD4+ T cells (Malmstrom et a/., 1990; Paquet 
& Pierard, 1997; Auquier-Durant et a/., 2002; Kokuba et a/., 1998). Studies have 
demonstrated the presence of IFN-y in HAEM to be potential effector of tissue damage 
(Staats & Lausch, 1993). IFN-y has shown not to be expressed in healed tissues that are 
negative for HSV proteins and T-cells, confirming the strong correlation between IFN-y 
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presence and HSV -protein expression in skin tissues (p<O.OOO 1) (Kokuba et al., 1998). 
The up-regulation of HLA class I and class II antigen expression by IFN-y may enhance 
antigen presentation of keratinocytes (Basham et al., 1984), thereby contributing to the 
immune-inflammatory process. Supporting this interpretation, virus-induced 
inflammatory responses can trigger autoreactive T cell generation (Rouse, 1996) and 
molecular mimicry or release of cellular antigens from lysed cells that express HSV 
proteins may lead to HAEM pathogenesis (Gyotoku et al., 2002; Koelle et al., 2002). 
Among individuals with depressed T-cell function, including HIV -infected persons, the 
immune mechanisms controlling HSV infection are not well understood. Previous data 
indicated that proliferative responses are reduced in HIV-positive persons compared to 
uninfected individuals (Hersh et al., 1985; Wainberg et a/., 1987). HIV -positive persons 
also show lower levels of HSV -specific CD8 T -cells (Posavad et al., 1997). A correlation 
has been observed between absolute CD4 cell count and memory proliferative responses 
to HSV (Posavad et a/., 1997). Suppression of HI V-I replication by HAART is paralleled 
with an increase in CD4 counts (Posavad et al., 2004). In addition, we demonstrated that 
HIV infected patients who were HSV-2 were four times less likely to receive a clinical 
diagnosis of genital herpes if diagnosed HIV -1 positive after 1997 (Ramaswamy et al., 
2006). This suggests that HAART may playa role in immune recovery. This is further 
supported by findings that have shown that HAART treated individuals have significantly 
fewer days of HSV lesions compared to untreated individuals (Posavad et al., 2004). This 
observation suggests a restoration of HSV immune control. 
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The aim of this study was to investigate prospectively HSV T-cell immunity in HSV-
seropositive HIV-I infected patients starting HAART. To this end, T-cell IFN-y recall 
responses to antigen stimulation were characterised in vitro using the ELISPOT assay. 
Further characterisation was done using intracellular cytokine staining. 
7.2 METHODS 
7.2.1 Study subjects and sampling 
Our cohort comprised 64 HIV -I positive persons and 20 HIV -1 negative healthy 
volunteers attending the Royal Free Hospital, London. Control samples from the healthy 
donors were obtained at 3 time points (weeks 0, 4 and 9) and included 11120 (55%) 
persons who were HSV IgG seropositive (positive control group) and 9/20 (45%) persons 
who were HSV IgG seronegative (negative control group). The Royal Free Hospital HIV-
I positive cohort included four groups of patients: (I) patients starting HAART 
(prospective cohort); (2) long term slow and non-progressors (LTNP/L TSP) with long-
standing HIV-I infection who had remained disease free and maintained a CD4 cell count 
above 400 cellsl mm3 over at least 10 years of follow-up since HIV diagnosis (n=3, 
sampled at three time points); (3) patients with recently diagnosed HIV-I infection who 
were not receiving HAART (n=9, sampled once); and (4) patients on HAART (n=33, 
sampled once). In addition 10 HIV-infected HSV IgG seronegative patients served as a 
further negative control group. Blood samples were collected in preservative-free sodium 
heparin tubes for PBMC isolation (Section 2.1.3). In addition serum samples were 
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collected for the determination of HSV IgG serostatus by EIA using the HSV I and 2 
DiaSorin kit (DiaSorin, Berkshire, UK) (Section 2.1.2). 
7.2.2 Isolation of PBMC, ELISPOT and flow cytometry 
PBMCs were isolated as previously described (Section 2.7.1). For the ELISPOT assay 
(Section 2.7.2), PBMCs (3 x 105 cells/well) were stimulated in triplicates with HSV-I 
and HSV -2 lysates at three different concentrations (I J,lg/ml, 5 J,lg/ml and 10 J,lg/ml). 
PHA (5 J,lg/ml) and tissue culture medium were used as positive and negative controls 
respectively. Frequencies of antigen-specific IFN-y secreting cells were calculated as 
mean of three wells, based on the numbers of responder cells and the number of spots per 
well after subtraction of background. Spots were enumerated using a Nikon 
stereomicroscope and an automated EllS POT reader (Karl Zeiss - Imaging Associates, 
Germany). Results were recorded as spot forming cells (SFC) per 106 PBMC. Since 
HSV-I and HSV-2 antigens at 10 J,lg/ml yielded the highest response, this concentration 
was used to address HSV-specific IFN- y responses. 
Intracellular IFN-y production following PBMC stimulation with HSV-I and HSV-2 
lysates (1 J,lg/ml) was assessed in 2 healthy subjects (1 HSV seropositive, 1 HSV 
seronegative) using flow cytometry as previously described (Section 2.7.3). Positive and 
negative controls included staphylococcal enterotoxin B (1 J,lg/ml) (Sigma, Dorset, UK) 
and uninfected Vero cell extracts respectively. Cells were stained with the following 
monoclonal antibodies: IFN-yFITC/CD69-PE/CD4-PerCP/CD3-APC (BD Biosciences, 
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Oxford, UK), and analysed by a F ACScan flow cytometer (Becton Dickinson, Oxford, 
UK). CD69 is expressed on activated T cells, B cells and NK cells and is one of the cell 
surface proteins which are rapidly up-regulated after lymphocyte activation. Results were 
calculated by setting a gate around the CD3+CD4+ cell population on a forward versus 
side scatter dot plot; 10,000 events were collected for each sample. Dead cells and debris 
was excluded by forward and side scatter gating. 
7.2.3 Statistical analysis 
Sample size calculations were not carried out as this was a pilot study that investigated 
the effects of HIV and HSV status on the production of SFCn. In addition, we were not 
aware of any previous work that would have enabled us to estimate the level of response 
that may be expected amongst our control population. Furthermore, practical constraints 
determined that 64 HIV positive individuals and 20 HIV negative individuals were 
recruited. 
7.3 RESULTS 
7.3.1 HSV-specific T-cell responses of healthy donors 
A total of 20 HIV-l negative healthy adult volunteers were enrolled in the study, with a 
median age of 53.5 years (range 29-78 years); 11120 (55%) were HSV JgG seropositive 
and 9/20 (45%) were HSV JgG seronegative. The IFN-y responses to HSV-I and HSV-2 
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obtained at 3 time points over 9 weeks are summarised in Table 7.1. At all time points, 
the mean number of SFC was higher among HSV IgG seropositive patients (>150 
SFCs/106 PBMC) than among those who were HSV IgG seronegative «30 SFCs/106 
PBMC) (Table 7.1). Response to the negative medium control and the positive PHA 
control were comparable in patients who were HSV IgG seropositive and HSV IgG 
seronegative. Mean SFC for the negative medium control was 3 ± 3/106 PBMC. Mean 
SFC for the positive PHA control was 542 ± 154/106 PBMC. Patient 7 who was HSV IgG 
seropositive had the strongest PHA and HSV-specific response (821 SFC/106 PBMC and 
443 SFC/I06 PBMC respectively). 
There were modest variations in the mean number of SFC measured at the three time 
points and responses to HSV-I and HSV-2 antigens were similar. Overall, the mean SFC 
number to HSV-I and HSV-2 combined among HSV IgG seronegative patients were 
significantly lower than HSV IgG seropositive patients (28 ± II versus 318 ± 90). In the 
HSV IgG positive donors, responses correlated well with the level of antigenic PBMC 
stimulation in vitro. Figure 7.1 illustrates the IFN-y response to HSV-I and HSV-2 
antigens of one healthy donor at three different antigen concentrations (l, 5 and 10 
Ilg/ml). The mean number of SFC increased progressively with increasing HSV 
concentration used for PBMC stimulation. 
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7.3.2 HSV-specific T-cell responses of HSV IgG seronegative IIIV infected 
patients 
Ten HIV-infected patients who lacked serum HSV IgG served as an additional negative 
control group. Their median CD4 count was 457 cells/mm3 (range 264-970) (Table 7.2). 
The mean IFN-')' responses to both HSV-I (25 SFCIl06 PBMC) and HSV-2 (27 SFC/I06 
PBMC) were similar to those of HSV seronegative healthy controls (HSV -I, 29 SFC/I06 
PBMC; HSV-2, 27 SFC/I06 PBMC). 
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Table 7.1a. IFN-y responses to HSV-l and HSV-2 in HSV IgG seronegative healthy 
donors at 3 subsequent time points (week 0, 4 and 9) 
Mean number of IFN-y SFC at 3 time points 
HSV-l HSV-2 
Week 
Patient 0 Week 4 Week 9 Mean Week 0 Week 4 Week 9 Mean 
1 30 40 47 39± 8 23 30 47 33 ± 12 
3 33 27 20 27± 7 33 20 27 27± 7 
4 30 23 37 30± 7 50 33 47 43 ±9 
5 17 10 23 17 ± 7 33 20 37 30±9 
6 40 33 27 33 ± 7 33 43 30 36± 7 
9 37 43 40 40±3 30 27 33 30±3 
14 17 10 13 13 ± 3 13 10 7 1O±3 
17 20 23 27 23 ±3 23 13 13 17 ± 6 
19 37 33 33 34±2 13 17 30 20±9 
Mean of 29± 
group 9 27 ± 12 30 ± 10 29±9 28 ± 11 24 ± 11 30± 13 27±3 
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Tahle 7.th. IFN-y responses to HSV-t and HSV-2 in HSV IgG seropositive healthy 
donors at 3 subsequent time points (week 0, 4 and 9) 
Mean number of IFN-y SFCs at 3 time points 
Age 
Patient HSV-l HSV-2 (years) 
Week 0 Week 4 Week 9 Mean Week 0 Week4 Week 9 Mean 
HSV IgO seropositive individuals 
305 ± 
2 35 337 300 277 257 277 
30 
287 273 ± 15 
453 ± 
7 37 483 460 417 387 443 470 433 ± 43 
34 
142 ± 
8 39 133 170 123 223 237 260 240 ± 19 
25 
336± 
10 40 367 323 317 390 387 353 377 ± 20 
27 
179 ± 
11 39 163 173 200 273 290 277 280±9 
19 
346± 
12 31 377 337 323 353 333 313 333 ± 20 
28 
140 ± 
13 33 130 157 133 410 447 
15 
430 429 ± 18 
323 ± 
15 34 333 323 313 270 310 320 300 ± 26 
10 
16 32 320 313 330 321 ± 9 317 330 353 333 ± 19 
248 ± 
18 27 230 260 253 423 
16 
437 450 437 ± 13 
371 ± 
20 32 377 387 350 357 
19 
403 430 397 ± 37 
Mean of 295 ± 287± 333 ± 354± 
34±4 291 ± 90 276 ± 91 358 ± 75 348 ± 70 
group 115 95 68 73 
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Table 7.2. IFN-y responses to HSV-l and HSV-2 in HIV-infected HSV IgG 
seronegative patients 
CD4 counts Mean number of IFN-y SFCs 
Patient ( cells/mm3) HSV-l HSV-2 
29 970 47 30 
41 590 37 20 
33 470 23 23 
47 403 33 30 
10 264 3 17 
35 395 10 20 
61 353 13 20 
62 464 23 30 
63 530 30 37 
64 450 33 43 
Mean of 
group 489 ± 192 25 ± 13 27±9 
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7.3.3 Characterisation of HSV-specific T-cell responses by intracellular staining 
To further characterise the HSV specific T-cell responses of healthy donors, flow 
cytometry was performed to detect intracellular IFN- y production by activated 
CD3+CD4+CD69+ T cells following antigenic stimulation with HSV lysates, 
staphylococcal enterotoxin B (SEB) or medium control. Figure 7.2 illustrates the 
responses observed in one HSV IgG seronegative and one HSV IgG seropositive donor. 
Both donors responded to the positive SEB control. In the HSV IgG seropositive donor, 
HSV-specific IFN-y producing T-cells were measured at a frequency of 1.4% for HSV-I 
and 1% HSV -2 (Figure 7.2a). The IFN-y response to both HSV -I and HSV -2 as 
measured by ELISPOT in this patient was 304 ± 30 SFC /106 PBMC for HSV-I and 273 
± 15 SFC/I06 PBMC for HSV-2. In the HSV IgG seronegative donor (Figure 7.2b), the 
frequency oflFN-y producing T-cells after stimulation with HSV antigens was negligible 
and comparable to the response observed after stimulation with the medium control. 
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b) IFN-y responses in a HSV IgG seronegative donor 
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Figure 7.2: Flow cytometric analysis of intracellular IFN-y expression in a) HSV 
IgG seropositive individual and b) HSV IgG seronegative individual. PBMCs were 
stimulated with HSV-l lysate, HSV-2 lysate, SEB positive control, or uninfected Vero 
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cell extracts, in the presence of Brefeldin A and anti-CD28 antibody. Cells were 
penneabilised and stained with anti-CD3-APC, anti-IFN-y FITC, anti-CD4PerCP and 
anti-CD69PE antibodies. In the analysis, gating identified lymphocytes (RI, not shown), 
CD3+ T-cells (R2) and CD4+ T-cells (R3). The IFN-y expression of activated CD3+CD4+ 
T -cells was detennined using CD69 as an early T-cell activation marker. 
7.3.4 HSV-specific T-cell responses of HI V-I positive persons 
The study cohort included 54 HSV IgG seropositive HIV -I infected patients. The 
composition of the study group, patient's age, absolute and percent CD4 cell counts and 
HIV plasma RNA load as detennined at the time of enrolment are summarized in Table 
7.3. 
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Table 7.3. Characteristics of HSV JgG seropositive HIV-l infected patients 
HIV-l infected patient groups (n=54)a 
Group 1 
Total 9 
Time points sampled Median 5 (range 3-6) 
Median age (range) yr 41 (30-45) 
Median CD4 (range) 208 (5-308) 
celVmm3b 
Median % CD4 cells 18 (1-32) 
Median Viral load 4.7 
(lOgIO copies/ml) 
Group 2 
3 
3 
42 (28-45) 
1219 (480-
1261) 
39 (23-47) 
<1.7 
Group 3 
9 
1 
35 (27-56) 
453 (320-843) 
25 (16-40) 
4.6 
Group 4 
33 
1 
40 (18-71) 
360 (90-
1040) 
20 (7-43) 
<1.7 
aGroup 1: Prospective cohort starting HAART; Group 2: Long-term slow/non-
progressors; Group 3: Newly diagnosed patients not on HAART; Group 4: Patients on 
stable HAART. bLab oratory reference CD4 count 400-1500 cells/mm3. 
7.3.4.1 Long term slow and non-progressors (L TNP/L TSP) 
Three patients classified as L TNP/LTSP were investigated. The patients (patient 1, 14, 
21) had been diagnosed HIV positive 10, 22 and 19 years previously respectively and had 
shown CD4 cell counts above 400 cells/mm3, undetectable HIV viral load «50 
copies/ml) and no evidence of clinical progression in the absence of antiretroviral 
therapy. The three patients had no clinical history of HSV disease and were not on 
acyclovir. They showed overall HSV-spccific T-cell responses similar to those observed 
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in healthy donors (Table 7.4). Mean responses to HSV-l and HSV-2 were similar. IFN-y 
responses to HSV-l and HSV-2 antigens were lower in the patient with the lowest CD4 
cell counts. Figure 7.3 illustrates an example of IFN-y responses to HSV-l and HSV-2 
antigens in a patient with CD4 count of 1219 cells/mm3• 
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Table 7.4. IFN-y responses to HSV-I and HSV-2 in HAART naive HIV-infected 
long-term slow and non-progressors 
Mean number of lFN-y SFC 
HlV plasma 
CD4 counts Time point viral load (loglO 
Patient ( cells/mm3) (weeks) HSV-l HSV-2 copies/ml) 
1 1219 (47%) 0 427 367 <1.7 
953 (21%) 22 377 333 <1.7 
855 (42%) 43 367 327 <1.7 
Mean of 3 time points 390 ± 32 342 ± 21 
14 1261 (39%) 0 437 370 <1.7 
1452 (44%) 16 460 403 <1.7 
1042 (42%) 33 400 353 <1.7 
Mean of 3 time points 432 ± 30 376 ± 25 
21 480 (23%) 0 270 290 <1.7 
400 (27%) 6 230 223 <1.7 
370 (28%) 30 193 217 <1.7 
Mean of 3 time points 231 ± 38 243 ± 41 
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Figure 7.3. IFN-y responses to HSV-J and HSV-2 in a LTNP 
The plot illustrates IFN-y responses to three different concentration of H -1 and H 
2 antigens, At the time of sampling, the patient had been infected for 10 year wa 
asymptomatic and had a CD4 count of 1219 celIs/mm3 without receiving antir tro iral 
therapy. The patient did not have a clinical hi tory of H V di ea e, 
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7.3.4.2 Newly diagnosed HAART-naive subjects 
HSV-specific responses were measured at the time of HIV diagnosis in 9 patients (Table 
7.5). The median CD4 count in this population was 453 (range 320-843) and HSV-
specific responses appeared to correlate with CD4 counts (Figure 7.4). Mean responses to 
HSV-l and HSV-2 were similar (184 ± 56 and 189 ± 49 SFC/106 PBMC respectively) 
(Figure 7.4). Overall 6/9 (67%) patients received a clinical diagnosis of HSV infection 
and of these 4/6 had genital herpes and 2/6 orolabial herpes; 3/6 (50%) were taking 
acyclovir at the time of sampling. The mean SFC number was 179 ± 49 versus 202 ± 56 
SFC/l06 PBMC in persons with or without clinical HSV disease, and 167 ± 54 versus 
196 ± 49 SFC/l06 PBMC in person receiving or not receiving acyclovir. 
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Table 7.5. IFN-y responses to HSV-l and HSV-2 in newly diagnosed HAART-naYve 
HIV -infected patients 
HIV plasma Mean number of IFN-y SFC On anti-HSV 
viral load therapy at 
CD4 counts (log 10 History of time of 
Patient ( cells/mm3) copies/ml) HSV-1 HSV-2 HSV disease sampling 
44 320 (36%) 4.8 163 170 Oral herpes No 
4 369 (25%) 5.0 110 123 Genital herpes Yes 
11 374 (19%) 4.6 130 140 No No 
15 416 (16%) 5.4 140 163 Genital herpes Yes 
43 453 (16%) 4.6 150 163 Oral herpes No 
58 660 (29%) 2.6 260 257 No No 
16 686 (40%) 4.5 223 200 No No 
18 718 (23%) 5.4 237 230 Genital herpes Yes 
12 843 (26%) 4.5 243 253 Genital herpes No 
Mean of 
group 538 (26%) 4.6 184 ± 56 189 ± 49 6/9 3/9 
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Figure 7.4. IFN-y responses in a newly diagnosed HAART naive patient 
The plot illustrates IFN-y responses to three di fferent concentration of H - \ and H 
2 antigens. This patient had a 0 4 count of 369 cell Imm3 at the tim of H I _I 
diagnosi . The patient had diagno is of genital herpe and wa recei ing ac 10 ir at th 
time of ampling. 
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7.3.4.3 Patients on HAART 
The study included 33 HIV-infected patients who had received HAART for a median of 
30 months (range 1-109), including the current HAART regimen for median 12 months 
(range 1-60). Of these, 13/33 (39%) were on first-line HAART (Table 7.6a). The 
remaining 20 patients had experienced median 5 (range 3-13) previous antiretroviral 
drugs and median 3 (range 1-13) previous antiretroviral regimens. At the time of 
sampling, the HAART regimen included ~2 NRTIs (nucleoside transcriptase inhibitor) 
and one NNRTI (non-nucleoside transcriptase inhibitor) in 21133 (64%); 2 NRTIs and 
one ritonavir-boosted PI (protease inhibitor) in 8/33 (24%); a double-boosted PI with one 
NRTI or NNRTI in 3/33 (9%) and a triple NRTI in 1133 (3%). Of the 33 patients, 28 
(82%) patients had a HIV-l plasma viral load <50 copies/ml and 30/33 (91%) ~ 400 
copies/mt. 
Overall, 5/33 (15%) individuals reported a history of clinical HSV disease, including 3/5 
cases of orolabial herpes and 2/5 cases of genital herpes and one patients was on 
acyclovir at the time of sampling. As shown in Tables 7.6a and 7.6b, overall, HSV-
specific responses increased with CD4 counts. Patients 40 and 26 with the highest CD4 
counts (1040 and 920 cells/mm3 respectively) showed the strongest IFN-y response 
(Table 7.6). Responses were not dissimilar in persons with or without clinical HSV 
disease (184 ± 62 versus 167 ± 59 SFC/106 PBMC for HSV-l and 184 ±59 versus 157 ± 
57 SFCIl06 PBMC for HSV-2). Only one person was on acyclovir therapy. 
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Table 7.6a. IFN-y responses to HSV-l and HSV-2 in patients on first-line therapy 
CD4 counts HlVplasma HAART regimen Duration of Mean IFN-y SFC History of HSV Onanti-HSV 
( cells/mm3) viral load at time of sampling HAART number diseaset therapy at time of 
(loglO (months) HSV-l HSV-2 sampling 
Patient copies/ml) 
28 90 (7%) 4.8 3TC/DDIIIEFV 2 73 63 Oral herpes No 
24 170(10%) <1.7 FTCIDDIIEFV 14 140 113 No No 
48 210 (8%) <1.7 3TCITDFITPV/r 12 130 153 No No 
38 240 (15%) <1.7 FTC/DDIlEFV 1 153 163 No No 
32 310 (14%) <1.7 3 TCIDDIIIEFV 13 123 150 No No 
46 320 (21%) <1.7 3TCIDDI//EFV 18 163 177 No No 
39 360 (30%) <1.7 3 TCILPV /r/FPV 24 180 190 Oral herpes No 
51 420 (35%) <1.7 FTCIDDIINVP 15 190 190 No No 
19 470 (21%) <1.7 FTCITDF/EFV 7 230 183 Genital herpes No 
52 480 (18%) <1.7 3TCIDDIIIEFV 12 197 183 No No 
50 520 (19%) <1.7 3TCIDDIIIEFV 18 223 237 No No 
54 670 (32%) 1.8 3TCIDDIIIEFV 13 257 250 No No 
26 920 (40%) <1.7 3TCIDDlINVP 28 290 303 No No 
Mean 
of 11/13 <50 
group 398(21) copies/ml 14 181 ± 59 181 ± 60 3/13 0/13 
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Table 7.6b. IFN-y responses to HSV-l and HSV-2 in drug-experienced patients on HAART 
CD4 counts HIV plasma viral HAART regimen Duration of Total months Mean lFN-y SFC History of HSV Onanti-HSV 
(cells/mm3) load (lOglO at time of sampling current of therapy number diseaset therapy at time 
copies/ml) HAART HSV-l HSV-2 of sampling 
Patient (months) 
45 90 (10%) 5.0 3 TCrrDF ILPV Ir 17 71 70 100 No No 
49 170 (10%) <1.7 3TCrrDF/EFV 26 30 110 133 No No 
42 200 (23%) 2.0 TDFIDDIIATV/r 5 23 150 147 No No 
30 200 (19%) <1.7 3TC/DDlIEFV 7 17 123 110 No No 
56 210 (9%) <1.7 TDF/ABC/ATV/r 8 23 90 83 No No 
53 220 (12%) <1.7 3TCIDDlIlEFV 3 57 137 120 No No 
25 240 (17%) 4.0 TDF/LPV/rlSQV 10 90 220 223 No No 
55 270 (14%) <1.7 FTCrrDF ILPV Ir 5 41 107 130 No No 
2 282 (19%) <1.7 NVP, LPV/rlSQV 12 69 157 170 Genital herpes No 
31 350 (27%) <1.7 3TCrrDFlEFV 14 56 173 167 No No 
23 370 (15%) <1.7 TDF/d4T/ATV/r 7 70 197 180 Oral herpes Yes 
36 420 (20%) <1.7 3TCIDDlI/EFV 21 45 200 193 No No 
57 430 (20%) <1.7 3TCI ABCI AZTINVP 60 74 173 197 No No 
6 470 (23%) <1.7 TDF, AZT, ABC 33 45 223 237 No No 
34 530 (22%) <1.7 3 TCrrDFINVP 2 34 217 203 No No 
60 590 (23%) <1.7 TDF/ABC/ATV/r 8 67 203 223 No No 
59 610 (25%) <1.7 3TC/ABC/EFV 11 44 250 230 No No 
20 780 (43%) <1.7 TDF/3TC/EFV 16 58 250 237 No No 
22 970 (29%) <1.7 3TCrrDFINVP 24 84 277 257 No No 
40 1040 (30%) <1.7 3 TCrrDF/ATV/r 6 109 303 297 No No 
Mean 
of 17120(50 
group 422 (21%) co~ies/ml 15 55 182 ± 64 180 ± 58 2/20 1/20 
200 
180 .H -I 
• 160 · H -2 
• 
~ • Q) 140 
u 
00 
s::l 
'§ 120 • 
cB 100 
..-
• 0 0.. 80 VJ • <;-
~ 60 
40 
20 
0 
0 5 10 
HSY concentration (1, 5 and 1 0 ~glml) 
Figure 7.5.IFN-y responses to HSV-J and H V-2 in a HAART treated patient 
The plot illustrates IFN-y responses to three different concentration of H -1 and H 
2 antigens. The patient was receiving therapy with NYP, SQY, LPY/r and howed a 04 
count of 282 cell s/mm3. He had a history of genital herpes but wa not on ac clo ir at the 
time of sampling. 
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7.3.4.4 Prospective study of patients starting first-line HAART 
Nine patients starting first line HAART with either an NNRTI-based regimen (5/9, 56%) 
(Table 7.7a) or a boosted-PI based regimen (4/9, 44%) (Table 7.7b) were sampled 
prospectively over median 40 weeks of follow-up (range 26-64 weeks). At baseline, the 
median CD4 count was 208 cells/mm3 (range 5-308). No patients reported a change of 
HAART regimen during follow-up and all patients achieved an undetectable HIV plasma 
RNA load «50 copies/ml) within median 23 weeks of follow-up (range 7-39 weeks). The 
median CD4 gain during follow-up was +296 cells/mm3. Only 3/9 (30%) patients had a 
clinical history of HSV infection and two of these were on acyclovir at the time of 
sampling. 
In five patients (no 5, 7, 27, 3 and 13) with low or absent HSV responses at baseline, 
HAART-induced increases in CD4 cells were accompanied by parallel increases in the 
mean number of SFCs. In this group the median baseline CD4 count was 189 celVmm3 
(range 5-236) and increased by +202 cells/mm3 (range 26-559) during median 48 weeks 
(39-60) of follow-up. The median SFC increase was +72/106 PBMC (range 23-187). The 
IFN-y response to HSV-l and HSV-2 before and after the initiation of HAART are 
plotted in Figures 7.6, 7.7a-7.7j. Responses remained stable in 2 other patients (9 and 37). 
One of the two showed a substantial increase in CD4 counts (+357 cells/mm3) over 38 
weeks of follow-up. However in the 2 individuals (9 and 37), a reduction in HIV viral 
load (50 copies/mt) was not achieved until week 38. In the other patient, the CD4 count 
did not improve during 26 weeks of follow-up, despite the patient demonstrating 
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undetectable viral load by week 15. Finally two patient (17 and 37) with trong H 
responses at base line showed a modest decline in F number over time. 
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Figure 7.6. IFN-y responses to HSV-l and H V-2 in a pro pecti e patient b fore and 
after the initiation of HAART 
The plot illustrates IFN-y response to three different oncentration f H - I and H 
2 antigens. Thi patient exhibited a 04 count of 107 ell Imm at ba lin whi h 
increased to 169 cell Imm3 at week 5 . The patient al had a lini al hi t ry f g nital 
herpes and wa on acyclovir th rapy. 
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Table 7.7a. Prospective IFN-y responses to HSV-l and HSV-2 in patients both 
before and after the initiation of NNRTI-based HAART 
On anti-HSV 
therapy at 
Time point Previous history time of 
Patient (weeks) HAART regimen of HSV infection sampling 
5 0 None No No 
4 AZT/3TC/NVP No 
14 AZT/3TC/NVP No 
23 AZT/3TC/NVP No 
36 AZT/3TC/NVP No 
40 AZT 13 TC/NVP No 
7 0 None No No 
22 TDF/D4T-XRlEFV No 
26 TDF ID4 T -XRlEFV No 
48 TDF ID4T -XRlEFV No 
9 0 None No No 
12 AZT 13 TC/EFV No 
31 AZT 13 TC, EFV No 
38 AZT, 3TC, EFV No 
13 0 None Genital herpes Yes 
7 TDF/D4T-XRlEFV No 
24 TDF/D4T-XRlEFV No 
32 TDF/D4T-XRlEFV No 
44 TDF ID4T -XRlEFV No 
58 TDF/D4T-XRlEFV No 
37 0 None No No 
15 AZT/3TC/NVP No 
26 AZT 13 TC/NVP No 
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Tahle 7.7h. Prospective IFN-y responses to HSV-l and HSV-2 in patients both before and 
after the initiation of PI-based HAART 
Previous history On anti-HSV 
Time point ofHSV therapy at time of 
Patient (weeks) HAART regimen infection sampling 
27 0 None Oral herpes Yes 
4 TDF 13TC/LPV Ir No 
11 TDF 13 TC/LPV Ir No 
30 TDF 13TC/LPV Ir No 
39 TDF/3TC/LPV/r No 
8 0 None No No 
18 AZT 13TC/LPV Ir No 
36 AZT 13TC/LPV Ir No 
53 AZT 13 TC/LPV Ir No 
64 AZT 13 TC/LPV Ir No 
3 0 ABC/3 TC,I A TV Ir No No 
23 ABC/3TC,I A TV Ir No 
35 ABC/3 TC,I A TV Ir No 
48 ABC/3TC,IATV/r No 
60 ABC/3 TC,I A TV Ir No 
17 0 None Genital herpes No 
16 TDF/3TC/LPV/r No 
25 TDF 13TC/LPV Ir No 
32 TDF/3TC/LPV/r No 
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Figure 7.7a-7.7i. HSV specific IFN-y responses among patients before and after the 
initiation of HAART. IFN-y responses to HSV-l and HSV-2 lysates are plotted for each 
of the 9 patients before and after commencing HAART. The initial sample at baseline is 
referred as week 0, and sequential samples thereafter post HAART. 
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7.3.5 Correlation between HSV responses and CD4 counts in HSV IgG 
seropositive HIV -1 infected patients 
Mean IFN-y responses for HSV-l and HSV-2 were similar among the 54 HIV-l infected 
individuals (189 versus 187 SFC/106 PBMC) (Figure 7.9). The coefficient of correlation 
was 0.75. 
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Figure 7.8. Correlation between CD4 count and HSV-specific IFN-y responses 
among HIV-l infected HSV IgG seropositive patients.IFN-y responses to HSV-l and 
HSV-2 lysates (averaged from HSV-l and HSV-2 data) are plotted for the 54 patients. 
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7.4 DISCUSSION 
Highly active anti-retroviral therapy has shown to restore CD4+ T-cell counts in HIV-I 
infected individuals (Jevtovic et al., 2005). However, there are limited data on HSV 
specific CD4 T-cell responses among HIV -1 infected subjects at different stages of HIV-
1 disease and on the effects of HAART on immune reconstitution of HSV-specific T-cell 
responses. In the present study, we examined HSV-specific T cell responses among HIV-
1 infected patients, using IFN-y as an immunological marker following HSV-I and HSV-
2 antigenic stimulation of PBMC in vitro. We present data within 4 distinct groups of the 
HIV -1 infected population, each group representing individuals at different clinical stages 
of HIV-l infection: prospective patients starting HAART; long-term slow and non 
progressors; newly diagnosed HIV -I infected patients not receiving HAART; and 
patients on stable HAART. Results demonstrated that HSV-specific T-cell mediated 
production of IFN-y correlated with CD4 cell counts. Responses were highest in patients 
who had elevated CD4 cell counts associated with LTNP/LTSP status, early HIV 
infection or HAART-induced CD4 restoration. Taking the mean HSV-specific response 
of healthy HSV IgG seropositive donors as a reference (318 ± 90 SFC/I06 PBMC), a 
CD4 count >500 cells/mm3 was generally required to achieve comparable responses in 
HIV-infected patients. 
Patients with long-standing infection in the absence of clinical progression showed HSV 
responses comparable to healthy HIV -I uninfected controls, consistent with the preserved 
immune function that characterises these patients. Previous observations have indicated 
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that L TNP control viremia with no diminution of CD4 cells (Sankaran et a/., 2005; 
Valdez et a/., 2002; Paroli et al., 2001). In addition, LTNP may remain clinically healthy 
for >7 years in the absence of HAART (Sankaran et al., 2005). Evidence suggests that 
these patients have vigorous HIV-I specific CD4 T cell responses with high levels of 
IFN-y production (Paroli et al., 2001). However, after several years of HIV-I infection, 
evidence of disease progression may start to appear reflected by a decline in CD4 cell 
counts, so that at least some of these patients are better defined as Long-term slow 
progressors (LTSP). These observations are consistent with findings from patient 21, who 
after 19 years since the diagnosis had a CD4 count of 480 cells/mm3 but lost 110 cells 
during 30 weeks of follow up. 
Data (Lundgren et al., 2002; Ghani et ai., 2001; Lewden et al., 2002) has indicated that 
the CD4 count acts as a strong predictor of clinical outcome in HIV infected patients. 
HAART has been previously shown to effectively restore CD4 counts and reconstitute 
immune functions in HIV-l infected individuals (RD et al., 2005; Anastos et al., 2004; 
Servais et al., 2000). In a study of377 HIV-I infected women in resource limited settings 
who initiated HAART with pre-HAART CD4 counts <200 cells/mm3, 43% exhibited 
CD4 counts >200 and 11% >350 cells/mm3 within I year of starting HAART (Anastos et 
al., 2004). The authors also reported reduction of AIDS-defining illness among women to 
be associated with increased CD4 counts >350 cells/ mm3• However, data on delayed 
type hypersensitivity (DTH) responses from this study was limited since factors other 
than HIV -I infection could impair DTII responses and that variability in DTH itself can 
exist over short time periods (I year). 
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A recent study of 153 HAART naIve patients demonstrated mean CD4 count increases of 
149 and 204 cells/mm3 at 24 weeks and 48 weeks respectively after the initiation of 
HAART, paralleled with a reduction in the patient's HIV-l viral load (Wester et al .• 
2005). Previous studies have reported CD4 counts to increase at least 50 cells/mm3 after 
4-8 weeks of initiating HAART, followed by an increase of 50-100 cells/mm3 per year 
thereafter (Yamashita et al .• 2001; Le Moing et al .• 2002). 
These observations are in agreement with our findings. Among the 9 individuals who 
started first line HAART with either NNRTl or boosted PI-based-regimens, HIV-l RNA 
load was reduced to undetectable levels «50 copies/ml) within median 23 weeks. The 
overall CD4 increase in the cohort was median +296 cells/mm3 over median 40 weeks of 
follow-up. One patient (n=27) demonstrated a dramatic increase of+213 cells/mm3 after 
just 4 weeks of HAART and of +455cells/mm3 after 11 weeks followed by a slower 
subsequent increase. Initial rises in CD4 count after 1-2 months of therapy have been 
shown to occur as a result of redistribution of cells from the bone marrow (Bucy et al .• 
1999; Michael et al .• 2002), but this data must be interpreted with caution since only 7 
HIV -1 infected patients were followed up (Bucy et al .• 1999). This may be followed by a 
decline in CD4 cell numbers followed by a second, slower rise with continued 
suppression of viral replication, which may continue for> 12 months (Wu et al .• 2001; 
Kaufmann et al .• 1998). 
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The poor HSV-specific response observed in the newly diagnosed HAART nai've 
subjects, suggests a relationship between the inability to produce IFN-y following HSV 
stimulation and dysfunctionality of CD4+ T cells (Hardy et al., 2003). Conversely, the 
recovery of IFN-y responses after commencing HAART in patients with low or absent 
responses at baseline is in agreement with observations from other studies that have 
demonstrated increased proliferative responses to HSV antigenic stimulus following the 
initiation ofHAART (Hardy et al., 2003). 
Clinical manifestations of HSV infection were overall uncommon in the HIV-infected 
population, with 14/54 (26%) patients having a recognised clinical history of orolabial or 
genital HSV disease. These findings are in contrast with the recognised association 
between HIV infection and HSV disease burden, and are likely to reflect the beneficial 
effects of HAART in restoring HSV specific T-ceII responses. In a study of 28 HAART 
treated and 49 HAART naive persons co-infected with HIV-l and HSV-2, HAART 
treated individuals reportedly had HSV lesions on fewer days with lower HIV viral load 
compared to drug nai've individuals (2.8% versus 11.3% of days respectively; 170 
copies/ml versus 18793 copies/ml respectively) (Posavad et al., 2004). This is in 
agreement with the findings reported in chapter 6, which showed that HIV-l infected 
patients diagnosed with genital herpes after 1997 were four times less likely to receive a 
clinical diagnosis of genital herpes than patients diagnosed in the pre-HAART era 
(adjusted odds ratio 5.11; 95% CI: 3.28-7.98; P=O.OOOI) (Ramaswamy et al., 2006). 
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Findings from this study have shown that HAART improves the clinical course of HSV 
infection. Conversely, other studies have also shown that immune reconstitution 
following HAART may aggravate the immunopathology of HSV and other opportunistic 
infections (Fox et a/., 1999; Leidner & Aboulafia, 2005; Goebel, 2005; Shelburne et a/., 
2005; Buckingham et a/., 2004). To date, there is only one study which has documented 
the adverse effect of immune reconstitution by HAART resulting in chronic erosive HSV 
infection of the penis in a male patient within 4-6 weeks after commencing HAART (Fox 
et a/., 1999). It has been postulated that HSV was present prior to the initiation of 
HAART and that the recovery of the immune system following HAART, resulted in a 
hypersensitivity response leading to immune restoration disease (lRD). No HSV-related 
IRD was observed in this study. 
The results support the consideration that HAART enables immunological reconstitution 
of CD4 cells and HSV specific responses. This can be further demonstrated by improved 
control of HSV clinical disease as observed in our cohort of HAAR T -treated patients. In 
addition, HSV -specific immune responses comparable to those of healthy donors were 
only evident at CD4 cell counts above 500 cells/mm3• This provides a threshold for HSV-
immune reconstitution that may assist with clinical management. 
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8. Chapter 8. General Discussion 
Despite the availability of effective antiviral therapy to control and possibly prevent 
infection, genital herpes is increasingly common in both developed and developing 
countries. The work described in this thesis addressed the following topics: I) the 
optimal diagnostic strategies for genital herpes; 2) the epidemiology of genital herpes 
in an ethnically diverse population of GUM attendees including an analysis of virus 
genetic variability 3) the epidemiology and natural history of HSV-2 infections in a 
cohort of HIV-l infected individuals, and 4) the impact of HAART on HSV-specific 
T-cell mediated immune responses. 
The optimal diagnostic strategies for genital herpes 
The feasibility of using real-time PCR as a diagnostic tool for detecting genital herpes 
in genital swabs was investigated among GUM clinic attendees with suspected genital 
herpes (Chapter 3a). Results demonstrated real-time PCR to have a significantly 
higher diagnostic yield compared to virus culture in patients who presented early after 
the onset of symptoms, and had visible genital ulceration. These findings were 
consistent with those from other studies and supported the use of PCR as the 
preferred diagnostic tool (Sharon et al., 1997; Cone et al., 1991; Rand et al., 2005; 
Scoular et al., 2002; Schmutzhard et aI., 2004). 
221 
One of the potential limitations of PCR is the risk of false negative and false positive 
results. False negative results may be the consequence of inhibitors present within the 
sample (Bezold et al., 2000). We sought to detect inhibitory substances when 
developing our LightCycler PCR assay by spiking HSV negative samples with HSV-
1 and HSV-2 DNA, however no significant inhibition was found. In addition no 
sample that tested positive by virus culture failed to be detected by PCR. We also 
compared the three specimen preparation methods for PCR to determine the one that 
allowed optimal virus detection. The three methods showed a high level of 
concordance, although there were a few specimens positive by PEGlNaCI 
precipitation and negative by manual and automated DNA extraction. By adapting the 
PEG virus precipitation method for HSV detection, we enhanced the diagnostic 
feasibility of real-time PCR for HSV detection by decreasing costs and time required 
for specimen preparation. Further studies are ongoing to ascertain whether it may be 
possible to retain high diagnostic sensitivity while avoiding specimens preparation 
altogether. 
Additional information for patient management and counselling can be provided by 
HSV typing. The HSV LightCycJcr PCR protocol allowed HSV typing by melting 
curve analysis. The level of sequence conservation for the hybridisation probe targets 
is critical for the success of melting curve analysis (Whiley et al., 2004). It was 
interesting to note that although the PCR assay was specific in HSV type 
discrimination, atypical melting curves were apparent in 14 (18%) HSV-2 positive 
specimens. Consistent with earlier observations (Anderson et al., 2003; Issa et al., 
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2005), nucleotide differences in the probe binding region of the DNA polymerase 
gene was observed in 4114 (29%) specimens. One novel observation was that melting 
curves were influenced by specimen preparation methods, in the presence of 
conserved gene sequences. 
The application of HSV type specific serology was investigated to determine its 
potential contribution to the diagnosis of genital herpes. Commercially available tests 
accurately discriminate between HSV-I and HSV-2 antibodies and are based on HSV 
.. ~ 
type-specific sequences within the viral glycoprotein G. We optimised and evaluated 
a commercially available HSV type-specific EIA to accurately identify HSV-I and 
HSV -2 antibodies in several defined populations. Our evaluation studies indicated 
that increasing the manufacturer's recommended cut-off from 1.1 to 3.1 improved 
specificity without compromising sensitivity. This was particularly evident in patient 
sera from sub- Uganda and Kenya. 
The observation that HSV EIA and Immunoblot can be successfully employed to 
determine newly acquired HSV-2 infection has been previously documented (Ashley-
Morrow et 01., 2003; Howard et 01., 2003; Ashley, 2002). We demonstrated HSV-2 
seroconversion in two clinical cases, including a case of HSV-2 encephalitis which 
showed HSV -2 seroconversion within 4 weeks of onset of symptoms. These findings 
supported previous observations, which suggested the median time of HSV-2 
seroconversion was 21-23 days after the onset of symptoms. 
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Among patients who presented with genital herpes, HSV type-specific serology 
detected HSV -2 antibodies in all patients with recurrent genital herpes and with a 
HSV -2 positive genital swab. However, among patients with first-episode genital 
herpes and a HSV-2 positive, 38% were HSV-2 seropositive at time of presentation. 
This indicated the infection to be recurrent. Hence, the correct characterisation of 
patients presenting with genital herpes cannot rely on clinical grounds alone. We also 
observed 37% of patients clinically diagnosed with genital herpes with negative 
genital swab by peR to be HSV -2 seropositive. This suggested that even when using 
peR as a diagnostic tool, type-specific serology can assist with the diagnostic process 
in patients suspected of having genital herpes. 
The epidemiology of genital herpes in an ethnically diverse population if GUM 
attendees 
Genital ulceration is most commonly caused by Herpes simplex virus types 1 and 2 
(HSV -I and HSV -2) (Mertz, 1990). The natural history of HSV -I and HSV-2 
infection differs particularly in the likelihood of recurrences. HSV -2 is five times 
more likely to cause recurrent disease than HSV-l (Engelberg et 01., 2003). 
Traditionally HSV-2 has been associated with genital infection and HSV-l with oral 
mucocutaneous disease. However, published studies have reported HSV-I to account 
for over 50% of cases of genital herpes in the UK (Ross et 01., 1993; Scoular et 01., 
2002; Slomka et 01., 1998; Lamey & Hyland, 1999). We used real-time peR to 
explore the epidemiology of HSV genital infection in a cohort of GUM attendees 
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suspected of having genital herpes (Chapter 4). A clinical diagnosis of first-episode 
and recurrent genital herpes was made in 61 % and 39% of individuals respectively. 
HSV DNA was detected in 58% of genital swabs by real-time PCR. In contrast with 
other published studies in the UK (Coyle et al., 2003; Ross et al., 1993; Tayal et al., 
1994; Manavi et al., 2004), we found that HSV -2 accounted for 93.5% of cases of 
HSV genital infection. However, results from these published studies must be 
interpreted with caution, due to the lack of demographic data. Interestingly in our 
study, HSV type associated with genital infection was influenced by ethnicity. 
Persons of white ethnicity were more likely to be infected with HSV-l and persons of 
black ethnicity were more likely to be infected with HSV -2. Most studies to date have 
documented initial HSV -1 genital-tract infection to be prevalent in persons of white 
ethnicity than non-white ethnicities (Siegel et al., 1992; Nageswaran et al., 1996; 
Schillinger et al., 2004). Possible explanations could be that oropharyngeal HSV-l 
infection in childhood may playa role in determining the risk of genital infection with 
HSV -1 in adult life. In addition, it could be proposed that patients of black ethnicity 
were more reluctant than patients of white etlmicity to attend the GUM clinic if 
infected with HSV -1. The levels of oropharyngeal HSV -1 infection remain high in 
much of the developing world and are generally higher in poor social strata of the 
population. In contrast, the infection is becoming less common among affiuent 
populations in developed countries which could be attributed to differences in sexual 
behaviour between different ethnicities (Lafferty, 2002). 
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A significant difference in the delay between the onset of symptoms and clinical 
presentation was also observed between men and women. Earlier presentation of 
HSV infection women compared to men may relate to biological factors such as the 
larger and more vulnerable mucosal surface of women causing intense pain 
(Carpenter et al., 1999; Nicolosi et al., 1994). Differences in awareness and reporting 
of symptoms or greater ease of accessing medical care may also be a contributing 
factor. 
HIV testing was offered routinely to all patients presenting to the GUM clinic, but 
was declined by a large proportion of persons of black-Caribbean origin. This was 
worrying finding considering the high incidence of HIV in black-Caribbean 
populations (McBride et al., 2005; Fenton et aI., 2005). 
The variability of the HSV-2 UL 14 gene in patients clinically diagnosed with genital 
herpes and a positive genital swab was also studied using PCR (Chapter 4). Besides 
showing a high degree of conservation in 69% of specimens, we also demonstrated 
nucleotide differences in 8 patients (418 white ethnicity; 4/8 black ethnicity). Of the 8 
patients, 6 patients had amino acid changes with no consistent trends in HSV 
variability. One patient also had a nucleotide insertion which resulted in multiple 
amino acid changes. Previous data have shown amino acid sequences in the N-
terminal region of HSV-2 ULl4 protein to be homologous to the C-terminal region of 
Hsp70 (Yamauchi et al., 2002a). No changes were observed in this region. This 
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indicated the function of the UL 14 protein to be preserved as an Hsp-like molecular 
chaperone, and have an important role in virus replication and infectivity. 
The epidemiology and natural history of HSV-2 infections in HIV-l infected 
individuals 
Given the recent number of studies documenting a strong epidemiological association 
between HSV -2 and HIV -1, the seroprevalence of HSV -1 infection and its correlation 
with a clinical diagnosis of genital herpes was investigated in newly diagnosed 
individuals. In addition, we also determined HSV-2seroincidence following HIV 
diagnosis and its association with other STIs (Chapter 6). HSV-2 seroprevalence was 
high (63%) among HIV-l infected individuals, confirming the strong positive 
association between the two viruses (Wald & Link, 2002; Ramjee et al., 2005). 
Interestingly, our findings contrast previous observations on the protective effect of 
HSV -1 infection for HSV -2 (Gopal et al., 2000; Mertz et al., 1985), however others 
have found no evidence of this (Brown et al., 1997; Langenberg et al., 1999). 
HSV-2 seroprevalence increased with age, and was significantly associated with 
female gender, heterosexual risk group and black ethnicity. This is consistent with 
previous data which have shown women to have a higher risk of HSV-2 infection 
than men (Langenberg et a/., 1999; Ross et al., 1993; Fleming et al., 1997; Vyse et 
a/., 2000; Cowan et aI., 1994). However, the relationship between HSV-2 
seropositivity and sexual orientation is not well understood. This is due to the strong 
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association between gender and sexual orientation and the paucity of data comparing 
homosexual and heterosexual males. The strong association between black ethnicity 
and HSV -2 seropositivity found in our study has been reflected in other studies 
(Armstrong et al., 2001; Gottlieb et al., 2004; Mbopi-Keou et al., 2000; Siegel et al., 
1992; Breinig et al., 1990) but had not been previously demonstrated in HIV -infected 
patients. Elevated HSV-2 rates in HIV-l infected patients may have major 
consequences for HIV-l acquisition and transmission (Andn~oletti et al., 2005). In 
our study, HSV-2 infections continued to occur after a diagnosis of genital herpes. Of 
the 123 patients monitored prospectively and 12 patients (10%) seroconverted to 
HSV -2. HSV -2 seroconversion was strongly associated with a new diagnosis of HPV 
infection, gonorrhoea, hepatitis A or B and scabies and therefore was a marker of 
high risk sexual behaviour. 
Genital herpes was significantly under-diagnosed in a large proportion of our HSV-2 
seropositive HIV infected study population. Only 22% of HSV -2 seropositive patients 
received a clinical diagnosis of genital herpes and a fraction of those had a positive 
swab by virus culture. Similar findings have been reported elsewhere (Koutsky et al., 
1992). The presence of atypical genital lesions, asymptomatic viral shedding and poor 
sensitivity of virus culture could all have contributed to the lack of diagnosis. More 
importantly, HSV -2 seropositive patients diagnosed after 1997 were four times less 
likely to receive a clinical diagnosis of genital herpes than those diagnosed in the pre-
HAART era. These observations suggested HAART to have a positive impact on the 
clinical expression of genital HSV-2 infection. Similar findings have been reported 
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elsewhere which showed HIV-l positive persons on HAART reported significantly 
fewer days with HSV lesions than untreated subjects (Posavad et al., 2004). CD4 cell 
counts have also shown to correlate with the clinical expression of genital herpes 
(Van Benthem et al., 2001). 
The impact ofHAART on HSV-specific T-cell mediated immune responses 
IFN-y T-cell mediated immune responses in HIV-infected persons were investigated 
using an ELlS POT method (Chapter 7). Four different populations were studied 
representing different phases of the infection. These included LTNP/LTSP. newly 
diagnosed patients, patients on HAART and patients starting first line HAART. The 
strongest HSV -specific IFN-y response was measured in LTNP/LTSP patients who 
had responses comparable to those of healthy HSV seropositive donors. Restoration 
of CD4 cell numbers was evident among patients on HAART and was accompanied 
by a parallel increase in HSV-specific IFN-y responses. Overall responses in all 
patient groups correlated well with CD4 counts. A threshold of approximately 450 
cells/JlI predicted immune-reconstitution to levels similar to those in healthy donors. 
A larger proportion of newly diagnosed patients (67%) also received a clinical 
diagnosis of HSV disease compared to HAART treated individuals (23%). This 
observation is in agreement with our previous findings (Chapter 6) and fonn the basis 
for a future study aimed at assessing the dynamics of HSV-specific CDS T 
lymphocytes in patients starting first-line HAART. 
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